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Abstract 
 
Members of the family Hepadnaviridae have been detected in both avian and 
mammalian species.  They have a very limited host range, and among the non-
human primates, have been found to occur naturally in chimpanzees, gorillas, 
gibbons, orang-utans and woolly monkeys.  The human hepatitis B virus (HBV) 
has been shown to infect chimpanzees, Barbary macaques and tree shrews.  
During the course of a previous study, to determine the susceptibility of baboons 
(Papio ursinus orientalis) to HBV infection, HBV DNA was detected in the 
serum of 2 baboons prior to their inoculation with HBV-positive human serum, 
raising the possibility that baboons are naturally infected with a hepadnavirus.  
Therefore the aim of this study was to determine the prevalence of HBV in wild-
caught baboons and to molecularly and functionally characterise the virus isolated 
from these baboons. 
 
DNA was extracted from the sera of wild-caught baboons and four separate 
regions of the HBV genome amplified by nested polymerase chain reaction 
(PCR).  Samples were only considered to be positive for HBV if at least three of 
these regions amplified.  DNA was extracted from the liver tissue of one of the 
HBV DNA-positive baboons using a proteinase K digestion followed by a phenol-
chloroform extraction and ethanol precipitation.  From this extract, the complete 
HBV genome was amplified by nested PCR of eight overlapping subgenomic 
fragments, and sequenced.  This sequence was analysed phylogenetically using 
both the PHYLIP and Simmonic software packages.  A selective real time PCR 
using SYBR®-green detection was used to detect covalently closed circular (ccc) 
DNA.  RNA was extracted from the baboon liver tissue using a guanidinium-acid-
phenol extraction method, reverse transcribed and portions of the HBV genome 
amplified by nested PCR.  Transmissibility of the virus was tested by injecting 
four experimentally naïve baboons individually with serum from four HBV DNA-
positive baboons and followed for 26 weeks.   
 
HBV was detected in the serum of 5/69 (7,2%) wild-caught baboons by Southern 
hybridization and in 11/49 (22,4%) adult and 4/20 (20,0%) juvenile wild caught 
vi 
 
baboons.  This gave an overall prevalence of 21,7% in the baboon population 
surveyed.  Serologically, the baboon sera were negative for all markers of HBV 
infection and alanine aminotransferse (ALT) levels were normal.  In the one 
baboon liver tissue available, HBcAg was detected by immunohistochemical 
staining in some of the hepatocyte nuclei, but HBsAg was not detected.   
 
Phylogenetic analysis of the complete genome of the HBV isolate found it to 
cluster with subgenotype A2, a surprising result considering that subgenotype A1 
predominates in South Africa.  However, unlike other subgenotype A2 isolates, 
the basic core promoter had the G1809T / C1812T double mutation characteristic 
of subgenotypes A1 and A3 and the precore region had the G1888A mutation 
unique to subgenotype A1.  These mutations in the basic core promoter and pre-
core regions have previously been shown to reduce the expression of the precore 
and core proteins.  Four additional mutations in the polymerase, surface, X and 
core open reading frames (ORFs) further differentiated the baboon HBV strain 
form the majority of previously sequenced subgenotype A2 isolates.   
 
cccDNA was detected at low levels in the baboon liver tissue.  Regions of the 
precore/core and surface ORFs were amplified off reverse transcribed cDNA.  
These results demonstrate HBV replication in the baboon liver.  Transmission of 
the virus was shown by the detection of HBV DNA in the sera of the four 
inoculated baboons at various times throughout the 26 week follow-up period.  
These baboons also showed transient seroconversion for HBsAg and HBeAg 
during this period with intermittent fluctuations in ALT levels.  Moreover, using 
DNA extracted from liver tissue obtained at necropsy from one of the injected 
baboons, the sequence of the HBV surface gene amplified was found to be 
identical to the sequence of the isolate from inoculum.   
 
The finding of subgenotype A2 in the baboon is paradoxical because 
subgenotypes A1 and A3 as well as genotypes D and E predominate in Africa.  
The possibility exists that subgenotype A2 is an older strain that has been 
overtaken by these other strains.  There is however a scarcity of subgenotype A2 
sequencing data from Africa and a higher circulation of this subgenotype could be 
uncovered with more extensive molecular epidemiological studies in more remote 
vii 
 
areas.  Alternatively, a recent discovery of alternative compartmentalization of 
subgenotype A2 infections in the peripheral blood lymphocyte population of 
individuals from India, where subgenotype A1 also predominates, could explain 
the lack of detection of this subgenotype in Africa. 
 
Occult hepatitis B infection is defined as the presence of HBV DNA in the liver 
(with detectable or undetectable HBV DNA in the serum) of individuals testing 
negative for HBsAg by currently available assays.  The detection of HBV DNA in 
the baboon liver and serum in the absence of serological markers therefore 
classifies this infection as occult.  To our knowledge, this is the first study to 
demonstrate a naturally occurring occult HBV infection in non-human primates. 
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1.  Introduction 
 
Hepatitis viruses infect the liver, causing both acute and chronic diseases.  
According to the World Health Organisation (WHO), approximately 2 billion 
people worldwide have been infected with the hepatitis B virus (HBV), 350 
million people are chronic carriers of the virus and 600 000 die each year as a 
result of either acute or chronic infections with the virus (WHO, 2008).  
Approximately 10% of adults and 90% of children infected with HBV become 
chronically infected (Sugiyama et al., 2007).   
 
1.1  The hepatitis B virus 
 
One of the first records of hepatitis or yellow jaundice epidemics was by Pope 
Saint Zacharias in the 8th century, and descriptions of the disease can be found as 
far back as the writings of Hippocrates (Deinhardt, 1976).  Hippocrates described 
hepatitis as a disease “produced by black bile when it flows into the liver” and 
correctly listed the symptoms as anorexia, vomiting, fever, livid or pale-yellow 
complexion, and liver pain (Lai and Locarnini, 2002).   
 
The hepatitis viruses comprise a group of five unrelated, often unusual pathogens, 
designated hepatitis A through E, grouped according to the disease they cause 
rather than their virological properties (Zuckerman, 1997; Howard, 2002).   
 
HBV is a partially double-stranded DNA virus that replicates by reverse 
transcription.  It is classified in the family Hepadnaviridae (for HEPAtropic DNA 
VIRUSES).  The hepadnaviridae are further separated into two genera – the 
orthohepadnaviruses found in mammals and the avihepadnaviruses found in birds 
(Ganem, 1996; Zuckerman, 1997; Howard, 2002).  Although these two genera 
differ in genetic organisation, structure and biological properties – for example the 
avihepadnaviridae lack a separate gene encoding the HBV-X protein - all the 
hepadnaviruses are able to induce persistent infections in their natural hosts 
(Howard, 1994; Scaglioni et al., 1996).   
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All hepadnaviruses share a number of common properties.  They: are enveloped 
viruses containing a 3 - 3,3 kb relaxed-circular, partially double-stranded genome; 
have a viral polymerase able to repair the gap in the DNA template; produce an 
excess of subviral lipoprotein particles composed of envelope proteins; have a 
narrow host range infecting only species closely related to their natural host and 
produce persistent infections that are largely (but not completely) hepatotropic 
(Ganem, 1996).   
 
HBV infections are often associated with hepatocellular carcinoma (HCC) in 
humans and the integration of viral DNA into the host’s genome has been found 
in many of these tumours.  Approximately one-third of all cases of cirrhosis and 
one-half of all HCC cases can be attributed to chronic HBV infections.  Because 
HCC is the 4th most common cause of cancer- related deaths globally, chronic 
HBV infections are considered to be, after tobacco, the most common carcinogen 
to which humans are exposed (de Franchis et al., 2003; Shepard et al., 2006; 
WHO, 2009).  HBV is transmitted via sexual contact, blood and blood products 
and, according to the WHO, is 50 to 100 times more infectious than the human 
immunodeficiency virus (HIV) (Zuckerman, 1997).  It can remain stable and 
infectious on an environmental surface for more than 7 days (Shepard et al., 
2006). 
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Figure 1:  Geographical prevalence of HBV.  The prevalence of the hepatitis B surface 
antigen, a marker of chronic HBV infections, can be used to show the worldwide endemicity 
of HBV.  Source: http://www.library.northwestern.edu/govinfo/news/090519.jpg (accessed 
9 December 2009)  
 
1.2  Clinical manifestations of HBV infection 
 
The prevalence of HBV differs greatly in different parts of the world (figure 1).  
Areas with low HBV endemicity (less than 1% chronic infections) include North-
western Europe, North America and Australia (de Franchis et al., 2003).  
Transmission of the virus in these countries occurs mainly via high risk sexual 
activity and injection drug use.  Areas with intermediate HBV endemicity 
(between 1% and 8% chronic infections) include the Mediterranean, Middle East 
and the Indian subcontinent.  Sub-Saharan Africa, South East Asia, the Pacific 
Islands and parts of the Arctic are classified as regions highly endemic for HBV 
with a chronic infection prevalence of greater than 8% (Brechot, 1996; de 
Franchis et al., 2003; Fattovich, 2003).  In South East Asia, the source of infection 
in highly endemic regions is mainly perinatal (with a small contribution from  
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Figure 2:  Outcomes of HBV infection.  This schematic representation provides a 
summary of the natural history of HBV infections. 
 
transplacental transmission) whereas in sub-Saharan Africa, infections are mainly 
transmitted through horizontal infection during infancy and early childhood.  
Clinical observations have shown that HBV infection can evolve from acute 
hepatitis to chronic hepatitis, cirrhosis and finally HCC (figure 2) (Brechot, 1996).  
The outcome of an infection is determined largely by the host’s immune response, 
with the severity of the hepatic injury correlating directly with the strength of this 
immune response to one or more of the viral proteins (Rehermann et al., 1995; 
Villeneuve, 2005).  Persistent infections can be separated into three distinct 
clinical states based on their serological profiles: chronic HBV, inactive or 
asymptomatic carriers, and occult HBV (table 1) (Torbenson and Thomas, 2002).  
 
Table 1:  Serological profiles of patients with HBV infection (Torbenson and Thomas, 2002). 
 
Serological 
Tests 
HBV 
Immunisation 
Acute 
HBV 
HBV 
Recovery Chronic HBV 
Inactive or 
asymptomatic 
carrier 
Occult HBV 
Anti-HBs + - + - - - / + 
Anti-HBc  
- + + + + - / + 
Anti-HBe 
- - + - + - / + 
HBsAg 
- + - + + - 
HBeAg 
- + - + - - / + 
HBV DNA 
- + - +, >105 copies +, <105 copies +, <103 copies 
Perinatal or 
childhood acute 
infection 
Recovery Adult acute infection Recovery 
Chronic 
Infection 
Chronic Hepatitis 
Cirrhosis 
Transplantation / death Decompensation HCC 
Inactive 
carrier state 
 
Occult Hepatitis 
? 
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1.2.1  Acute infections  
 
Acute HBV infections have an average incubation period of 90 days (range: 60 – 
150 days) and can be defined as an abrupt clinical, biochemical, and/or 
histopathological manifestation of hepatic injury that occurs within six months of 
HBV exposure and that resolves spontaneously, in more than 90% of cases, within 
six months of the onset of symptoms (de Franchis et al., 2003; Raimondo et al., 
2003; Shepard et al., 2006).  Clinical symptoms include nausea, vomiting, 
abdominal pain, fever, jaundice, dark urine, changes in stool colour, and 
hepatomegaly (Shepard et al., 2006).  HBV DNA can normally be detected one to 
two weeks after exposure, during which time patients generally have no 
symptoms and only very slightly increased serum alanine aminotransferase (ALT) 
levels (Fattovich, 2003; Huang et al., 2006).  The first serological HBV markers, 
namely HBsAg and hepatitis B e antigen (HBeAg) may be detected (Fattovich, 
2003; Shepard et al., 2006).   
 
Two to six weeks after exposure patients enter an immunoactive phase that is 
characterised by a decrease in serum HBV DNA and an increase in ALT levels 
and histological activity, indicating lysis of infected hepatocytes by the host’s 
immune system.  HBV antibodies, including antibodies to the hepatitis B core 
antigen (Anti-HBc), can be detected between four and eight weeks post exposure 
(Huang et al., 2006; Shepard et al., 2006).  In the third phase of an acute HBV 
infection, there is a reduction of serum HBV DNA to below 105 copies per ml, 
normalisation of ALT levels, resolution of any necroinflammation and 
seroconversion from HBeAg to anti-HBe (Fattovich, 2003).   
 
Patients are considered to have resolved the HBV infection when they become 
HBsAg negative and develop antibodies to HBsAg (anti-HBs), indicating 
clearance of the virus (Yim and Lok, 2006). 
   
A severe form of acute HBV infection is fulminant hepatitis in which the course 
of the infection is complicated by encephalopathy, with HBsAg often being 
undetectable at the time of diagnosis (de Franchis et al., 2003).  The severity of 
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the liver injury in fulminant hepatitis indicates a vigorous immune response from 
the host and is associated with rapid viral clearance (Villeneuve, 2005). 
 
1.2.2  Chronic infections  
 
Chronic HBV infections can be defined as the presence of HBsAg in the serum of 
an infected individual for at least six months or as the presence of HBsAg in a 
patient negative for immunoglobulin (Ig) M antibodies to the hepatitis B core 
antigen (HBcAg) (Shepard et al., 2006).  Approximately 90% of babies 
perinatally infected with HBV and 30% of children horizontally infected develop 
chronic infections, but only 5 - 10% of adult infections become chronic (de 
Franchis et al., 2003; Huang et al., 2006; Yim and Lok, 2006).  Most chronically 
infected individuals present with HBeAg-positive chronic hepatitis B ten to thirty 
years after their initial infection (Fattovich, 2003).  Chronic HBV infections can 
be divided into four phases: immune tolerance; immune clearance (HBeAg 
positive); inactive carrier (HBeAg negative) and reactivation, although not all 
individuals pass through every phase (Yim and Lok, 2006).   
 
In the initial immune tolerance phase, analogous to the incubation period of an 
acute infection, infected individuals have high HBV viral loads and are positive 
for HBeAg (Villeneuve, 2005).  Their ALT levels are normal and there is minimal 
or no liver inflammation.  Most of those infected at birth or in early childhood 
pass through this phase, which can last between one and four decades (de Franchis 
et al., 2003; Yim and Lok, 2006).  In individuals infected in later childhood or as 
adults this phase is either very short or completely absent.   
 
The second phase, the immune clearance phase, can be compared to symptomatic 
hepatitis in acutely infected individuals.  HBeAg persists along with high HBV 
viral loads and abnormal ALT levels (de Franchis et al., 2003; Villeneuve, 2005; 
Yim and Lok, 2006).  The immunological response of the host results in active 
inflammation of the liver tissue, and hence progressive liver damage.  There is an 
increased T cell response to HBcAg and HBeAg resulting in the lysis of infected 
hepatocytes and flares of aminotransferase levels.  The frequency and the severity 
of these flares increase the risk of cirrhosis and HCC developing.  The immune 
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clearance phase culminates in seroconversion from HBeAg to anti-HBe.  This 
seroconversion occurs spontaneously at a rate of 5 – 10% per year, but may also 
result from treatment with interferon or other nucleoside analogs.   
 
The third phase of chronic HBV infection, the inactive carrier state, is 
characterised by the absence of HBeAg, the presence of HBsAg and anti-HBe, 
low or undetectable serum HBV DNA levels (<105 copies/ml), minimal to no 
liver inflammation and normal ALT  levels.  In some individuals, this state may 
persist indefinitely resulting in a sustained remission and a generally good 
prognosis.   
 
Approximately 1 - 5% of chronically infected individuals progress from the 
inactive carrier state to the fourth phase of infection, where there is a reactivation 
of HBV replication leading to HBeAg-negative chronic hepatitis B.  HBsAg, anti-
HBe and HBV DNA are all detectable in the serum but HBeAg is not, ALT levels 
are elevated and there is necro-inflammation of the liver tissue.   
 
Annually, approximately 8 - 10% of patients with HBeAg-negative chronic HBV 
infections develop cirrhosis compared to 2 - 5% in HBeAg-positive patients 
(Villeneuve, 2005; Yim and Lok, 2006).  Patients with chronic HBV infections 
and cirrhosis have a five year cumulative risk of 15 - 20% of developing HCC.  
Additional risk factors for the progression to cirrhosis and HCC include being 
male (suggesting a tumourogenic effect of androgens especially high serum 
testosterone levels); older age; alcohol abuse (a six fold higher risk of progression 
to cirrhosis); co-infection with HCV, HDV or HIV; aflatoxin exposure; cigarette 
smoking; increased levels of HBV replication and the genotype of the HBV 
infection (Fattovich, 2003; Villeneuve, 2005; Chan and Sung, 2006; Yim and 
Lok, 2006). 
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1.2.3  Occult Infections 
 
Occult HBV infections (OBIs) are defined as  
“the existence of HBV DNA in serum, lymphoid cells (PBMC) and / or the liver 
and virus genome replicative intermediates (i.e. covalently closed circular DNA 
(cccDNA) and / or mRNA) in lymphoid and / or hepatic tissue in the absence of 
serum HBV surface antigen, symptoms and biochemical evidence of liver 
injury” (Michalak et al., 2007). 
 
OBIs can therefore only be definitively diagnosed by the detection of HBV DNA 
in the liver tissue.  Screening for HBV DNA in the serum alone underestimates up 
to 40% of the OBI cases (Gibney et al., 2008).   
 
The existence of OBI was first suspected early in the 1980s with the first cases 
being reported from the mid 1980s (Raimondo et al., 2007).  In these cases, a 
number of both alcoholic and non-alcoholic patients with varying degrees of liver 
damage from normal liver function to alcoholic cirrhosis were reported to have 
HBV DNA present in their serum in the absence of HBsAg (Nalpas et al., 1985).  
The transmissibility of these infections was demonstrated by injecting serum from 
two individuals (negative for all conventional HBV markers, but positive for HBV 
DNA) into two chimpanzees, which subsequently developed acute hepatitis 
(Thiers et al., 1988).  Over the years, OBIs have been variably called 
“serologically silent hepatitis B”, “silent hepatitis B”, “surface antigen negative 
carriers”, “inapparent HBV”, “unrecognised HBV” and “cryptic” infections 
(Torbenson and Thomas, 2002; Pollicino et al., 2004).  Approximately 20% of all 
OBIs are negative for all serological HBV markers (termed seronegative OBI), 
with the remainder being positive for anti-HBc and/or anti-HBs in the serum 
(seropositive OBI) (Raimondo et al., 2008a; Hollinger and Sood, 2010).   
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Figure 3:  Animal models of occult infections.  Occult HBV infections have been 
detected in (A) woodchucks (Marmota monax) and (B) ground squirrels (Spermophilus 
beecheyi).  Photograph (A) by Eiffelle and photograph (B) by Thomas O'Brien. 
 
 
1.2.3.1  Occult woodchuck hepatitis virus infections 
Occult infections have been identified in both ground squirrels and woodchucks 
(figure 3) infected with the ground squirrel hepatitis virus (GSHV) and 
woodchuck hepatitis virus (WHV) respectively (Raimondo et al., 2007).  WHV is 
closely related to HBV especially in terms of its molecular and pathobiological 
properties (Coffin et al., 2004).  Woodchucks that have recovered both 
serologically and histologically from acute hepatitis, maintain a lifelong 
persistence of small amounts of viral DNA in both their liver and lymphoid 
tissues, with the liver being the main site of viral replication (Michalak et al., 
1999).  The occult infections frequently result in a low grade inflammation of the 
liver tissue and HCC develops in approximately 20% of woodchucks within three 
to five years of apparent resolution of the acute infection (Michalak et al., 1999). 
 
(B) 
(A) 
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Antibodies against WHV core antigen (anti-WHc) alone can be detected 
continuously in seropositive OBI as opposed to seronegative OBI, where 
serological markers are absent (Michalak et al., 1999; Coffin et al., 2004).  The 
maintenance of anti-WHc indicates a sustained stimulation of the woodchuck 
immune system by the nucleocapsid proteins and the presence of small amounts 
of WHV covalently closed circular (ccc) DNA indicate low levels of ongoing 
viral RNA transcription and protein translation (Menne et al., 2007).  A 
subsequent study has shown that female woodchucks with occult infections can 
transmit WHV to their offspring as an asymptomatic, serologically-negative 
infection that progresses for years post-natally and, in some cases, results in HCC.  
This virus was shown to be biologically competent because WHV could be 
transmitted from the offspring to healthy animals (Coffin and Michalak, 1999). 
 
In the woodchuck, OBIs have been divided into two categories:  
 primary occult infections (POIs), which are confined to the lymphatic 
system and have very low levels of replication (Michalak et al., 2004; 
Michalak et al., 2007).  These infections are found in offspring born to 
dams recovered from acute infections and experimentally in adult 
woodchucks inoculated with either small doses of WHV (<103 viral 
genome equivalents (vge)) or with lymphoid cells from animals with long 
resolved acute infections.  The POIs found in the woodchuck are negative 
for all serological markers and are thus analogous to seronegative OBIs in 
humans and do not confer protection against subsequent infection. 
 
 secondary occult infections (SOIs) occur in both the liver and lymphatic 
tissues of woodchucks following recovery from an acute infection 
(Michalak et al., 2004; Michalak et al., 2007).  SOIs are negative for 
WHV surface antigen (WHsAg) but positive for anti-WHc and sometimes 
antibodies to WHsAg (anti-WHs), making them analogous to seropositive 
human OBIs.  They provide protection against re-exposure to pathogenic 
doses of WHV (Mulrooney-Cousins and Michalak, 2007). 
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1.2.3.2  Methods of OBI detection 
Occult HBV is characterised by low copy numbers of viral genomes per cell in 
liver tissue and very low levels of circulating viral DNA - serum levels below 
103 vge/ml and averaging 102 vge/ml (Brechot et al., 2001).  These levels are 
much lower than those found in HBsAg positive, HBeAg negative sera, which 
average 104 vge/ml and HBsAg positive, HBeAg positive sera which have more 
than 108 vge/ml (Brechot et al., 2001; Chemin and Trepo, 2005).  The reasons for 
these very low levels are not known but it is thought that both host and viral 
factors could contribute (Carreno et al., 2008).  The host immune response is 
hypothesised to play a role in keeping viral replication levels low, a theory 
supported by the fact that viral replication is reactivated in immunosuppressed 
patients with OBI.    
 
Although OBIs can be diagnosed by the testing of serum or peripheral blood 
mononuclear cells (PBMCs) for HBV DNA using a highly sensitive PCR, the 
most accurate way of identifying these infections is by the detection of HBV 
DNA in the liver (Mulrooney and Michalak, 2003; Carreno et al., 2008; 
Raimondo et al., 2008a).  Total DNA extractions using Proteinase K digestion, 
followed by phenol-chloroform extraction and ethanol precipitation, result in 
maximum amounts of high quality nucleic acid and so are preferred to ready-to-
use extraction kits (Michalak et al., 2007).   
 
The detection of HBV DNA in the absence of HBsAg by the nested PCR 
amplification of at least three non-overlapping, highly conserved regions of the 
HBV genome, with viral DNA being detected in at least two of these regions, is 
the gold standard for detection of OBI (Brechot et al., 2001; Raimondo et al., 
2007; Raimondo et al., 2008a).  The sensitivity and specificity of detection can be 
increased by Southern hybridisation of the nested PCR amplicons using an HBV 
specific probe (Mulrooney-Cousins and Michalak, 2007).   
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1.2.3.3  Molecular characterisation of HBV isolated from OBIs 
It is very difficult to clone full-length genomes from low viraemic carriers and 
therefore only a limited number of such genomes have been isolated and 
characterized from OBIs (Hass et al., 2005).  Irrespective of genotype, amino acid 
diversity within the pre-S / S region was shown to be significantly higher in 
strains from OBI sera compared to strains from chronic carriers, (Candotti et al., 
2008).  There was also a significant increase in nucleotide diversity in strains 
isolated from anti-HBs-positive individuals compared to samples without this 
marker.  Substitutions appeared to be concentrated in the Major Hydrophilic 
Region of the S antigen as well as the CD8+ cytotoxic T-lymphocyte epitopes 
(Candotti et al., 2008). 
 
1.2.3.4  Clinical implications of occult infections 
There are three main clinical implications of OBIs: 
 Transmission 
The presence of anti-HBs was previously considered to signal resolution 
of HBV infection, but the identification of OBIs means that blood positive 
for anti-HBs alone cannot be safely used for transfusion.  Transmission of 
HBV to two immunocompetent transfusion recipients from an anti-HBs 
positive occult HBV carrier was recently demonstrated (Levicnik-Stezinar 
et al., 2008).  Thus, serological testing of blood alone is not sufficient to 
guarantee the safety of the blood.   Nucleic acid testing (NAT) of blood 
donations for the presence of HBV DNA is therefore routinely used and in 
South Africa and Brazil, this method of testing has detected a number of 
occult infections (Almeida and Cardoso, 2006; Allain et al., 2009).  
Furthermore, there is a risk of transmission of HBV to orthotopic liver 
transplant recipients from OBI donors.  Therefore NAT of donors is 
recommended (Ciesek et al., 2008; Raimondo et al., 2008b). 
 
 Reactivation 
Reactivation of OBI occurs frequently in individuals undergoing 
immunosuppressive therapy, for example in patients who have received 
organ transplants - particularly liver, kidney and bone marrow – and in 
those receiving systematic chemo-, radio- or immuno-therapy (Besisik et 
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al., 2003; Knoll et al., 2006; Raimondo et al., 2008a).  OBIs are also often 
reactivated in HIV-positive individuals (Mulrooney-Cousins and 
Michalak, 2007).  The prevalence of occult HBV and HIV co-infections 
remains controversial with reports varying from 0% to 89% (Cohen Stuart 
et al., 2009).  In South Africa, between 7,5% and 22% of HIV-positive and 
2,4% of HIV-negative individuals have been reported to be positive for 
OBIs (Mphahlele et al., 2006; Firnhaber et al., 2009). 
 
 Liver disease 
Individuals with OBI and HCV co-infections have an increased risk of 
developing severe liver disease (Cacciola et al., 1999).  OBIs appear to 
interfere with the clinical outcomes of chronic HCV infections and favour 
or accelerate the progression to cirrhosis.  Individuals with OBI alone also 
have an increased risk of developing chronic liver disease and HCC 
(Pollicino et al., 2004; Ikeda et al., 2009).  The precise role of OBIs in 
malignant transformation is however unclear (Ikeda et al., 2009). 
 
In a recent paper, Hollinger and Sood (2010) cautioned that not all cases of occult 
HBV are clinically relevant because detection of HBV DNA only in the serum 
does not always translate into infectivity of the virus and they therefore 
differentiate between occult hepatitis B (OHB) and OBI.   
 
“False” cases of OBI can be identified by serum HBV DNA levels that are 
comparable to those detected at the various stages of serologically evident 
infections (Raimondo et al., 2008a; Raimondo et al., 2008b).  These “false” cases 
are usually the result of infections with surface gene mutant HBV strains that 
produce a modified HBsAg that is not recognised by the detection assay leading 
to the HBsAg-negative phenotype.   
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Figure 4:  Structures of HBV 
Panel A:  Electron micrograph of HBV virions.  This electron micrograph shows 
complete virions (v) as well as spherical (s) and filamentous (f) subviral particles which can 
be detected in the blood of chronic carriers. 
Panel B:  The architecture of a Dane particle.  This schematic shows the structural and 
enzymatic proteins found within the Dane particle (modified from Lai and Locarnini, 
2002). 
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1.3  HBV structure 
 
The viral agent responsible for hepatitis B was first isolated by Blumberg et al. in 
1965.  Five years later, in 1970, Dane et al. described the 42 nm complete HBV 
virion particle, which they called the Dane particle (Kann, 2002).  Electron 
microscopy of the serum of infected individuals has shown two types of particles 
– the 42 nm to 47 nm Dane particles at a titre of up to 109 particles per ml, as well 
as an excess of 20 nm spherical subviral particles at a concentration of up to 
1014 spheres per ml (Kann, 2002).  These subviral particles (figure 4, panel A) 
consist of viral surface proteins and host-derived lipid components and are not 
infectious as they lack nucleic acids (Ganem, 1996).  The Dane particle (figure 4, 
panel B) is double shelled with the outer shell or envelope consisting of viral 
surface particles embedded in host derived lipid and the inner shell consisting of 
an icosahedral nucleocapsid composed of viral core protein (Kann, 2002; Huang 
et al., 2006).  
 
A 3,2 kb relaxed circular partially double stranded DNA molecule, together with a 
covalently bound viral polymerase protein on the 5’ end of the negative strand, is 
contained within the nucleocapsid.  The negative or minus strand of the DNA 
molecule has a defined nick and a terminal redundancy of seven to nine 
nucleotides (Kann, 2002; Huang et al., 2006).  The positive or plus strand is of 
variable length and shorter than the negative strand (Kann, 2002; Yokosuka and 
Arai, 2006).  The binding of the viral polymerase protein to the 5’-end of the 
negative strand, means that the negative strand is not covalently closed.  The 
positive strand bridges this gap and keeps the genome circular by base pairing on 
either side of the gap to the complementary negative strand.  
 
1.3.1  HBV gene products 
 
The HBV genome has four overlapping open reading frames (ORFs) encoding the 
polymerase, envelope, core and X gene products (figure 5).   
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Figure 5:  The organisation of the HBV genome.  The 3,2 kb HBV genome has four 
overlapping open reading frames (drawn as arrows) encoding seven different transcripts.  
The negative strand has a 7 to 9 nucleotide terminal redundancy and the viral polymerase 
(purple oval) is linked to its 5’ end.  The variable length of the positive strand is represented 
by the dotted line.  The 5’ end of the positive strand is capped by an RNA primer ( ).  
The positions of the two 11 nucleotide direct repeat sequences (DR1 and DR2) are shown. 
 
1.3.1.1 Polymerase gene 
The polymerase protein is translated from the pregenomic RNA and consists of 
between 834 and 845 amino acids.  It has at least four domains – the N-terminal; 
spacer; polymerase and C-terminal domains (Kann, 2002; Yokosuka and Arai, 
2006).  The N-terminal domain contains a tyrosine residue, whose hydroxyl group 
is necessary for the binding of the polymerase protein to the first nucleotide of the 
negative DNA strand, and hence it primes negative strand synthesis.  The C-
terminal domain encodes an RNaseH that removes the template RNA during 
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replication, allowing for the synthesis of the positive DNA strand.  The HBV 
polymerase protein is both structurally and functionally similar to the HIV reverse 
transcriptase, both of which contain a classical tyrosine-methionine-aspartic acid-
aspartic acid (YMDD) motif in their catalytic centres.  Mutations within this motif 
are often associated with resistance to nucleoside analogs, such as lamivudine 
(Yokosuka and Arai, 2006). 
 
1.3.1.2 Surface gene 
The surface gene has three in-frame initiator codons encoding three different 
proteins, all of which terminate at a single stop codon (Chouteau et al., 2001).  
These three proteins, termed the small (S), middle (M) and large (L) proteins, all 
share an identical 226 amino acid C-terminal region called the surface domain 
(Barrera et al., 2005).  The M protein contains an additional 55 amino acid N-
terminal domain called the pre-S2 domain, and the L protein is further extended in 
the N-terminal direction with the addition of the 108 amino acid pre-S1 domain.  
Posttranslational modifications of all three proteins into glycoproteins contribute 
to their biological activities (Chouteau et al., 2001).   
 
The three surface glycoproteins all contain the “a” determinant epitope, located at 
codon positions 124 to 147 of the S gene.  The “a” determinant is one of the main 
initial immune response targets of anti-HBs antibodies during acute hepatitis B 
and amino acid substitutions within this determinant can lead to conformational 
changes affecting the binding of neutralising antibodies (Chongsrisawat et al., 
2006; Lada et al., 2006).  The serological subtype of the virus is determined by 
two additional determinants: a lysine residue at codon 122 denotes a subtype d 
whereas an arginine at this position denotes a subtype y ; a lysine at codon 
position 160 denotes subtype w whereas an arginine denotes subtype r (Kann, 
2002).  The amino acid residue at codon 127 further differentiates the w 
serological subtypes into w1 to w4.  The adr subtypes are further divided into q+ 
and q- (Courouce-Pauty et al., 1978).  By combining these different determinants, 
a total of nine different serological subtypes have been identified (Yokosuka and 
Arai, 2006).  Initially, HBV isolates were grouped according to their serological 
subtype or serotype (Magnius and Norder, 1995).  These serotypes however did 
not correspond with the geographical distribution of HBV and so this 
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classification was superseded by the classification of HBV into genotypes (section 
1.5), which display a geographical distribution. 
 
The surface or envelope proteins play a vital role in the host specificity of the 
virus.  During the viral life cycle, the virus binds to the surface of the hepatocyte 
and fuses with it (Chouteau et al., 2001).  The nucleocapsid is then released into 
the cytosol where it migrates to the hepatocyte nucleus.  In vitro studies have 
shown that if the normal pathway of viral entry is artificially bypassed, HBV is 
able to replicate in the hepatocytes of a different species, indicating that it is the 
binding of the virus to the hepatocyte’s surface that confers host specificity 
(Chouteau et al., 2001).  This binding depends on the interaction of the viral 
envelope glycoproteins with cellular receptors on the surface of the hepatocyte 
(Barrera et al., 2005).  Differences in the structural features of the receptors 
between species would explain the specificity of hepadnaviral infections.  In vitro 
experiments have shown that if the N-terminal portion of the L protein 
(specifically amino acids 1 to 10 and 21 to 30) from the woolly monkey hepatitis 
B virus, which normally cannot infect human hepatocytes, is replaced with its 
HBV counterpart, infection can be achieved (Chouteau et al., 2001).  Studies 
using the duck hepatitis B virus (DHBV) have identified carboxypeptidase D as 
the cellular receptor to which the DHBV surface proteins bind on duck 
hepatocytes, but the cellular receptor for HBV in humans has not yet been 
identified (Chisari, 2000; Chouteau et al., 2001).  A recent study using primary 
Tupaia hepatocyte cultures has suggested that cell surface heparan sulphate 
proteoglycans are low affinity receptors for HBV (Leistner et al., 2008). 
 
1.3.1.3 Core gene 
The core gene encodes two proteins that are translated from two different 
transcripts.  The pregenomic RNA (pgRNA) is translated into the core protein and 
the polymerase, whereas the precore messenger RNA (mRNA) is translated into 
the precursor of HBeAg (Yokosuka and Arai, 2006; Sugiyama et al., 2007).  The 
core and precore proteins are post-translationally processed, differing only in their 
N-terminus amino acids (Huang et al., 2006; Sugiyama et al., 2007).   
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The core protein, a structural protein, is 183 – 185 amino acids in length 
depending on the genotype of the virus and, compared to the envelope gene, is 
relatively well conserved (Jazayeri et al., 2004; Yokosuka and Arai, 2006).  This 
protein dimerises in the cytoplasm of the hepatocyte and, after reaching a 
concentration threshold of 0,8 µM, spontaneously assembles into the icosahedral 
capsid (Kann, 2002; Yokosuka and Arai, 2006).  World-wide, the distribution of 
HBV tends to follow a geographical pattern, but the ethnic background of an 
infected individual also seems to play a role.  Infected individuals with related 
ethnicity often have common amino acid substitutions in specific regions of the 
core gene, despite the individual’s current geographical location.  It is 
hypothesised that these substitutions may be driven by host T-cell selection 
(Jazayeri et al., 2004).   
 
The HBeAg is a soluble, secreted, non-particulate form of the viral nucleocapsid 
that is not necessary for either viral replication or infection (Cabrerizo et al., 
2000; Visvanathan et al., 2007).  It differs from the core protein in that it contains 
an extra 29 amino acids at the amino end (Kann, 2002).  The role of HBeAg in the 
viral life cycle is not well understood although production of this antigen is 
thought to be required for the establishment of persistent infections in acutely 
infected individuals (Jazayeri et al., 2004).  In vitro, HBeAg has been shown to 
slow the replication of HBV DNA by reducing dimerisation of the core antigen 
and hence decreasing the encapsidation of pgRNA, which in turn induces 
immunological tolerance (Yokosuka and Arai, 2006).  HBeAg negative chronic 
HBV is often associated with more aggressive liver disease (Visvanathan et al., 
2007). 
 
1.3.1.4 X gene 
The HBV X-protein (HBx) is another non-structural protein, 154 amino acids in 
length (Hoare et al., 2001).  Found only in the orthohepadnaviridae, the precise 
function of HBx is not well understood although it appears to be essential for the 
establishment of viral infections in mammalian animal models (Scaglioni et al., 
1996; Kann, 2002; Yokosuka and Arai, 2006).  In vitro, HBx has been shown to 
activate the AP-1 and NF-κB signalling pathways and to bind to p53 (Yokosuka 
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and Arai, 2006).  HBx also appears to have an enhancing effect on the metabolism 
of intrahepatic purines and pyrimidines needed for the efficient replication of 
HBV.  Carboxyl terminally truncated forms of HBx have been known to integrate 
into the host genome of chronically infected individuals and are believed to play a 
role in the development of HCC (Poussin et al., 1999; Yokosuka and Arai, 2006). 
 
1.3.2  cis-acting elements 
 
The HBV genome contains a number of both ubiquitous and hepatocyte specific 
transcription factor binding sites, parts of which cluster in the enhancer 1 (Enh1) 
and 2 (Enh2) regions.  Enh1 spans approximately 200 nucleotides between the S 
and X genes and is the major enhancer, stimulating transcription of all the viral 
RNAs (Kann, 2002).  Both ubiquitous (e.g. NF-1, AP-1 and NF-κB) and liver cell 
specific (e.g. C/EBP, HNF4 and HNF3) transcription factors bind to the Enh1 
region.  Enh2 is located immediately upstream of the core ORF and confers 
hepatocyte specificity on the virus as it binds only liver specific transcription 
factors such as C/EBP and HNF-4 (Kann, 2002; Chang et al., 2004).  Two 11 
nucleotide direct repeat sequences (DR1 and DR2) are located one on either side 
of the gap in the negative DNA strand.  DR1 is located at nucleotides 1826 – 1836 
and DR2 at nucleotides 1592 – 1602 (Jilbert et al., 2002).  Both these direct repeat 
sequences are necessary for the replication of HBV. 
 
1.4  HBV replication 
 
The HBV life cycle (figure 6) begins with the binding of the enveloped virion, 
most likely via the pre-S proteins, to a specific but as yet unidentified receptor on 
the surface of the hepatocyte (Ganem, 1996; Pawlotsky, 2005).  The viral 
envelope fuses with the membrane of the host cell and delivers the nucleocapsid 
into the cytoplasm.  The viral genomic DNA is transferred to the nucleus where it 
is converted into cccDNA using the host cell’s enzymes (He et al., 2002).  During 
this process, the viral polymerase protein bound to the 5’-end of the negative 
strand, as well as the 7 - 9 nucleotide terminal redundancy, is removed and the 
two ends of the DNA strand are ligated (Caselmann, 1994).  An endogenous DNA  
21 
 
 
Figure 6:  The life cycle of hepadnaviruses (Ganem and Prince, 2004).  HBV virions bind 
to an as yet unidentified receptor on the hepatocyte surface and are internalised.  The 
nucleocapsid is released into the cytoplasm and migrates to the nucleus where the partially 
double stranded DNA genome is converted into cccDNA.  This cccDNA serves as template 
for the transcription of the pgRNA and subgenomic mRNAs that are translated in the 
cytoplasm into the viral proteins.  Progeny viral capsids are assembled using the pgRNA, 
core and polymerase proteins.  The pgRNA is reverse transcribed into viral DNA within the 
capsid and the mature nucleocapsids either bud into the preGolgi compartment where they 
are enveloped and exported from the cell via the endoplasmic reticulum or else the genome 
is recycled back into the nucleus to be converted into cccDNA. © 2004 Massachusetts 
Medical Society.  All rights reserved. 
 
polymerase then completes the positive strand forming the cccDNA (Laras et al., 
2006).  As chronic HBV infections progress, there is a decrease in viral 
replication and cccDNA becomes the predominant form of HBV DNA with a 
stable pool of between 5 and 50 cccDNA molecules found inside an infected 
hepatocyte’s nucleus (He et al., 2002).  In patients with HCC, the levels of 
cccDNA in tumourous compared to non-tumourous liver tissue are significantly 
higher (Wong et al., 2006).  The cccDNA molecules serve as template for the 
transcription of five different unspliced mRNAs of 3,5 kb (pgRNA and envelope 
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mRNAs); 2,4 kb (LHBs mRNA); 2,1 kb (MHBs and SHBs mRNA) and 0,9 kb (X 
mRNA) which are translated into seven different proteins – the pre-S1, pre-S2, S, 
polymerase, X, core and precore (Kann, 2002).  Once the pgRNA is synthesised, 
packaged into nucleocapsids and translocated to the cytoplasm, genomic 
replication begins.   
 
Replication of the HBV genome begins with the 5’ capping and 3’ 
polyadenylation of the 3,5 kb pgRNA transcript.  This transcript has identical 
terminal redundancies of roughly 200 bp (including the 11 nucleotide DR1 
sequence) at both the 3’ and 5’ ends (Ganem, 1996).  DR2 is found on the 3’ end 
of the pgRNA only (Jilbert et al., 2002).  Approximately 100 bp of this terminal 
redundancy encodes for a RNA stem-loop structure called the encapsidation 
signal, ε, which is phylogenetically conserved in all hepadnaviruses although 
there is significant sequence variation between the avi- and orthohepadnaviruses.  
The HBV polymerase binds to the bulge of the 5’ ε structure initiating 
encapsidation of the pgRNA (Jilbert et al., 2002).  In the cytoplasm, newly 
synthesised core protein dimerises, and then multimerises, to form a single capsid 
of 180 – 240 core particles which encapsidate the HBV pgRNA and polymerase 
(Zhou and Standring 1992; Seifer et al. 1993; Lingappa et al. 2005).   
 
Transcription is initiated by the binding of the HBV polymerase to the 5’ ε 
structure and the synthesis of the first three nucleotides (5’ – GAA – 3’) of the 
negative strand.  The polymerase, together with this covalently attached 3 
nucleotide oligonucleotide, transfers to the 3’ DR1 region which contains a 
complementary acceptor site for this oligonucleotide primer, and synthesis of the 
negative DNA strand proceeds.  As the negative strand extends, the RNaseH 
activity of the HBV polymerase simultaneously degrades the pgRNA template, 
stopping at the 5’ capped terminal 18 nucleotides which include the DR1 
sequence.  This 18 nucleotide RNA primer is then transferred to the 5’ end of the 
newly synthesised negative strand where it anneals to DR2, priming synthesis of 
the positive strand.  The positive strand contains the 18 nucleotide terminal 
redundancy on its 3’ end, enabling it to “jump” to the 3’ end of the negative 
strand, circularising the genome and allowing synthesis of the positive strand to 
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continue for a variable length.  This process results in a partially double stranded, 
relaxed circular DNA genome with the polymerase protein covalently attached to 
the 5’ end of the negative strand, characteristic of HBV.  The DNA containing 
nucleocapsids are enveloped by HBV surface proteins in the pre-Golgi 
compartment of the endoplasmic reticulum and are secreted, via the vesicular 
transport pathways, into the blood as complete Dane particles (Caselmann, 1994; 
Ganem, 1996; Schormann et al., 2006). 
 
The HBV reverse transcriptase lacks 3’ – 5’ exonuclease proof-reading activity 
resulting in an increased number of nucleotide substitutions during replication and 
hence the formation of viral ‘quasispecies’ within an infected individual 
(Pawlotsky, 2005).  The frequency of mutation in HBV ranges from 510−  to 410−  
substitutions per site per year, which is 410  times higher than that of DNA 
viruses, but approximately the same as that of RNA retroviruses ( )510−  (Holland 
et al., 1982; Kramvis et al., 2005a; Jazayeri et al., 2009).  Furthermore, the four 
overlapping ORFs of HBV places certain conservatory constraints on its 
variability (Miyakawa and Mizokami, 2003).  Over the course of an infection, the 
immune response of the individual, as well as any drug therapies, can result in 
different variants or mutations being selected for (Tong, 2005).  
 
1.5  HBV Genotypes 
 
An organism’s genotype can be defined as its genetic constitution (Hale and 
Margham, 1988).  In viruses, the term genotype refers to the replication 
competent sequence into which the genome has stabilised over a prolonged period 
of time (Francois et al., 2001).  The first four HBV genotypes (A – D) were 
identified by comparing 18 complete genomes and were shown to have an inter-
group divergence of between 8,5% and 10% and an intragenotype divergence of 
less than 5,6% (Okamoto et al., 1988).  In 1992, work by Norder et al. extended 
this to six genotypes and currently eight different genotypes (A – H) of HBV are 
recognised with two additional genotypes, I and J, having been proposed (Cao, 
2009; Kurbanov et al., 2009).  The different HBV genotypes are believed to 
influence HBeAg seroconversion rates, mutational patterns in the precore and core 
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promoter regions and the clinical manifestations and severity of HBV-related liver 
disease (Buti et al., 2005). 
 
When the first four genotypes of HBV were identified, none of the nucleotide 
divergences fell in the 6 - 8% range and so a sequence divergence of greater than 
8% in the entire HBV genome was used to separate isolates into genotypes 
(Kramvis et al., 2008).  As more sequences of complete HBV genomes have 
become available, an overlap between the inter- and intra-genotype divergences 
occurring between 6% and 8% has become evident.  A nucleotide divergence of 
greater than 7,5%  across the complete viral genome has therefore been proposed 
to separate the different strains of HBV into genotypes (Kramvis et al., 2008).  
Additionally, a sequence divergence of greater than 4% at the level of the S-gene 
has been shown to be sufficient to differentiate isolates into separate genotypes 
(Norder et al., 1993; Magnius and Norder, 1995).  The core and basic core 
promoter (BCP) regions of the HBV genome have also been used as an indication 
of genotype (Myers et al., 2006).  These two regions however contain greater 
variation than the surface gene and so the changes are not always genotype 
specific.  The classification of genotypes using these regions is therefore not as 
accurate as when the S ORF is used.   
 
Subgenotypes are separated on the basis of a complete nucleotide sequence 
divergence of between 4% and 7,5% and good bootstrap support (Kramvis et al., 
2008).  Five of the HBV genotypes (A, B, C, D and F) have been split into 
subgenotypes which, in certain instances, are separated either geographically or 
ethnically (table 2). 
 
 
25 
 
Table 2:  Relationship between HBV genotypes, subgenotypes, serotypes and their 
geographical distribution  
 
Genotype Sub-genotype 
Predominant 
Serotype 
Geographical 
Distribution References 
A A1 adw2 Sub-Saharan Africa, 
Southern Asia, Brazil, 
the Philippines 
2, 6, 11, 12 
 A2 adw2 Northern Europe, United 
States, the Arctic 10, 23, 36 
 A3 ayw1 Western and Central 
Africa, Cameroon, 
Gabon 
9, 14, 17 
 A4 ayw1 Mali, the Gambia 11, 19 
 A5 ayw1 Western Africa, Haiti 19, 31, 42 
 A6 ayw1, adw2 Democratic Republic of 
Congo, Rwanda 43 
 A7 ayw1, adw2 Cameroon, Rwanda 42 
   
 
 
B B1 adw2 Japan 10, 21 
 B2 adw2 Most of Asia except 
Korea 10, 21, 32 
 B3 adw2, ayw1 Indonesia 10, 21 
 B4 ayw1 Indonesia, Vietnam 10, 21, 32 
 B5 ayw1 Indonesia, Philippines 18, 21, 24, 32 
 B6 adw2 Alaska, Northern 
Canada, Greenland 22, 36 
 B7 ayw Eastern Indonesia 26 
 B8 ayw Indonesia 38 
   
 
 
C C1 adr, ayr Vietnam, Thailand, 
Myanmar 7 
 C2 adr China, Korea, Japan, 
Rwanda 7, 35 
 C3 adr Pacific Islands 
(Micronesia, Melanesia 
and Polynesia), 
Indonesia 
24, 36 
 C4 ayw3 Australia 4, 10 
 C5 adw2 Indonesia, Philippines, 
Vietnam 24 
 C6 adr Papua Indonesia 25 
 C7 adr Indonesia 38 
 C8  Philippines 33 
   
  
D D1 ayw2 Mediterranean Europe, 
Middle East, Egypt, 
India, Asia 
20, 23, 32 
 D2 ayw3 Russia, the Baltic 
region, India, Japan 28, 32 
 D3 ayw2, ayw3 Europe, Asia, South 
Africa, United States 20, 36 
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 D4 ayw2 Australia, Japan, Papua 
New Guinea, Rwanda 24, 35 
 D5 awy3 Eastern India 15, 34 
 D6 ayw2 Papua Indonesia 25 
 D7 ayw2 Tunisia, Algeria, 
Morocco 37 
 D8 ayw2 Niger 41 
   
  
E  ayw4 West and Central Africa 9, 13, 30 
   
  
F F1 adw4 Alaska, Argentina, 
Bolivia, Chile 1, 32 
 F2 adw4 Venezuela, Brazil, 
Nicaragua 1, 32 
 F3 adw4 Venezuela, Columbia, 
Panama 1, 32 
 F4 adw4 Argentina, Bolivia, 
France 32 
   
  
G  adw2 France, United States, 
Vietnam, Mexico, 
Canada 
3, 16, 36 
   
  
H  adw4 Mexico, Nicaragua, 
California 5, 8, 36 
   
  
I  adw, ayw Vietnam, Laos, 
Northeast India, 
Northwest China 
27, 29, 40, 44 
   
 
 
J  ayw Japan (might be from 
Borneo) 39 
 
1(Arauz-Ruiz et al. 1997)  
2(Bowyer et al. 1997)  
3(Stuyver et al. 2000)  
4(Sugauchi et al. 2001)  
5(Arauz-Ruiz et al. 2002)  
6(Kramvis et al. 2002) 
7(Huy et al. 2004)  
8(Kirschberg et al. 2004)  
9(Mulders et al. 2004)  
10(Norder et al. 2004)  
11(Hannoun et al. 2005)  
12(Kramvis et al. 2005a)  
13(Kramvis et al. 2005b) 
14(Kurbanov et al. 2005) 
15(Banerjee et al. 2006) 
16(Chudy et al. 2006)  
17(Makuwa et al. 2006)  
18(Nagasaki et al. 2006)  
19(Olinger et al. 2006)  
20(Kramvis and Kew 2007)  
21(Liu et al. 2007)  
22(Sakamoto et al. 2007)  
23(Schaefer 2007)  
24(Schaefer 2007b)  
25(Lusida et al. 2008)  
26(Nurainy et al. 2008)  
27(Olinger et al. 2008)  
28(Tallo et al. 2008) 
29(Tran et al. 2008)  
30(Andernach et al. 2009a)  
31(Andernach et al. 2009b)  
32(Cao 2009) 
33(Cavinta et al. 2009)  
34(Chandra et al. 2009)  
35(Hubschen et al. 2009)  
36(McMahon 2009)  
37(Meldal et al. 2009)  
38(Mulyanto et al. 2009)  
39(Tatematsu et al. 2009)  
40(Arankalle et al. 2010)  
41(Abdou Chekaraou et al. 
2010)  
42(Hubschen et al. 2010)  
43(Pourkarim et al. 2010)  
44(Yu et al. 2010)  
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 1.5.1  Genotypes and subgenotypes found in Africa 
 
1.5.1.1  Genotype A and its subgenotypes 
 
Genotype A has been found in Africa, Asia, Northern Europe, the United States 
and the Arctic (Hannoun et al., 2005; Kramvis et al., 2005b; McMahon, 2009).  It 
is characterised by a six nucleotide insertion at the carboxyl terminus of the core 
ORF resulting in an overall genomic length of 3221 nucleotides (Kramvis et al., 
2005a).  Genotype A isolates have a cytosine (C) residue at position 1858 that 
prohibits a guanidine (G) to adenine (A) point mutation at position 1896 and 
stabilises the encapsidation (ε) signal’s stem-loop structure (Sugauchi et al., 2004; 
Schaefer, 2007).     
 
The splitting of this genotype into subgenotypes is strongly supported 
phylogenetically, with 100% bootstrap values when complete genome sequences 
are analysed (Makuwa et al., 2006).  Subgenotype A1 is predominant in sub-
Saharan Africa including South Africa, Zimbabwe, Mozambique, Somalia and 
Malawi, and in India and Nepal and has also been found in Brazil, the Philippines 
and Yemen (Kramvis et al., 2005a).  Subgenotype A2 is predominant in Western 
Europe and the United States, as well as Alaska and Greenland.   Subgenotype A2 
has also been found in Argentina, Mexico, Venezuela, Nicaragua, Zanzibar and 
Kenya (Mwangi et al., 2008; Mbayed et al., 2009).  Subgenotype A3 can be found 
in Western African countries such as Cameroon and Gabon (Kurbanov et al. 
2005; Makuwa et al. 2006; Olinger et al. 2006).  Newer subgenotypes of genotype 
A have been tentatively designated subgenotypes A4 (found in Mali and the 
Gambia), A5 (found in Nigeria, Cameroon and Haiti) and A6 (found in Rwanda 
and the Democratic Republic of Congo) (Hannoun et al. 2005; Olinger et al. 
2006; Andernach et al. 2009b; Hubschen et al. 2010; Pourkarim et al. 2010). 
 
1.5.1.1.1  Subgenotypes A1 and A2 
Subgenotypes A1 and A2 can be separated on the basis of their distinct 
epidemiological distributions, but they also have marked virological differences.  
An example is an asparagine at position 207 and a leucine at position 209 in 
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subgenotype A1 isolates whereas subgenotype A2 isolates have a serine at 
position 207 and a valine at position 209 (Kimbi et al., 2004).  The genetic 
distance between subgenotypes A1 and A2 suggests that they diverged a relatively 
long time ago (Hannoun et al., 2005).   
 
Individuals infected with subgenotype A1 have lower levels of HBV DNA in their 
serum compared to those infected with A2, as well as a lower prevalence of 
HBeAg and a higher incidence (4,5 fold increased risk) of HBV-related HCC 
(Hasegawa et al., 2004; Kimbi et al., 2004; Kusakabe et al., 2007; McMahon, 
2009).  Individuals infected with subgenotype A2 have a lower rate of liver 
disease related deaths compared to individuals infected with the other genotypes, 
as well as a higher rate of sustained remission after seroconversion (Hasegawa et 
al., 2004).   
 
Subgenotype A1 isolates have unique double or triple point mutations (G1809T, 
A1811T and C1812T/G) in the precore Kozak sequence (Kimbi et al., 2004).  
Mutations in this region have been shown to reduce the translation of HBeAg by a 
ribosomal leaky scanning mechanism and could be responsible for the early loss 
of HBeAg seen in Southern African Blacks (Ahn et al., 2003).  Subgenotype A2 
isolates that have either decreased levels or a lack of HBeAg have a greater 
prevalence of the 1762T and 1764A double mutation in the precore promoter 
region (Schaefer, 2007).   
 
Within the pregenome ε signal there are a number of nucleotides that differ 
between the A1 and A2 subgenotypes (figure 7).  The third nucleotide in the six 
nucleotide ε bulge, nucleotide 1862, is a G in the majority of subgenotype A2 
isolates, as well as in the wild-type HBV, but most A1 isolates have a thymine (T) 
in this position (Kramvis et al., 1998).  At nucleotide 1888 in the upper stem, the 
A2s have a G while most A1s have an A, introducing an additional start codon in 
the precore region (Kimbi et al., 2004).  This extra start codon can affect the 
expression of the core protein leading to a decrease in levels of the virus (Kimbi, 
2005).  These nucleotide substitutions could account for the clinical differences 
observed between these two subgenotypes. 
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Figure 7:  Conformation of the pregenome (ε) signal for subgenotypes A1 and A2 
(Sugauchi et al., 2004).  A characteristic of genotype A isolates is the Watson-Crick pair 
between the C at nucleotide position 1858 and the G at nucleotide 1896.  Subgenotype A2 
isolates have a G at both nucleotide positions 1862 and 1888.  Approximately 80% of 
subgenotype A1 isolates have an 1862T and approximately 75% have an 1888A.  The 
initiation codon of the core gene is shaded in grey. 
 
1.5.1.1.2  Subgenotypes A3, A4, A5 and A6 
Subgenotype A3 has been found in Western and Central Africa (Kurbanov et al., 
2005; Makuwa et al., 2006).  Similar to subgenotype A1, subgenotype A3 isolates 
have a high intra-subgenotype nucleotide divergence (mean of 3,9% ± standard 
deviation of 1,1% (range 1,8% - 4,8%)) suggesting a long natural history in its 
native population (Kurbanov et al., 2005).  Three amino acid substitutions in the 
pre-S2 domain - N152S, P155Q and N174T – are specific for this subgenotype 
(Makuwa et al., 2006).   
 
Subgenotype A4, found in Mali and the Gambia, has also been proposed with a 
bootstrap value of 97% based on the complete genome (Olinger et al., 2006). The 
mean nucleotide divergence between this subgenotype and subgenotype A3, 
however, is only 3,8%, so it has been suggested that subgenotype A4 be 
considered a clade of subgenotype A3 as opposed to a separate subgenotype 
(Kurbanov et al., 2009).   
 
 
A1 - 
 
 
A2 - 
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A fifth subgenotype from Nigeria, subgenotype A5, has also been proposed 
(Olinger et al., 2006).  Additional complete genome sequences from Haiti and 
Cameroon, that cluster with the subgenotype A5s from Nigeria, have also been 
published (Andernach et al. 2009b; Hubschen et al. 2010). 
 
The proposed subgenotype A6 was isolated from three African-Belgian patients 
two of whom were originally from the Democratic Republic of Congo and one of 
whom was from Rwanda (Pourkarim et al. 2010).  The A6 isolates diverge at the 
main node from all other subgenotypes of A with high bootstrap support (94%) 
and have an inter-subgenotypic nucleotide divergence over the complete genome 
of greater than or equal to 4% when compared to the other subgenotypes of A. 
 
A seventh subgenotype of A was recently described in isolates from Rwanda and 
Cameroon (Hubschen et al. 2010).  Designation of these strains as a new 
subgenotype is based on good bootstrap support and a mean inter-subgenotype 
nucleotide divergence of at least 3,81 ± 0,24%. 
 
1.5.1.2  Genotype D and its subgenotypes 
 
Worldwide genotype D, with eight subgenotypes, is the most widely spread of all 
the genotypes but is found predominantly in the Mediterranean area, Eastern 
Europe, Russia and the Near and Middle East extending into India (Lazarevic et 
al., 2007; Abdou Chekaraou et al. 2010).  In Africa, isolates from subgenotype 
D1, D3, D4, D7 and D8 have been found in Egypt, South Africa, Rwanda, Tunisia 
and Niger respectively (Kramvis and Kew 2007; Hubschen et al. 2009; Meldal et 
al. 2009; Abdou Chekaraou et al. 2010).  Genotype D is characterised by a 33 
nucleotide deletion at the N terminus of the preS1 region resulting in it having the 
shortest genome of the eight HBV genotypes (3182 nucleotides) (Kramvis et al. 
2005a; Schaefer 2007).  Individuals infected with this genotype are found to be 
anti-HBe positive significantly more often than individuals infected with the other 
genotypes and to have significantly higher ALT levels indicating a more active 
form of the disease (Kidd-Ljunggren et al., 2004). 
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1.5.1.3  Genotype E 
 
Genotype E strains are characterised by a very low genetic diversity spanning a 
large geographic area and could be a recent introduction into the human 
population (Mulders et al., 2004; Hubschen et al., 2008).  They have been found 
in Western and Central Africa including Angola, Liberia, Senegal, Ivory Coast, 
the Gambia, Ghana, Nigeria, Mali, Burkina Faso, Togo, Benin, Cameroon, 
Namibia and the Democratic Republic of Congo (Kramvis et al., 2005b).  The 
absence of this genotype in the African-American population, despite the slave 
trade in the 19th century, supports a recent introduction of this genotype, possibly 
within the last 200 years (Andernach et al., 2009a).   
 
1.5.2  Putative genotypes  
 
A new genotype, genotype I, has been proposed to describe an aberrant strain 
originating from Hanoi in the northern part of Vietnam and has also been found in 
voluntary blood donors from Laos (Olinger et al., 2008; Tran et al., 2008).  
Recently, additional genotype I isolates have been reported in a primitive tribe 
from northeast India as well as in the northwest of China (Arankalle et al. 2010; 
Yu et al. 2010).  This variant seems to have evolved from a series of complex 
recombination events combining genotypes C, A and G – a surprising result as the 
prevailing genotypes in this region are B and C with genotype A being identified 
very rarely and genotype G so far undetected in Vietnam. 
 
A novel HBV strain has been isolated from a Japanese patient with HCC who 
served in Borneo during World War II (Tatematsu et al., 2009).  Tentatively 
designated genotype J, this isolate occupies a unique phylogenetic position, 
clustering amongst the non-human HBV isolates closest to isolates from the 
gibbon and orang-utan. 
 
1.5.3  Recombination of genotypes 
 
When more than one genotype co-circulate in a region, there can be 
recombination of these genotypes, resulting in viral variants in both individuals 
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and the population in general (Kramvis et al., 2005a; Cao, 2009).  Recombination 
events between genotypes A and D in South Africa, India and Italy, A and G in 
the USA, B and C in Asia, C and D in Tibet and C and G in Thailand have been 
reported (Owiredu et al. 2001; Chauhan et al. 2008; Tran et al. 2008).  
Recombination events can contribute to the genetic diversity of HBV and lead to 
the formation of new genotypes.  An example is subgenotype B2, which 
predominates in mainland Asia, is composed of genotype B recombined in the 
precore/core region with genotype C (Sugauchi et al., 2002; Sugauchi et al., 
2003).  Recombination may also help the virus evade the host’s immune response 
by generating unfamiliar antigenetic configurations (Owiredu et al., 2001). 
 
The study of HBV is limited by the absence of suitable tissue culture systems and 
therefore, as an alternative, animal models have been used.   
 
1.6  Non-human hepadnaviruses 
 
Hepadnaviruses infect both avian and mammalian hosts. 
 
1.6.1  Avihepadnaviridae 
 
DHBV was first detected in the serum of Pekin ducks (Anas domesticus) from 
both China and the United States in the early 1980s (Mason et al., 1980).  Its 3,0 
kb genome is the smallest of the hepadnaviruses and contains just three 
overlapping ORFs: the precore/core, pre-S/S and polymerase (Sprengel et al., 
1988).  DHBV, along with the other avian hepatitis viruses, lacks the X ORF and 
infected ducks do not develop HCC (Feitelson and Larkin, 2001).  The duck 
model system is extremely well characterised and has been used to analyse the 
early steps of hepadnaviral infections, to discover how the hepatitis viruses 
replicate, and for the testing of drugs that inhibit viral replication (Feitelson and 
Larkin, 2001; Stoeckl et al., 2006).  A closely related avihepadnavirus, designated 
the heron hepatitis B virus (HHBV), has been found  in the grey heron (Ardea 
cinerea) (Sprengel et al., 1988).   
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1.6.2  Orthohepadnaviridae 
 
The orthohepadnaviruses all have similar genomic organisation and infect both 
rodents and primates.  Animal models have been used to study hepadnaviral 
infections, especially the pathogenesis of chronic liver disease and the 
development of HCC (Feitelson and Larkin, 2001). 
 
1.6.2.1  Rodent hepadnaviruses 
In 1978 WHV was discovered at the Philadelphia Zoo in a colony of captive 
woodchucks (Marmota monax) with chronic hepatitis and HCC (Summers et al., 
1978).  Woodchucks infected with this virus have a disease course that is very 
similar to that seen in HBV-infected humans, making them a good model for 
investigating the viral life cycle and the oncogenic potential of hepadnaviruses 
(Hodgson and Michalak, 2001).  Following acute WHV infection, woodchucks 
can develop an occult form of the infection that can be transmitted to virus-naïve 
animals.  
 
GSHV was first isolated from northern Californian Beechey ground squirrels 
(Spermophilus beecheyi) (Marion et al., 1980).  Compared to HBV, GSHV has a 
slightly larger Dane particle (47 nm compared to 42 nm) and it has slightly longer 
and more abundant filamentous forms in the serum. 
 
The arctic squirrel hepatitis virus (ASHV) has been found in wild Alaskan arctic 
ground squirrels (Spermophylus parryi kennicotti) with liver disease and large 
hepatic nodules (Testut et al., 1996).  This virus is more closely related to WHV 
and GSHV having a similar genome size and virtually identical genetic 
organisation. 
 
1.6.2.2  Non-human primate hepadnaviruses 
Phylogenetically, non-human primates are very closely related to humans, making 
them excellent model systems (Sibal and Samson, 2001).  Of the more than 200 
species of non-human primates, only about 30 are used in research.   
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In the late 1960s and early 1970s, a number of studies looked for hepadnaviral 
infections in non-human primate serum samples by screening for the HBsAg 
(Robertson and Margolis, 2002).  Evidence of these infections was found most 
consistently in chimpanzees but also in gibbons and orang-utans (Hirschman et 
al., 1969; Blumberg et al., 1972).  Subsequently, using more sensitive molecular 
techniques, naturally occurring strains of HBV have been found in a number of 
Old and New World primates, namely the chimpanzee, gibbon, woolly monkey, 
orang-utan and gorilla (figure 8) (Robertson and Margolis, 2002).  The rate of 
infection in the non-human primates is approximately 16,7%, a rate similar to that 
observed in humans in regions of endemic infection such as Central Africa and 
South East Asia (Starkman et al., 2003).  The non-human primate hepadnaviral 
sequences have a number of amino acid residues differentiating them from the 
consensus sequences of each of the human HBV genotypes (Robertson and 
Margolis, 2002).  These include a glutamic acid at position 16 of the pre-S region, 
a leucine at position 133 of the S region and a leucine at position 28 of the precore 
region (Revill et al., 2010).  They also have an 11 amino acid deletion at the 
amino terminal end of the preS region, found in genotype D (Aiba et al., 2003).  
 
1.6.2.2.1  Chimpanzee Hepatitis B Virus 
In 1978 it was reported that a colony of chimpanzees (Pan troglodytes) at London 
Zoo had a high carrier rate of HBV infection (Zuckerman et al., 1978).  At that 
time, the source of this infection was believed to be the practice of inoculating 
newly captured chimpanzees with pooled human HBV-positive blood to passively 
immunize the animals (Zuckerman et al., 1978). Two of the infected 
chimpanzees, a male and a female, had been captured in the wild and three of their 
offspring were also HBV carriers, indicating perinatal transmission.  Subsequent 
publication of the complete sequence of the HBV isolated from one these animals 
showed it to be approximately 10% divergent from human HBV sequences 
(Vaudin et al., 1988).  Genomic and serological analyses of HBV isolated from 
additional infected chimpanzees confirmed that the virus was genetically distinct 
from the known human HBV genotypes  and therefore indigenous to chimpanzees 
(Hu et al., 2000; MacDonald et al., 2000; Takahashi et al., 2000).  This led to the 
designation of this virus as the chimpanzee HBV (ChHBV) (Takahashi et al., 
2000).   
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Figure 8:  Hepadnaviral animal models.  Orthohepadnaviridae occur naturally in both 
Old and New World non-human primates namely: (A) chimpanzees; (B) gorillas, (C) 
woolly monkeys, (D) gibbons and (E) orang-utans.   
Photographs by: (A) Thomas Lersch; (B) Nesnad; (C) Evgenia Kononova; (D) Trisha Shears and (E) 
Nehrams2020. 
 
(A) (B) (C) 
(D) (E) 
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The various subspecies of chimpanzee are found in geographically distinct regions 
of Africa – Pan troglodytes troglodytes and P.t. vellerosus in Central Africa, P.t. 
versus in West Africa and P.t. schweinfurthi in East Africa (Takahashi et al., 
2001; Vartanian et al., 2002; Makuwa et al., 2005).  Phylogenetically, when 
compared to the human and other non-human primate HBV sequences (with the 
exception of the gorilla) the ChHBV sequences cluster together.  When compared 
to each other however, the ChHBV strains from different subspecies appear to 
cluster according to their geographical origins, similar to the clustering seen in the 
human subgenotypes (Hu et al., 2001; Vartanian et al., 2002). 
 
1.6.2.2.2  Gorilla Hepatitis B Virus 
Only one complete HBV sequence from a Western lowland gorilla (Gorilla 
gorilla gorilla) has been reported (Grethe et al., 2000).  Phylogenetically gorilla 
HBV (GoHBV) clusters with the chimpanzee strains.  HBV-DNA has also been 
reported in gorillas from Gabon (Makuwa et al., 2003). 
 
1.6.2.2.3  Gibbon Hepatitis B Virus 
Gibbons are found throughout the tropical rainforests of South and Southeast Asia 
including Thailand, Laos, Cambodia, Indonesia and Malaysia (Noppornpanth et 
al., 2003).  HBV has been found in a number of gibbon subspecies including 
Hylobates agilis, H. lar H. moloch and H. pileatus (Lanford et al., 1994; Norder et 
al., 1996; Aiba et al., 2003) and NAT has established the carrier rate to be 26.7% 
(Sa-nguanmoo et al., 2008).  Inoculation of HBsAg-positive gibbon serum into 
chimpanzees was shown to transmit the infection (Mimms et al., 1993).  The 
gibbon hepatitis B virus (GiHBV) genome is more closely related to the ChHBV 
genome than to the human HBV genome (Norder et al., 1996).  The pre-S region 
is the most divergent, differing from the ChHBV genome by 15,7% at the 
nucleotide level and 12,9% at the amino acid level, and has a number of changes 
including a glutamic acid at position 16 (also found in the ChHBV), a leucine at 
position 22 and a valine at position 115.  Gibbons chronically infected with 
GiHBV show no overt signs of liver disease or mortality as a result of liver 
disease (Lanford et al., 2000). 
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1.6.2.2.4  Orang-utan Hepadnavirus 
Orang-utans (Pongo pymarus), restricted to the islands of Borneo and Sumatra, 
are the only great apes found outside Africa (Warren et al., 1999).  NAT has 
shown 13,2% of orang-utans  to be infected with orang-utan hepadnavirus 
(OuHV), which is most closely related to the gibbon HBV (Verschoor et al., 
2001; Noppornpanth et al., 2003; Sa-nguanmoo et al., 2008).  Orang-utans 
infected with OuHV do not develop hepatitis and therefore, this virus has been 
classed as a hepadnavirus as opposed to a hepatitis B virus (Takahashi et al., 
2000).  The human genotype C strains, which also originate from Southeast Asia, 
are the human strains most closely related to OuHV (Warren et al., 1999).   
 
1.6.2.2.5  Woolly Monkey Hepatitis B Virus 
The woolly monkey (Lagothrix lagotricha), a New World primate, is found in 
Colombia, Ecuador, Peru and Brazil.  The woolly monkey hepatitis B virus 
(WMHBV) was first identified in an animal with fulminant hepatitis, and has 
subsequently been found in approximately 80% of the offspring of infected 
woolly monkey females, suggesting a vertical mode of transmission (Lanford et 
al., 1998).  WMHBV has also been shown to infect the black-handed spider 
monkey (Ateles geoffroyi), a close relative of the woolly monkey (Lanford et al., 
2003).  The 3197 nucleotide genome has the same genetic organisation as human 
HBV and is the most divergent of the primate strains, showing a 35% divergence 
from human HBV (Lott et al., 2003).  Phylogenetically, WMHBV is closest to the 
human genotype F isolates found in South and Central America (Lanford et al., 
1998).   
 
1.7  Animal models used to study HBV 
 
The limited host range of the hepadnaviruses means that these infections are 
optimal in their natural hosts.  Human HBV can infect other species although not 
very efficiently (figure 9). 
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Figure 9:  Animal models used to study HBV.  The chimpanzee (A), tree shrew (C) and 
Barbary macaque (D) can all be experimentally infected with HBV.  Baboons (B) have also 
been proposed as a model for HBV infection.   
Photographs by: (A) Delphine Bruyere; (B) David Dickens; (C) Cymothoa exigua and (D) Karyn Sig. 
(D) 
(C) 
(B) 
? 
(A) 
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1.7.1  Chimpanzee model 
 
The chimpanzee is one of the only non-human primates that can be persistently 
infected with human HBV (Ruiz-Opazo et al., 1982b).  Infected chimpanzees 
have elevated levels of HBsAg in their serum as well as anti-HBc, HBeAg and 42 
nm Dane particles (Ruiz-Opazo et al., 1982b).  In the liver tissue, HBV has been 
shown to exist in a covalently closed, supercoiled circular configuration (Ruiz-
Opazo et al., 1982a).  Although experimentally infected chimpanzees generally 
display a mild form of liver disease, they have been invaluable for the study of the 
transmission, natural history and pathogenesis of HBV infections (Feitelson and 
Larkin, 2001).  However, the availability of wild-caught chimpanzees for research 
is restricted as by nature they are highly intelligent animals.  Furthermore, the 
expansion of logging, large-scale hunting and agriculture into their forest habitats 
has led to them being classed as an endangered species (Feitelson and Larkin, 
2001; Prince and Brotman, 2001). 
 
1.7.2  Macaque model 
 
Barbary macaques (Macaca sylvanus) can be found in the Atlas Mountains of 
Algeria and Morocco as well as in Gibraltar. Macaques transfected with cloned 
HBV DNA develop markers of an acute HBV infection and HBsAg can be 
detected in the serum of infected macaques for between 4 and 7 weeks (Gheit et 
al., 2002).  HBV DNA can be detected by PCR and histological analysis of liver 
tissue shows evidence of pathological changes indicating an acute HBV infection 
(Gheit et al., 2002). 
 
1.7.3  Tree shrew model 
 
The tree shrew (Tupaia belangeri) is a non-rodent, primate-like animal found in 
tropical forests and plantation areas of Southeast Asia.  In vitro, primary Tupaia 
hepatocytes can be infected with HBV resulting in the synthesis of viral DNA and 
RNA and the secretion of HBsAg and HBeAg (Cao et al., 2003).  In vivo 55,2% 
of infections result in acute infections in which serum HBsAg levels decline 
rapidly followed by seroconversion to anti-HBs and anti-HBe.  Replication of 
40 
 
viral DNA, viral gene expression and cccDNA are evident in the liver.  The tree 
shrew model mirrors the epidemiology of liver cancer in humans and is thus 
useful for studying the mechanisms involved in the pathogenesis of liver disease. 
 
1.7.4  Baboon as a possible model of HBV infection? 
 
Baboons (Papio sp.) are one of the most intensively studied non-human primate 
species because their growth and aging parallels that of humans in many 
biological respects (Mukai et al., 1980).  Phylogenetically, baboons are very close 
to humans showing an approximately 96% homology at the DNA level (Murthy et 
al., 2006).  They also have an immune system very similar to that of humans 
(Murthy et al., 2006).    
 
Early studies involving the inoculation of baboons with HBV-positive sera failed 
to detect any clinical or biochemical signs of infection in these primates and initial 
serological surveys failed to detect HBsAg in the serum, leading to the conclusion 
that baboons were not susceptible to HBV infections (Deinhardt, 1976).  A 
subsequent serological survey, however, found anti-HBsAg in 36,2% of baboons 
tested (Eichberg and Kalter, 1980).  A more recent serological screening of 31 
adult male baboons (Papio cynocephalus) found one baboon to be positive using a 
human enzyme linked immunoabsorbent assay (ELISA) but this same animal was 
found to be negative when tested in a different laboratory using a different human 
ELISA test (Michaels et al., 1994).  In 1996, a pilot study involving four baboons 
inoculated with HBV positive serum was unable to detect any signs of HBV 
infection by PCR, liver biopsy evaluation or serology, although one of the 
baboons showed low levels of HBV DNA in weeks two through five (Michaels et 
al., 1996).  When these tests were repeated, HBV DNA was not detected.   
 
1.8  Interactions between humans and baboons 
 
Interactions between man and baboon have a long history making the 
transmission of viruses between species quite plausible.  Baboons are the most 
widely distributed of the African monkeys, found in virtually all parts of sub-
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Saharan Africa (Barrett, 2000).  They often appear in ancient Egyptian mythology 
and art being depicted as captives brought from the south, pets on leashes, dancers 
and jesters (Cheney and Seyfarth, 2007).  They have been shown climbing trees to 
collect dates and figs for their owners and are even depicted as police assistants 
attacking thieves in the marketplace (figure 10).  
 
Figure 10:  Baboons acting as police assistants (Cheney and Seyfarth, 2007).  This 
illustration from the Old Kingdom mastaba of Tepemankh at Saqarra, an Egyptian tomb, 
depicts two baboons, on leashes, attacking a thief in the marketplace.  The accompanying 
hieroglyphic reads, “Fear for this baboon”. 
 
In Southern Africa, interactions between humans and baboons are well 
documented.  Baboons have been kept as pets and even trained to work as oxcart 
drivers, railway labourers and goatherds on farms (Cheney and Seyfarth, 2007).  
One such story is of a baboon called Jack the Signalman.  In the latter part of the 
1800s, in a town called Uitenhage in the Eastern Cape, a railway guard fell under 
a moving train and had to have both legs amputated at the knees.  He was hired as 
a signalman but struggled with the work until he acquired a young baboon called 
Jack who quickly learned how to perform a signalman’s duties and operate the 
switches.  Jack died of tuberculosis in 1890. 
 
There have also been reports of children and young baboons playing together.  
Marais (1971) recounts one such incident on the bank of a stream where some 
young native children were digging clay from a hole in the river bank and 
fashioning it into small clay animals.  Joining in the digging was a group of young 
baboons.  The play got quite raucous as both children and baboons tried to access 
the hole containing the clay with plenty of pinching, kicking and dragging by both 
sides albeit all in jest. 
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More common, however, are reports of conflict between humans and baboons.  In 
the rural areas, baboons raid orchards, destroy irrigation pipes and kill sheep and 
goats.  Baboons can become aggressive when challenged and so are often killed 
by farmers for being pests.  In Africa, primates are often slaughtered for 
bushmeat, providing another source of exposure to viruses (Robertson, 2001). 
 
1.9  Rationale and objectives of study 
 
Patients with end stage liver disease require liver transplants, but the increasing 
need for donor organs means that a substantial number of these patients die on 
waiting lists before a liver becomes available (Williams, 2006).  HBV infected 
individuals are not good candidates for liver transplants as residual HBV in these 
patients can infect the donated organ resulting in rapid liver destruction (Lanford 
et al., 1995).  The use of xenotransplants from pigs and non-human primates to 
humans was considered in order to overcome the donor shortage and/or “bridge” 
patients with terminal hepatic failure until a human donor organ became available 
(Chapman et al., 1995; Luo et al., 1996). The supposed lack of susceptibility of 
baboons to infection with HBV meant that they were good candidates for liver 
xenotransplants.  Moreover, baboons are phylogenetically close to humans, can be 
matched to humans for tissue and blood group using standard immunological tests 
and, unlike chimpanzees, they are not an endangered species (Gridelli et al., 1993; 
Gridelli et al., 1994). 
 
Baboon to human liver xenotransplants were attempted in two individuals: a 35-
year-old HBV and HIV co-infected male who survived 70 days post transplant 
(Starzl et al., 1993) and a 62 year old male with chronic active HBV who survived 
27 days post transplant (Lanford et al., 1995).  Replication of HBV was not 
detected in either of the baboon donor livers at autopsy, but that could have been a 
consequence of the limited life-span of the transplants or the sensitivity of the 
detection methods.   
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Initial studies had shown baboons to be resistant to HBV infection (see section 
1.7.4) but these early studies used mainly biochemical and histological findings as 
well as serological markers to detect HBV infection.  In an attempt to confirm the 
previous findings, six wild caught Chacma baboons (Papio ursinus orientalis) 
were inoculated with pooled HBV positive serum and followed for 52 weeks 
using sensitive molecular techniques to detect evidence of transmission (Kedda et 
al., 2000).  HBV DNA was detected by nested PCR in both the serum and liver 
tissue of four of the baboons up to 52 weeks post inoculation.  Liver function and 
histology were normal and HBsAg was not detected in the serum. In two of the 
six baboons, HBV DNA was detected in the serum using nested PCR, at baseline 
prior to inoculation with HBV.  This was initially thought to be the result of 
experimental error but retesting in independent laboratories confirmed the 
presence of HBV DNA.   This raised the possibility that baboons are naturally 
infected with a hepadnavirus.   
 
The objective of the present study was to determine the prevalence of ‘HBV’ in 
baboons in the wild and to molecularly characterize the virus isolated from these 
baboons.  Thus the aims included: 
• Detection of HBV DNA in sera from 69 wild-caught baboons  
• Amplification of the complete genome of the virus isolated from baboon 
liver and/or serum samples 
• Sequencing of the complete genome of the isolate and determination of its 
phylogenetic relationship to other hepadnaviruses 
• Demonstration of replication in baboon liver 
• Transmission of the virus to experimentally naïve baboons.   
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2.  Materials and Methods  
 
Permission for this study was obtained from the Animal Ethics Committee of the 
University of the Witwatersrand (Ethics Clearance Number: 97/88/1, Appendix I).  
All procedures were approved by the committee and the baboons were cared for 
according to the guidelines of the South African Medical Research Council.   
 
2.1  Baboons 
 
Ten large, adult Chacma baboons (Papio ursinus orientalis) were wild-caught in 
the Eastern Cape province of South Africa.  The baboons were quarantined for six 
weeks in the Eastern Cape, but were not involved in any form of medical or 
veterinary research during this time.  The only injection these baboons received 
was an intradermal tuberculin test performed with a disposable needle and 
syringe.  Each baboon was housed in a separate cage during both the quarantine 
period and after their arrival at the Animal Unit of the University of the 
Witwatersrand Medical School in Johannesburg.  Ten millilitres of whole blood 
was obtained from each of the ten baboons, allowed to clot and separated by 
centrifugation at ~5000 revolutions per minute (rpm) for 15 minutes (min) at 
room temperature.  The serum was removed using a disposable pipette and stored 
at -70 °C. 
 
Additional blood samples were obtained from both 39 adult and 20 juvenile 
Chacma baboons wild-caught in the Western Cape and Limpopo provinces of 
South Africa.  Serum was isolated as described above and stored at -70 °C. 
 
One of the ten baboons, baboon 9732, arrived in Johannesburg with a fracture of 
the femur and the Animal Ethics Committee decided that it should be euthanized.  
During necropsy, liver tissue and serum were obtained from this baboon.  A 
section of the liver tissue was placed in formalin for histological examination 
while the remainder was snap frozen in liquid nitrogen and stored at -70 °C. 
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2.2  Immunocytochemical Examination of Samples 
 
Baboon serum samples were tested at the National Health Laboratory Services 
(NHLS, Johannesburg, South Africa) for HBsAg and for anti-HBc using the 
Abbott AxSYM Microparticle Enzyme Immunoassay system (Abbott 
Laboratories, Chicago, Ill. USA).  The alanine and aspartate aminotransferase 
levels were also measured using a Hitachi 747 Automatic Analyser.   
 
Histological and immunohistochemical analysis of baboon liver tissue was kindly 
performed by Prof. A Paterson from the Department of Anatomical Pathology, 
University of the Witwatersrand.  Formalin (10% v/v) fixed liver tissue from 
baboon 9732 was used for both histological and immunohistological preparations.  
The liver tissue was embedded in paraffin wax and 5 micron (µm) sections cut.   
 
2.2.1  Haematoxylin and Eosin Staining 
 
Sections were stained with haematoxylin and eosin for histological examination 
(Gamble and Wilson, 2002).  Briefly, sections were dewaxed in xylene and 
rehydrated by passing them through decreasing concentrations of alcohol.  After 
immersion in haematoxylin for five minutes, the sections were blued by placing 
them under running tap water and the nuclei differentiated by dipping the sections 
in acid alcohol (1% hydrochloric acid in 70% ethanol) once or twice.  Sections 
were rinsed in tap water, stained in 0,2% eosin for one minute and rinsed again in 
tap water.  The sections were dehydrated through increasing concentrations of 
alcohol, cleared in two changes of xylene, mounted in Entellan (Merck, 
Darmstadt, Germany) and viewed using a light microscope. 
 
2.2.2  Immunohistochemistry against HBsAg and HBcAg 
 
To detect HBsAg and HBcAg in the hepatocytes, 5 µm sections were dewaxed in 
xylene, rehydrated by passing through decreasing concentrations of alcohol, 
rinsed in distilled water and washed twice in PBS, pH 7,4 (Appendix II).  
Endogenous peroxidase activity was quenched by incubating the sections in      
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1% hydrogen peroxide (Merck) for 30 min and washed twice in PBS.  A serum 
block was performed by incubating the sections in 1% goat serum (made up in 
PBS) (Dako, Glostrup, Denmark) for 20 min.  The serum block was aspirated and 
primary antibody (monoclonal mouse anti-HBsAg (M3506, Dako) or polyclonal 
rabbit anti-HBcAg (B0586, Dako) added.  Sections were incubated overnight in 
primary antibody at 4 °C in a humidified chamber.  The following day, the 
sections were washed twice in PBS and incubated in secondary antibody (goat-
anti-mouse IgG / horseradish peroxidise (HRP) (P0447, Dako) or goat-anti-rabbit 
IgG/HRP (P0448, Dako)) for one hour at room temperature.  After washing three 
times in PBS, the sections were incubated for five minutes in diaminobenzidine 
(DAB) (Roche Diagnostics Ltd., Mannheim, Germany), rinsed in distilled water, 
dehydrated through increasing concentrations of alcohol, cleared in xylene and 
mounted in Entellan.  Sections were viewed using a light microscope. 
 
2.3  Extraction of DNA 
 
DNA was extracted from both the serum and liver tissue of the baboons using a 
variety of different methods. 
 
2.3.1  QIAGEN QIAamp® DNA Blood Mini Kit 
 
DNA was extracted from 200 µl of baboon serum using QIAamp® DNA Blood 
Mini Kit (QIAGEN, Inc., Hilden, Germany) according to the manufacturer’s 
instructions.  Briefly, the 200 µl aliquot of serum was incubated with QIAGEN 
protease and a lysis buffer at 56 °C from 10 min.  The lysate was applied to a 
QIAamp® spin column, washed twice and eluted in 50 µl best quality water 
(Sabax, Adcock Ingram Critical Care Ltd., Johannesburg, South Africa).   
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2.3.2  GeneReleaser® 
 
GeneReleaser® (Bioventures Inc., Murfyboro, Tenn.) is a proprietory agent which 
quickly facilitates the release of DNA from whole blood and cells.  DNA was 
extracted from 5 µl of baboon serum using GeneReleaser® according to the 
manufacturer’s instructions.  A 20 µl volume of GeneReleaser® was added to the 
serum sample and treated using the following thermocycle lysis program:  65 °C 
held for 30 s, 8 °C held for 30 s, 65 °C held for 180 s, 97 °C held for 60 s and     
65 °C held for 60 s.  Treated samples were held at 80 °C until the PCR mixture 
was added.  The full 25 µl of treated sample was used as template for a 100 µl 
first round PCR reaction (section 2.5.3). 
 
2.3.3  QIAGEN QIAamp® DNA Mini Kit 
 
DNA was extracted for cccDNA analysis from liver tissue using the QIAamp® 
DNA Mini kit tissue protocol.  Although this kit does not require any mechanical 
disruption of the tissue sample, 10-25 mg of liver tissue was ground in liquid 
nitrogen with a pestle and mortar to facilitate lysis of the cells.  The ground tissue 
was transferred to a 1,5 ml micro-centrifuge tube and DNA extracted according to 
the manufacturer’s instructions.  The samples were incubated with QIAGEN 
Proteinase K (>600 mAU/ml) and a lysis buffer overnight at 56 °C on a rocking 
platform to ensure complete lysis.  The following day, the lysed sample was 
transferred to a QIAamp® spin column, washed twice and eluted in 50 µl best 
quality water.  Eluting the DNA in 50 µl as opposed to 200 µl decreases the 
overall yield of DNA but increases the concentration significantly.  The samples 
were stored at     -20 °C.   
 
To maximise the quantity of DNA in each sample extracted from the baboon liver 
tissue, the extractions were repeated, using a number of variations:  (1) the 
starting amount of liver tissue was increased to 50 mg; (2) multiple extracts were 
pooled and re-extracted using a salt-ethanol precipitation; (3) DNA was extracted 
from both 25 mg and 50 mg of baboon liver tissue as before but in the final step of 
the extraction procedure, DNA was eluted from the extraction column three times, 
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using the maximum volume (200 µl) of elution buffer permitted each time, 
resulting in a final elution volume of 600 µl.  These extracts were reprecipitated 
using a salt-ethanol precipitation method and resuspended in a smaller volume of 
best quality water.   
 
2.3.4  Phenol-Chloroform Extractions 
 
This protocol is a modification of that described by Sykes in 1983 (Kramvis et al., 
1996; Sykes, 1983).  Approximately 500 mg of liver tissue was cut from frozen 
baboon liver.  The liver tissue had been stored for a number of years at -70 °C so 
the section was obtained from approximately 1 cm below the surface of the frozen 
tissue to prevent contamination and loss of DNA quality as a result of degradation 
by freezer burn.  The tissue was finely minced using a sterile scalpel blade and 
homogenised with a sterile 2 ml manual glass homogeniser in   1 ml phenol-
chloroform lysing buffer (Appendix II).  The homogenate was transferred to a 
sterile 50 ml Nunc™ tube (Nunc A/S, Roskilde, Denmark) and an additional 9 ml 
lysing buffer added.  The homogenate and extra buffer were blended using a 
blunt, sterile glass rod.  Two ml of 10% SDS (Appendix II) was added, the tube 
tightly capped and placed on a gentle shaker at 37 °C for 20 min.  Following this 
incubation, 10 ml tris-saturated phenol (pH 7) (SIGMA, Sigma-Aldrich Inc., St 
Louis, Mo.) and 5 ml chloroform: iso-amyl alcohol (24:1) (Appendix II) was 
added to the tube, which was tightly capped and shaken vigorously.  The sample 
was centrifuged at 2000 x g in a Sorvall® RT6000 tabletop refrigerated centrifuge 
(Global Medical Instrumentation Inc., Ramsey, Minn.) for 15 min at 4 °C to 
separate the phases.  The aqueous (upper) phase was removed using a sterile 10 
ml pipette, carefully avoiding the interphase, and transferred to a clean, sterile 50 
ml Nunc Tube.  This extraction with phenol and chloroform was repeated with the 
aqueous phase being transferred once more to a clean, sterile 50 ml Nunc tube.  
The sample was then extracted once with chloroform alone by adding 10 ml 
chloroform: iso-amyl alcohol (24:1) (Appendix II) to the tube, tightening the cap 
and shaking vigorously prior to centrifuging it at 2000 x g for 10 min at 4 °C to 
separate the phases.  After transferring the aqueous (upper) phase to a clean, 
sterile 50 ml Nunc tube, the DNA was precipitated by the addition of 2,5 volumes 
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(approximately 25 ml) ice-cold ethanol (Saarchem, Merck Ltd. Modderfontein, 
South Africa) and left overnight at -20 °C.  The following day, the DNA was 
pelletted by centrifuging at 200 x g in a Sorvall® RT6000 centrifuge for 30 min at 
4 °C, the supernatant was carefully decanted and discarded and the pellet 
resuspended overnight on a gentle shaker in 10 ml TE Buffer (pH 8) (Appendix 
II).  Two mg Proteinase K (Roche, F. Hoffmann – La Roche Ltd., Basel, 
Switzerland) was added to the sample and digested at 60 °C for 2 hours with 
occasional mixing after which an additional 200 µg Proteinase K was added and 
digestion continued at 60 °C for a further 2 hours.  The sample was extracted 
twice with phenol-chloroform and once with chloroform alone as described 
previously, the DNA re-precipitated by the addition of 2,5 volumes 
(approximately 25 ml) ice-cold ethanol and the sample left overnight at -20 °C.  
The DNA was pelletted by centrifuging at 200 x g for 30 min at 4 °C in a 
centrifuge and the pellet allowed to air-dry almost completely before being 
resuspended overnight on a gentle shaker in 1 ml sterile water (Sabax).  Once the 
sample was completely resuspended, it was stored in 100 µl aliquots at -70 °C. 
 
2.3.5  Quantification of DNA 
 
The DNA extracted from the samples was quantified using spectrophotometric 
analysis on a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies 
Inc., Wilmington, Del.).  The phenol-chloroform extracted DNA samples were 
highly concentrated and were thus diluted ten fold prior to analysis.  The 
concentration of the DNA was calculated by using the standard that                       
1 OD260 = 50 µg DNA/ml.  The quality of the samples was assessed by calculating 
the OD260/OD280 ratio.   
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2.4  Genotyping of HBV 
 
HBV DNA extracted from liver tissue using the phenol-chloroform extraction 
method was genotyped using a modification of the method first described by 
Lindh et al. in 1997.  
 
2.4.1  PCR amplification 
 
A region of the surface gene of HBV (nt 256 – 796) was amplified by nested PCR 
using the primers in table 3.  In the first round of amplification, a 22,5 µl mixture 
comprising 0,5 units (U) of BIOTAQ™ DNA polymerase (Bioline Ltd, 
Luckenwalde, Germany), 200 µM of each deoxynucleoside triphosphate (dNTP), 
1 µM of each primer (230F and 800R), 3 mM MgCl2, 16 mM (NH4)2SO4,           
67 mM Tris-HCl (pH 8,8) and 0,01% Tween-20, was added to 2,5 µl sample 
DNA.  Amplification was performed in a Techgene programmable thermocycler 
(Techne Inc., Princeton, NJ.) as follows:  denaturation at 94 °C held for 60 s, 
annealing at 53 held for 300 s and extension at 72 °C held for 180 s for a total of 
40 cycles with a final extension at 72 °C held for 7 min.  The second round of 
amplification added 5 µl of first round product to 45 µl of a mixture containing    
1 U of BIOTAQ™ DNA polymerase (Bioline), 200 µM of each dNTP, 1 µM of 
each primer (P7 and P8), 1,5 mM MgCl2, 16 mM (NH4)2SO4, 67 mM Tris-HCl 
(pH 8,8) and 0,01% Tween-20.  Amplification was performed in a programmable 
thermocycler (Techne) as follows:  denaturation at 94 °C held for 45 s, annealing 
at 53 °C held for 60 s and elongation at 72 °C held for 90 s for a total of 40 cycles 
with a final extension at 72 °C held for 10 min. 
 
Table 3:  First and second round primers for genotyping of HBV 
Name Positiona Nucleotide Sequence Orientation 
230F 231 - 249 5’ – TCA CAA TAC CGC AGA GTC T – 3’ Sense 
800R 801 - 782 5’ – AAC AGC GGT ATA AAG GGA CT – 3’ Antisense 
P7 256 - 278 5’ – GTG GTG GAC TTC TCT CAA TTT TC – 3’ Sense 
P8 796 - 776 5’ – CGG TAW AAA GGG ACT CAM GAT – 3’ Antisense 
a Denotes position on HBV subgenotype A2 genome (GenBank accession #X70185) with 
the EcoRI cleavage site at position 1. 
 Abbreviations:  W – A and T; M – C and A 
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A 10 µl aliquot of the second round PCR product was resolved on a 1% agarose 
gel (section 2.6) to confirm the successful amplification of the required product 
prior to restriction fragment length polymorphism (RFLP) analysis. 
 
2.4.2  Restriction Fragment Length Polymorphism (RFLP) analysis 
 
RFLP analysis was performed on the second round PCR product to determine the 
HBV genotype (A – F) (Lindh et al., 1997).  Fifteen µl of the second round PCR 
product was dispensed into two separate 0,5 ml thin-walled PCR tubes.  To one of 
these tubes, 5 U HinfI (New England Biolabs, Inc, Ipswich, Mass.) and               
1x NEBuffer 2 (10 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl2 and 1 mM 
Dithiothreitol; pH 7,9) was added, while to the other, 5 U Tsp509I (New England 
Biolabs) and 1x NEBuffer 1 (10mM Bis-Tris-Propane-HCl, 10 mM MgCl2 and    
1 mM Dithiothreitol; pH 7,0) was added.  Each reaction was overlaid with a thin 
layer of mineral oil before being incubated for 3 hours at 37 °C (for the HinfI 
restriction) or 65 °C (for the Tsp509I restriction).  The reaction was terminated by 
adding 4 µl gel loading dye (Promega Corp, Madison, Wis.).   
 
The entire restriction reaction was resolved on a 3% agarose gel (Appendix II) 
containing 10 µg/ml ethidium bromide (Bio Basics Inc., Markham, Ontario) at 
~3,5 volts/cm along with 10 µl 100 bp DNA ladder (Promega) and 10 µl 50 bp 
DNA ladder (Promega) until the bromophenol blue tracking dye had migrated 
approximately 80% of the length of the gel.  An image of the gel was recorded 
using the Bio-Rad Gel Doc XR Imaging System (Bio-Rad Laboratories Inc., 
Hercules, Calif.) and the sizes of the restricted fragments compared to those in 
table 3 of Lindh et al. (1997, p 1290) to determine the genotype of the samples. 
 
 52 
2.5  PCR amplification 
 
2.5.1  Full length PCR 
 
Amplification of the full HBV genome was performed using a modification of the 
protocol described by Günther et al. in 1995 (primers listed in table 4) and the 
Expand High Fidelity PCR System (Roche Diagnostics Ltd., Mannheim, 
Germany). 
 
Table 4:  Primers for amplification of full length HBV genome (Gunther et al., 1995) 
Name Positiona Nucleotide Sequence Orientation 
P1 1820 – 1841 5’ – CTT TTT CAC CTC TGC CTA ATC A – 3’ Sense 
P2 1825 - 1806 5’ – AAA AAG TTG CAT GCT GAG GG – 3’ Antisense 
a Denotes position on HBV subgenotype A2 genome (GenBank accession #X70185) with 
the EcoRI cleavage site at position 1. 
 
The full length PCR amplification used a manual “hot start” in which the 
polymerase was omitted from the initial reaction mixture, and only added once the 
samples reached annealing temperature for the first time.  The initial reaction 
therefore contained a 20 µl mixture comprising 1x Expand High Fidelity buffer 
with 1,5 mM MgCl2, 50 µM of each dNTP, 1 µM of each primer (P1 and P2) and 
5 µl sample DNA.  Amplification was preformed using a RoboCycler® Gradient 
40 programmable thermocycler (Stratagene, La Jolla, Calif.) as follows:  
denaturation at 94 °C held for 40 s, annealing using a gradient of 57 °C – 60 °C 
held for 90 s and elongation at 68 °C for 180 s with an increase of 120 s after each 
10 cycles for a total of 40 cycles.  Five µl of an enzyme mixture comprising       
1x Expand High Fidelity buffer and 3,75 U Expand High Fidelity enzyme mix 
was added to each reaction 30 s into the first annealing step.  Following full length 
PCR amplification, a 5 µl aliquot of each sample was resolved on a 1% agarose 
gel (section 2.6), together with a 1 kb DNA ladder (Promega) to confirm 
successful amplification of the sample. 
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2.5.2  Amplification of the full HBV genome using two overlapping 
PCR products 
 
This amplification was performed using the primers described by Takahashi et al. 
in 1998 (table 5) and the Expand High Fidelity PCR system.   
 
Table 5:  Primers for amplification of two overlapping PCR products (Takahashi et 
al., 1998) 
Name Positiona Nucleotide Sequence Orientation 
T715 1553 - 1572 5’ – CTG TGC CTT CTC ATC TGC CG - 3’ Sense 
#S1-2 704 - 685 5’ – CGA ACC ACT GAA CAA ATG GC - 3’ Antisense 
#ep1-1 1606 - 1625 5’ – GCA TGG AGA CCA CCG TGA AC - 3’ Sense 
#S2-2 687 - 668 5’ – GGC ACT AGT AAA CTG AGC CA - 3’ Antisense 
#S1-1 192 - 211 5’ – TCG TGT TAC AGG CGG GGT TT - 3’ Sense 
T734 3161 - 3143 5’ – CTT CCT GAC TGS CGA TTG G - 3’ Antisense 
#S2-1 455 - 474 5’ – CAA GGT ATG TTG CCC GTT TG - 3’ Sense 
T733 3100 - 3081 5’ – CCT GAG CCT GAG GGC TCC AC - 3’ Antisense 
a Denotes position on HBV subgenotype A2 genome (GenBank accession #X70185) with 
the EcoRI cleavage site at position 1. 
  Abbreviations:  S – G or C 
 
The amplification protocol used was similar to that described in section 2.5.1 for 
the full length amplification of the HBV genome except that a nested PCR was 
used.  The first round of amplification was identical to that of the full length 
amplifications except that the gradient for the annealing temperatures was 55 °C – 
57 °C.  The second round of the nested PCR used 5 µl of first round PCR product 
as template and a gradient of annealing temperatures of 53 °C – 55 °C but was 
identical to the full length PCR in all other respects.  The success of the 
amplifications was confirmed by resolving a 5 µl aliquot of each sample on a 1% 
agarose gel (section 2.6), together with a 1 kb DNA ladder (Promega). 
 
2.5.3  Subgenomic PCR 
 
Subgenomic PCR amplifications using HBV-specific primers were used both to 
confirm the presence of HBV DNA in the extracts and to amplify the complete 
viral genome by the amplification of eight overlapping subgenomic fragments.  
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The primers used for these PCR amplifications were obtained either from Hu et 
al. (2000) or else were primer combinations used routinely in the Molecular 
Hepatology Research Unit laboratory.  The subgenomic PCR amplifications were 
nested PCRs and the primers used, as well as the thermocycling conditions, are 
shown in table 6.  For the first round of the nested PCR amplification, a 22,5 µl 
mixture comprising 0,5 U of BIOTAQ™ DNA polymerase (Bioline), 200 µM of 
each dNTP, 1 µM of each primer, 3 mM MgCl2, 16 mM  (NH4)2SO4, 67 mM Tris-
HCl (pH 8.8) and 0,01% Tween-20, was added to 2,5 µl sample DNA and 
amplified in a Techgene programmable thermocycler (Techne).  All 
amplifications contained a final elongation step at 72 °C held for 7 min.  For the 
second round of amplification, 5 µl of first round product was added to a 45 µl 
mixture containing 1 U of BIOTAQ™ DNA polymerase (Bioline), 200 µM of 
each dNTP, 1 µM of each primer, 1,5 mM MgCl2, 16 mM (NH4)2SO4, 67 mM 
Tris-HCl (pH 8.8) and 0,01% Tween-20.  Amplification was once again 
performed in a Techgene programmable thermocycler (Techne) and included final 
elongation step at 72 °C held for 10 min. 
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Table 6:  Primers combinations and thermocycling profiles for amplification of subgenomic regions of the viral genome. 
 
Name Positiona Nucleotide Sequence Orientation Thermocycling Conditions Denaturation Annealing Elongation No. of cycles 
58Fd 56 – 75 5- CCT GCT GGT GGC TCC AGT TC - 3’ Sense 94 °C for 45 s 55 °C for 45 s 72 °C for 180 s b 45 1450Rd 1447 – 1426 5- GAT TCA GCG CCG ACG GGA CGT A - 3’ Antisense 
409Fd 409 – 431 5- CAT CCT GCT GCT ATG CCT CAT CT - 3’ Sense 94 °C for 45 s 55 °C for 45 s 72 °C for 180 s b 35 1101R 1120 – 1098 5- GAA AGG CCT TGT AAG TTG GCG AG - 3’ Antisense 
255F 253 – 275 5- CTC GTG GTG GAC TTC TCT CAA TT - 3’ Sense 94 °C for 30 s 56 °C for 50 s 72 °C for 60 s 40 759R 759 – 739 5- CCC CAA TAC CAC ATC ATC CAT - 3’ Antisense 
459F 460 – 480 5- TAT GTT GCC CGT TTG TCC TCT - 3’ Sense 94 °C for 30 s 56 °C for 50 s 72 °C for 50 s 40 710R 711 – 691 5- AGC CCT ACG AAC CAC TGA ACA - 3’ Antisense 
409Fd 409 – 431 5- CAT CCT GCT GCT ATG CCT CAT CT - 3’ Sense 94 °C for 45 s 55 °C for 45 s 72 °C for 180 s b 45 1800R 1800 – 1774 5- AGA CCA ATT TAT GCC TAC AGC CTC CTA - 3’ Antisense 
730Fd 682 – 704 5- AGT GCC ATT TGT TCA GTG GTT CG - 3’ Sense 94 °C for 45 s 55 °C for 45 s 72 °C for 180 s b 35 1575R 1573 – 1549 5- CCG GCA GAT GAG AAG GCA CAG ACG G - 3’ Antisense 
1528F 1528 – 1547 5- ACC TCT CTT TAC GCG GTC TC - 3’ Sense 94 °C for 45 s 55 °C for 45 s 72 °C for 180 s b 45 1921R 1921 – 1904 5- TTT ATA CGG GTC AAT GTC - 3’ Antisense 
1552F 1552 – 1571 5- TCT GTG CCT TCT CAT CTG CC - 3’ Sense 94 °C for 45 s 55 °C for 45 s 72 °C for 180 s b 35 1803R 1803 – 1783 5- CGC AGA CCA ATT TAT GCC TAC – 3’ Antisense 
1732F 1730 – 1747 5- CTG GGA GGA GTT GGG GGA - 3’ Sense 94 °C for 30 s 62 °C for 50 s 72 °C for 50 s 40 2045R 2043 – 2022 5- CAA TGC TCA GGA GAC TCT AAC GG - 3’ Antisense 
1765F 1763 – 1783 5- GGT CTT TGT ACT AGG AGG CTG - 3’ Sense 94 °C for 30 s 58 °C for 50 s 72 °C for 50 s 40 1968R 1966 – 1946 5- GTC AGA AGG CAA AAA CGA GAG - 3’ Antisense 
1860Fd 1859 – 1879 5- ACT GTT CAA GCC TCC AAG CTG - 3’ Sense 94 °C for 45 s 55 °C for 45 s 72 °C for 180 s b 45 58Rd 75 – 56 5- GAA CTG GAG CCA CCA GCA GG - 3’ Antisense 
1898F 1898 – 1917 5- GGC ATG GAC ATT GAC CCG TA - 3’ Sense 94 °C for 45 s 55 °C for 45 s 72 °C for 180 s b 35 2898R 2917 – 2896 5- GAG GAT TGG GAA CAG AAA GAT T - 3’ Antisense 
1860Fd 1859 – 1879 5- ACT GTT CAA GCC TCC AAG CTG - 3’ Sense 94 °C for 45 s 55 °C for 45 s 72 °C for 180 s b 45 58Rd 75 – 56 5- GAA CTG GAG CCA CCA GCA GG - 3’ Antisense 
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2440Fd 2416 – 2437 5- GCC GCG TCG CAG AAG ATC TCA A - 3’ Sense 94 °C for 45 s 55 °C for 45 s 72 °C for 180 s b 35 2853Rd 2842 – 2823 5- TGT TCC CAA GAA TAT GGT GA - 3’ Antisense 
1860Fd 1859 – 1879 5- ACT GTT CAA GCC TCC AAG CTG - 3’ Sense 94 °C for 45 s 55 °C for 45 s 72 °C for 180 s b 45 409Rd 431 – 409 5- AGA TGA GGC ATA GCA GCA GGA TG - 3’ Antisense 
2440Fd 2416 – 2437 5- GCC GCG TCG CAG AAG ATC TCA A - 3’ Sense 94 °C for 45 s 55 °C for 45 s 72 °C for 180 s b 35 58Rd 75 – 56 5- GAA CTG GAG CCA CCA GCA GG - 3’ Antisense 
1687F 1687 – 1706 5- CGA CCG ACC TTG AGG CAT AC - 3’ Sense 94 °C for 30 s 62 °C for 40 s 72 °C for 80 s 40 2498R 2498 – 2477 5- AAG CCC AGT AAA GTT TCC CAC C - 3’ Antisense 
2267F 2267 – 2284 5- GGA GTG TGG ATT CGC ACT - 3’ Sense 94 °C for 30 s 51 °C for 50 s 72 °C for 50 s 40 2436R 2436 – 2419 5- TGA GAT CTT CTG CGA CGC - 3’ Antisense 
2540F 2540 – 2561 5- TCC CTC CTT TCC TAA CAT TCA T - 3’ Sense 94 °C for 30 s 50 °C for 50 s 72 °C for 50 s 40 2896R 2896 – 2917 5- GAG GAT TGG GAA CAG AAA GAT T - 3’ Antisense 
2566F 2565 – 2586 5- CAG GAG GAC ATT ATT AAT AGA T - 3’ Sense 94 °C for 30 s 48 °C for 50 s 72 °C for 50 s 40 2858R 2857 – 2838 5- CCA TGC TGT AGC TCT TGT TC - 3’ Antisense 
2800F 2800 – 2834 5- CAG GTA GCG CCT CAT TTT GTG GGT CAC  
            CAT ATT CT - 3’ 
Sense 
94 °C for 45 s 55 °C for 45 s 72 °C for 180 s b 45 
1101R 1120 – 1098 5- GAA AGG CCT TGT AAG TTG GCG AG - 3’ Antisense 
2853Fd 2823 – 2842 5- TCA CCA TAT TCT TGG GAA CA - 3’ Sense 94 °C for 45 s 55 °C for 45 s 72 °C for 180 s b 35 409Rd 431 – 409 5- AGA TGA GGC ATA GCA GCA GGA TG - 3’ Antisense 
2853Fd 2823 – 2842 5- TCA CCA TAT TCT TGG GAA CA - 3’ Sense 94 °C for 45 s 55 °C for 45 s 72 °C for 180 s b 45 1101R 1120 – 1098 5- GAA AGG CCT TGT AAG TTG GCG AG - 3’ Antisense 
58Fd 56 – 75 5- CCT GCT GGT GGC TCC AGT TC - 3’ Sense 94 °C for 45 s 55 °C for 45 s 72 °C for 180 s b 35 730Rd 682 – 704 5- CGA ACC ACT GAA CAA ATG GCA CT - 3’ Antisense 
2440Fd 2416 – 2437 5- GCC GCG TCG CAG AAG ATC TCA A - 3’ Sense 
94 °C for 45 s 55 °C for 45 s 72 °C for 180 s b 35 c 
58Rd 75 - 56 5- GAA CTG GAG CCA CCA GCA GG - 3’ Antisense 
a Denotes position on HBV subgenotype A2 genome (GenBank accession #X70185) with the EcoRI cleavage site at position 1. 
b Ramping from annealing temperature to elongation temperature was performed at 0,4 °C per second. 
c This was a single round PCR amplification using a clone containing a portion of the HBV genome as template.  The conditions used for this amplification were 
identical to those used for the second round of nested PCR amplifications. 
d
 Hu et al.  2000 
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2.5.4  Real Time PCR 
 
Real time PCR was used to detect cccDNA in the liver tissue.  DNA was extracted 
using the QIAamp DNA Mini Kit (Qiagen).  Amplified product was detected with 
SYBR® Green. 
 
2.5.4.1  Plasmid-Safe™ DNase treatment 
The DNA extracts were treated with Plasmid-Safe™ ATP-Dependent DNase 
(Epicentre® Biotechnologies, Madison, Wis.), which selectively hydrolyses linear 
double-stranded DNA and, at a lower efficiency, linear and closed-circular single-
stranded DNAs.  This meant that the chromosomal DNA would be digested while 
the HBV cccDNA would remain intact.  Ten µl of total DNA extract was digested 
with 2 mM ATP solution and 20 U Plasmid-Safe DNase in 1 x reaction buffer   
(33 mM Tris-acetate (pH 7,8), 66 mM potassium acetate, 10 mM magnesium 
acetate and 0,5 mM DTT) for 45 min at 37 °C.  The reaction was terminated by 
incubation at 70 °C for 30 mins.  The restricted DNA was used directly as 
template for real time PCR analysis. 
 
2.5.4.2  PCR amplification using SYBR® green detection 
The Power SYBR® Green PCR Master Mix (Applied Biosystems, Foster City, 
Calif.) was used for this PCR.  To obtain optimal sensitivity, three primers were 
used for this amplification, two sense primers and one antisense primer (table 7).   
 
Table 7:  Primers for real time PCR using SYBR® Green detection (Bowden et al., 
2004) 
Name Position a Nucleotide Sequence Orientation 
CCC1 1540 – 1559 5’ – GCG GWC TCC CCG TCT GTG CC – 3’ Sense 
DRF1 1551 – 1570 5’ – GTC TGT GCC TTC TCA TCT GC – 3’ Sense 
CCC2 1906 – 1887 5’ – GTC CAT GCC CCA AAG CCA TC – 3’ Antisense 
a Denotes position on HBV subgenotype A2 genome (GenBank accession #X70185) with 
the EcoRI cleavage site at position 1. 
  Abbreviations:  W – A or T 
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For each sample, a 50 µl reaction containing 25 µl Power SYBR® Green PCR 
Master Mix, 0,5 mM of each of the three primers and 5 µl of sample DNA was 
prepared.  The amplification was performed using a 7500 Real-Time PCR system 
(Applied Biosystems) as follows:  initial denaturation at 95 °C held for 10 min 
and a total of 45 cycles of denaturation at 95 °C held for 15 s and annealing and 
elongation at 65 °C held for 60 s.  Data was collected during the 65 °C incubation.  
A dissociation curve was run at the end of the amplification using the following 
protocol: 95 °C held for 15 s, 64 °C held for 60 s and 99 °C held for 15 s.   
 
2.6  Agarose Gel Electrophoresis 
 
Products were resolved on agarose gels of the appropriate volume and 
concentration, prepared as described in appendix II, in order to visualise the DNA.  
Once completely solidified, the agarose gel was immersed fully in an 
electrophoresis tank containing 1x TBE Buffer (Appendix II).  The samples were 
prepared by adding 0,4 volumes 6x Blue/Orange Loading Dye (15% Ficoll® 400, 
0,03% bromophenol blue, 0,03% xylene cyanol FF, 0,4% orange G, 10mM Tris-
HCl (pH 7,5) and 50 mM EDTA) (Promega) and mixed thoroughly.  The entire 
sample volume was loaded into the agarose gel and the gel electrophoresed at    
~4 volts / cm until the bromophenol blue tracking dye front had migrated ~75% of 
the length of the gel.  An image of the gel was recorded using the Gel Doc XR 
Imaging System (Bio-Rad). 
 
2.7  Cloning 
 
Two different methods were used to clone fragments amplified by PCR.  The 
TOPO® XL PCR Cloning Kit (Invitrogen Corp., Carlsbad, Calif.) was used to 
clone fragments greater than 2 kb in length and the InsTAclone™ PCR Cloning 
Kit (Fermentas Life Sciences, Burlington, Ontario) was used to clone fragments 
smaller than 2 kb.  Both kits were used according to the manufacturer’s 
instructions.   
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PCR amplicons cloned with the TOPO® XL PCR Cloning Kit were isolated by 
resolving them on a 0,8% Crystal Violet agarose gel (Appendix II), and the 
fragments of interest excised and extracted using a S.N.A.P.™ purification 
column (Invitrogen).  The extracted DNA was eluted in 40 µl TE Buffer 
(Invitrogen) and 4 µl of this gel-purified product was used for the cloning 
reaction.  The TOPO® cloning reaction was incubated for 5 min at room 
temperature, after which 1 µl 6x TOPO® Cloning stop solution was added.  A 2 µl 
aliquot of the TOPO® cloning reaction was used immediately for the 
transformation of One Shot® TOP10 chemically competent cells (Invitrogen).  
Three different volumes of the transformation reaction (50 µl, 100 µl and 150 µl) 
were spread onto prewarmed Luria-Bertani (LB) agar plates containing 50 µg/ml 
kanamycin (Bio Basic Inc.) and incubated overnight at 37 °C.  Individual colonies 
were selected and re-plated onto fresh LB agar-kanamycin plates, incubated at   
37 °C overnight and stored at 4 °C until required. 
 
For PCR amplicons cloned with the InsTAclone™ PCR Cloning Kit, the final 
elongation step of the second round of the nested PCR amplification was 
increased from 10 min to 30 min.  This was to increase the number of 3’-A 
overhangs on the ends of the amplicons.  The amplicons were gel purified using 
the QIAGEN QIAquick Gel Extraction Kit according to the manufacturer’s 
instructions and eluted in 50 µl best quality water.  A 10 µl aliquot of this elute 
was resolved on a 1% agarose gel (section 2.6) together with a O’GeneRuler        
1 kb DNA ladder (Fermentas).  This molecular weight marker is composed of 
fragments of known concentration and the concentration of the eluted DNA can 
be determined by comparing the intensity of the resolved fragment to the 
intensities of the fragments in the molecular weight marker.  This concentration 
was used to determine the volume of extracted DNA equivalent to the 0,54 pmol 
ends required for the cloning reaction which was set up according to the 
manufacturer’s instructions and incubated overnight at 22 °C.  A 2,5 µl aliquot of 
the cloning reaction was transformed into One Shot® TOP10 chemically 
competent cells (Invitrogen).  As with the TOPO® XL PCR Cloning Kit, three 
different volumes of the transformation reaction (50 µl, 100 µl and 150 µl) were 
spread onto prewarmed LB agar plates containing 50 µg/ml ampicillin (Roche) 
and incubated overnight at 37 °C.  The next day, individual colonies were selected 
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and re-plated onto fresh LB-ampicillin plates, incubated at 37 °C overnight and 
stored at 4 °C until required. 
 
Plasmid DNA was isolated from individual colonies using the GenElute™ 
Plasmid Miniprep Kit (SIGMA) according to the manufacturer’s instructions.  
The cells were cultured overnight in 5 ml LB medium containing either 
kanamycin or ampicillin as required.  The cells were harvested, lysed and the 
DNA purified using a GenElute™ Miniprep Binding Column.  The DNA was 
eluted in 50 µl best quality water.   
 
A 5 µl aliquot of extracted plasmid DNA was restricted at 37 °C for 1 hour with 
20 U EcoRI (New England BioLabs) in 1x NEBuffer EcoRI, comprising 50 mM 
NaCl, 100 mM Tris-HCl, 10 mM MgCl2 and 0,025% Triton X-100 at a pH of 7,5.  
The restricted products were resolved overnight on a 1% agarose gel (section 2.6) 
together with a 1 kb DNA ladder (Promega) to determine whether or not the 
plasmids contained the fragment of interest. 
 
2.8  Sequencing of amplified products 
 
Products amplified by PCR, as well as cloned PCR products, were sequenced by 
Inqaba Biotechnical Industries Ltd (Pretoria, South Africa) using a SpectruMedix 
model SCE 2410 automated sequencer (SpectruMedix, State College, PA), and 
the ABI Big Dye Terminator Cycle Sequencing kit version 3.1 (Applied 
Biosystems).  The primers used for sequencing the PCR amplicons were the same 
as those used for the second round PCR or, in the case of the cloned products, the 
vector specific primers recommended by the manufacturers.  Chromatograms of 
the sequences generated were inspected with Chromas software (version 1.45; 
Technelysium Pty. Ltd., Helensvale, Queensland, Australia).  Sequences were 
subjected to a standard nucleotide-nucleotide BLAST search 
(http://www.ncbi.nlm.nih.gov/Blast.cgi) to ensure that the amplicons belonged to 
the family Hepadnaviridae rather than being the result of the non-specific 
amplification of genomic DNA   
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2.9  Phylogenetic Analysis 
 
Sequences were aligned manually with complete HBV genome sequences from 
GenBank® (http://www.ncbi.nlm.nih.gov/Genbank/index.html) using the 
GeneDoc program (Nicholas and Nicholas, 1997).  Overlapping sequences were 
used to generate a complete sequence which was fed into PHYLIP (PHYLogeny 
Inference Package) version 3.6 (Felsestein, 1995).  Neighbour joining 
phylogenetic trees were generated by calculating the evolutionary distances using 
the DNADIST program and the Kimura-2-parameter model and a dendogram was 
generated with the NEIGHBOR program.  Bootstrap analysis using 1 000 
bootstrap replicates was performed using the SEQBOOT, DNADIST and 
NEIGHBOR programs.  Bootstrap values below 75% indicated that a 
monophyletic group was not well supported, while values greater that 95% 
indicated very solid nodes.  A consensus tree was generated using the 
CONSENSE program and the trees visualised using the TreeView Win 32 
program (Page, 1996).  Trees were rooted using either a WMHBV isolate 
(GenBank accession no. AY226578) or an HBV genotype F isolate (GenBank 
accession no. X69798) and the scale bar at the bottom of the dendogram showed 
the scaled evolutionary distance. 
 
2.10  Recombination Analysis 
 
Evidence of possible recombination with the complete HBV genome from 
baboons was investigated using the Simmonic 2005 version 1.6 software package 
implementing PHYLIP (Simmonds and Midgley, 2005).  The complete genome 
sequence was compared to a reference set of 228 non-recombinant HBV isolates 
and a GroupScanning plot generated (Tatematsu et al., 2009).  Consecutive 
fragments of 500 bp in length, with 15 bp incremental steps between fragments, 
were analysed. 
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2.11  Southern Blotting DNA samples 
 
This protocol was obtained from Martins-Furness (2009) 
 
2.11.1  Blotting of samples onto a nylon membrane 
 
Samples were blotted onto nylon membrane either by using a slot blot manifold or 
by first resolving the samples on an agarose gel and then transferring the DNA to 
the membrane using the capillary transfer method. 
 
2.11.1.1  Slot Blotting 
Serum samples from a number of different baboons and vervet monkeys were 
blotted onto a nylon membrane using a modification of the protocol described by 
Zaaiger et al. (1994).  A 50 µl aliquot of serum was incubated with 50 µl slot blot 
denaturing solution (Appendix II) for two hours at 56 °C followed by a 95 °C 
incubation for ten min.  The samples were quick chilled on ice to allow them to 
thicken and 200 µl 20 x SSC (Appendix II) added.  After mixing thoroughly by 
vortexing, the samples were clarified by centrifuging at 13 000 rpm in a 
microfuge (Eppendorf GmBH., Hamburg, Germany) for 15 min.  Meanwhile, the 
Bio-Dot® SF microfiltration apparatus (BioLab Laboratories, South Richmond, 
Calif.) was prepared by cutting a piece of Hybond N nylon membrane (Amersham 
Biosciences UK Ltd., Buckinghamshire, UK), to the size of the slot blot manifold.  
This membrane, together with a piece of Bio-Dot® SF filter paper (BioLab) the 
same size as the membrane, was pre-wet in 20 x SSC (Appendix II) and placed on 
the manifold on top of the filter paper before being clamped tightly in place.  Two 
hundred µl of supernatant from each of the centrifuged samples was loaded, one 
sample per well, and allowed to blot by applying a vacuum to the manifold.  Once 
the entire sample had passed through the membrane, the vacuum was released, the 
apparatus disassembled and the bound DNA denatured by placing the membrane 
(DNA side up) on a pad of filter paper soaked in 0,4 M NaOH (Appendix II) for  
5 min.  The membrane was transferred to a neutralising solution comprising            
2 x SSC for one minute and placed, DNA side up, on a clean piece of filter paper 
to air-dry.  The DNA was immobilised by baking the blot at 80 °C for two hours 
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and the blot was then stored, between two pieces of filter paper, at room 
temperature until required. 
 
2.11.1.2  Transfer of DNA from the agarose gel 
A 10 µl aliquot of each of the PCR amplified products to be blotted was resolved 
on a 1% agarose gel (section 2.6).  Following electrophoresis, the DNA was 
prepared for transfer to the nylon membrane by trimming any excess agarose from 
the sides of the gel and placing it in a trough and covered with depurination 
solution (Appendix II) on a gentle horizontal shaking platform for 20 min at room 
temperature.  Soaking the gel in depurination solution for 10 – 20 min increases 
the efficiency of the transfer of large DNA fragments (>15 kb) to the nylon 
membrane by nicking the DNA (Sambrook et al., 1989).   The depurination 
solution was poured off, the gel rinsed twice in distilled water and then covered in 
denaturation solution (Appendix II) to ensure that the DNA is single stranded 
(Sambrook et al. 1989).  After gently shaking for 45 min at room temperature, the 
denaturation solution was poured off and the gel rinsed twice in distilled water.  
Following denaturation, the gel was covered in neutralisation solution (Appendix 
II) and placed on the shaking platform for 30 min at room temperature after which 
the neutralisation solution was poured off and the gel rinsed twice in distilled 
water.  The DNA was transferred to the nylon membrane using the capillary 
transfer method. 
 
Approximately one litre of 20 x SSC (Appendix II) was poured into a trough and 
a glass plate, slightly wider than the length of the agarose gel, was placed across 
the width of the trough (figure 11).  A wick, composed of a long piece of 3MM 
Whatman paper (Whatman Plc., Maidstone, Kent, UK), was wet thoroughly with 
20 x SSC and placed across the glass plate with both ends sitting in the buffer.  A 
glass rod was carefully rolled across the wick to remove any air bubbles.  The 
agarose gel was positioned upside down on the wick, the glass rod rolled carefully 
over the gel to remove any air bubbles and the areas around the gel covered with 
plastic cling wrap.   
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Figure 11:  Capillary transfer of DNA from an agarose gel.  This schematic illustrates 
the set-up required to transfer DNA from an agarose gel to a nylon membrane.  Buffer is 
drawn up from the trough via the wick passing through the gel and into the stack of paper 
towels.  As the buffer passes through the agarose gel, it elutes the DNA from the gel and 
deposits it on the nylon membrane.  A weight is applied to the top of the paper towels to 
ensure that there is a tight connection between the various layers of the transfer set-up 
(Sambrook et al. 1989).  
 
A piece of Hybond-N nylon membrane (Amersham Biosciences) was cut to the 
exact size of the gel and pre-wet in distilled water and followed by 20 x SSC 
(Appendix II).  The membrane was placed on top of the agarose gel and the glass 
rod rolled carefully over the membrane to remove air bubbles.  One corner of the 
membrane was carefully marked at this time to allow for the correct orientation of 
the membrane after transfer.  Two sheets of 3MM Whatman filter paper cut to the 
same size as the gel were pre-wet in 20 x SSC (Appendix II) and placed over the 
membrane, removing any air bubbles by rolling the glass rod over the filter paper.  
An additional four sheets of dry 3MM Whatman filter paper cut to the same size 
as the gel were placed on top of the wet sheets and any air bubbles removed as 
before.  The filter paper was covered with a stack of paper towels ~15 cm high, 
trimmed to the same size as the agarose gel, ensuring that there was no contact 
between the gel and the paper towels to prevent short-circuiting the transfer of the 
DNA.  A second glass plate was placed on top of this stack and covered with a 
weight of ~800g evenly distributed across the entire gel.  Transfer was allowed to 
take place for between 12 and 48 hours, replenishing the buffer in the bottom tank 
if and when needed, being careful not to disturb the transfer set-up in the process.  
Once transfer was complete, the set-up was dismantled, the membrane washed in 
2 x SSC (Appendix II) and placed DNA side up on a clean piece of filter paper to 
paper 
towels 
nylon membrane 
filter paper wick 
glass plate across 
width of trough 
weight 
glass plate 
filter paper 
agarose gel 
trough 
transfer buffer 
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air-dry.  The membrane was baked at 80 °C for two hours to immobilise the DNA 
and stored between two pieces of filter paper at room temperature until required. 
 
2.11.2  Preparation of probe for Southern hybridisation 
 
DNA was extracted from the serum of a patient known to be positive for a HBV 
infection using the QIAGEN QIAamp® DNA Blood Mini Kit and used as 
template for a full length PCR amplification (section 2.5.1) of the complete viral 
genome.  The full length amplicon was cloned using the TOPO® XL PCR Cloning 
Kit (section 2.7) and the plasmid DNA extracted using the GenElute™ Plasmid 
Miniprep Kit (SIGMA).  The plasmid DNA extract, diluted one in ten, was used 
as template for amplification of the complete genome by full length PCR 
amplification (section 2.5.1).  The full length amplicon was resolved on a          
1% agarose gel (section 2.6), the 3,2 kb fragment excised with a clean scalpel 
blade and the DNA purified using the QIAGEN QIAquick Gel Extraction Kit 
according to the manufacturer’s instructions.  The DNA was eluted in 10 µl 
elution buffer (10mM Tris-HCl, pH 8.5) and stored at -20 °C until needed. 
 
The gel purified full length HBV genome amplicon was quantified by resolving a 
dilution series of the DNA on a 1% agarose gel (section 2.6).  The DNA was 
diluted in sterile water and 10 µl of each dilution resolved on the agarose gel.  The 
concentration of the probe was approximated from this gel using the standard that 
the fragment just visible contains 10 ng of DNA. 
 
2.11.3  Radioactive labelling of probe DNA 
 
The probe was labelled using the Megaprime™ DNA Labelling System 
(Amersham Biosciences).  A 200 ng aliquot of the gel purified 3.2 kb full length 
HBV amplicon (section 2.11.2) was placed in a 1,5 ml microcentrifuge tube 
together with 5 µl primer solution (random nonamer primers in an aqueous 
solution) and the volume adjusted to 33 µl with TE Buffer (Appendix II).  The 
probe was denatured at 99 °C for five min, briefly centrifuged and placed on ice.  
Five µl of labelling buffer (dATP, dTTP and dGTP in Tris-HCl (pH 7,5),            
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2-mercaptoethanol and MgCl2), 2 µl enzyme solution (1 U/µl DNA polymerase I 
Klenow fragment (cloned) in 100 mM potassium phosphate (pH 6,5), 10 mM      
2-mercaptoethanol and 50% glycerol) and 5 µl Amersham Redivue™ α-32P-dCTP 
250 µCi (Amersham Biosciences) was added and the reaction incubated at 37 °C 
for 20 min after which it was briefly centrifuged, placed on ice and 50 µl of       
TE Buffer (Appendix II) added to adjust it to a total volume of 100 µl. 
 
The radioactively labelled probe was purified by passing it through a Sephadex 
column (Appendix II) to remove any unincorporated nucleotides.  A labelled     
1,5 ml microcentrifuge tube was placed at the bottom of an equilibrated sephadex 
column to collect the labelled probe.  The entire 100 µl of probe was added to the 
Sephadex column and centrifuged at ~3 500 x g for 5 min.  An equal volume 
(100 µl) of TE buffer (Appendix II) was added to the column and the columns left 
to stand at room temperature for 5 min before centrifuging once again for 5 min at 
~3 500 x g.  The collection tube containing the purified probe was removed from 
the bottom of the column, the volume of the probe adjusted to 1 ml with TE buffer 
(Appendix II) and placed on ice. 
 
The amount of radioactivity incorporated into the probe was established using a 
scintillation counter.  The sample was prepared by adding 10 µl of labelled probe 
to 5 ml INSTA-GEL scintillation gel (United Technologies, Packard Instrument 
Company, Dowers Grove, Ill.) in a glass scintillation vial (Packard Instrument 
Company).  After mixing thoroughly by vigorous shaking, the sample was 
counted for one minute on the scintillation counter and the amount of probe 
required for the Southern hybridisations calculated.  For each blot, between        
25 x 106 and 100 x 106 incorporated counts per minute (cpm) of probe was 
necessary. 
  
2.11.4  Hybridisation of Southern Blots with Radioactive probes 
 
A piece of nylon mesh was cut slightly larger (~1 cm) than the dimensions of the 
nylon membrane to be hybridised and pre-wet in distilled water.  The nylon 
membrane onto which the DNA had been blotted (section 2.11.1) was placed in a 
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suitable trough and pre-wet in distilled water before being rolled, DNA side up, 
inside the pre-wet piece of nylon mesh allowing any overlapping areas of the blot 
to remain separated during hybridisation.  The rolled blot was placed in a 
hybridisation tube (Hybaid Ltd., Middlesex, UK) in such a way as to ensure that, 
when placed in the hybridisation oven, the movement of the rotor would keep the 
blot unrolled.  If more than one membrane was to be blotted simultaneously, each 
blot was placed in a separate hybridisation tube.  After unrolling the blot in the 
hybridisation tube, it was rinsed in a small volume of Church and Gilbert (C&G) 
hybridisation buffer (Appendix II), which was discarded, and any excess liquid in 
the tube drained off.  Fifty ml C&G Hybridisation Buffer was added to each tube 
and the blots pre-hybridised at 65°C for 30 min in a Hybaid hybridisation oven.  
Meanwhile, an appropriate volume of radioactively labelled probe (8 x 107 cpm) 
was placed in a 2 ml microcentrifuge tube together with 100 µl salmon sperm 
DNA (Appendix II) and mixed thoroughly.  A separate tube of probe was 
prepared for each blot to be hybridised.  The probe was incubated at 99 °C for      
5 min, snap cooled on ice and briefly centrifuged.  One ml of pre-heated C&G 
Hybridisation buffer was added to the probe and mixed thoroughly just prior to 
the addition of the entire mixture to the pre-hybridised blot in the hybridisation 
tube.  Care was taken to avoid placing the probe directly on the membrane; 
instead it was added to the hybridisation buffer already in the tube.  The blot was 
hybridised overnight at    65 °C. 
 
2.11.5  Washing of the Southern Blot after hybridisation 
 
The following day the blots were washed to remove any excess probe and any 
non-specifically bound probe.  The hybridisation tube was removed from the oven 
and the C&G hybridisation buffer poured off and discarded.  Approximately     
200 ml of the first wash buffer (Appendix II) was added to the hybridisation tube 
and the blot washed at room temperature for 8 min in the hybridisation oven.  This 
first wash buffer was poured off and discarded and the wash repeated.  After 
pouring the wash buffer off once again, ~200 ml of the second wash buffer 
(Appendix II) was added to the tube.  The tube was returned to the hybridisation 
oven and the blot washed at 65 °C for 10 min.  The second wash buffer was 
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poured off and discarded and the blot rinsed twice at room temperature with the 
third wash buffer (Appendix II).  The blotted nylon membrane, together with the 
nylon mesh, was removed from the hybridisation tube and unrolled.  The 
membrane was placed between two sheets of plastic and sealed on all sides with a 
plastic sealer being careful to remove any air-bubbles.  The nylon mesh was 
placed in a 10% SDS solution so that it could be re-used, after extensive rinsing in 
distilled water, if ever the membrane was re-probed with the same probe.  The 
membrane, sealed in plastic, was placed in a light-tight X-ray cassette with an 
intensifying screen and exposed to α-32P-sensitive KODAK BioMax MS Film 
(Carestream Health, Rochester, NY.) for ~2 weeks at -70 °C before developing. 
 
2.12  Analysis of RNA 
 
2.12.1  Extraction of RNA from liver tissue 
 
RNA was extracted using the guanidinium-acid-phenol method first described in 
1987 by Chomczynski and Sacchi (Chomczynski and Sacchi, 1987; Farrell, 
1993).  Liver tissue was obtained from ~1cm below the surface of the frozen 
baboon 9732 liver to prevent contamination and the degradation of nucleic acids 
by freezer burn.  A section of the liver tissue weighing approximately 100 mg was 
ground in liquid nitrogen using an RNase-free mortar and pestle and the ground 
liver tissue transferred to a 2 ml glass homogeniser.  The tissue was homogenised 
in 1ml Solution D (Appendix II) and the homogenate transferred to a 15 ml 
disposable, RNase free polypropylene tube after which the following were added 
in order: 100 µl 2M sodium acetate, pH 4,0 (Appendix II), 1 ml water saturated 
phenol (Appendix II) and 200 µl 49:1 chloroform: iso-amyl alcohol (Appendix II).  
The tube was capped and mixed thoroughly by inversion following the addition of 
each reagent and, after all the reagents had been added, shaken vigorously for ten 
seconds.  The sample was cooled on ice for 15 min and then centrifuged at     
2000 x g at 4 °C to separate the phases.  The aqueous (upper) phase, which 
contained the RNA, was transferred to a fresh 15 ml tube and mixed with an equal 
volume of isopropanol (approximately 1ml, Associated Chemical Enterprises cc., 
Johannesburg, South Africa) and stored at –20 °C overnight to precipitate the 
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RNA.  The following day, the precipitate was collected by centrifugation at 
maximum speed (>2000 x g) for 20 min at 4 °C, the supernatant was carefully 
decanted and discarded and the RNA pellet completely resuspended in 300 µl of 
Solution D (Appendix II).  This resuspension was transferred to an RNase free  
1,5 ml microcentrifuge tube (Eppendorf) and the RNA precipitated by adding an 
equal volume of ice cold isopropanol and storing at –20 °C for one hour.  The 
RNA pellet was collected at top speed in a microcentrifuge for ten minutes at 4 °C 
and the supernatant carefully decanted and discarded.  The pellet was washed 
twice in 500 µl 75% ethanol (Appendix II), recentrifuged and incubated to near 
dryness.  Finally, the pellet was redissolved in ~100 µl DEPC-treated water 
(Invitrogen) and stored at –70 °C in suitable aliquots.  Repeated freezing and 
thawing of the RNA was avoided as this has been known to increase the risks of 
RNA degradation.   
 
2.12.2  Quantification of RNA 
 
The concentration of each RNA sample was determined by spectrophotometry 
using the NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies).  
The concentration of the RNA was calculated by using the standard that                
1 OD260 = 40 µg RNA/ml.  The quality of the samples was assessed by calculating 
the OD260/OD280 ratio.   
 
2.12.3  DNase treatment of extracted RNA 
 
An appropriate volume of guanidinium-acid-phenol extracted RNA was digested 
with RNase-free Deoxyribonuclease I (DNase I, Fermentas) to remove any 
contaminating DNA from the sample.  Digestions were set up in an RNase-free 
0,2 ml thin-walled PCR tube (Eppendorf).  For each µg of RNA, one U of DNase 
I (1 U/µl) and one tenth the final volume of 10 x Reaction Buffer (100 mM Tris-
HCl (pH 7,5), 25 mM MgCl2, 1 mM CaCl2) were added and the sample made up 
to the correct volume using DEPC-treated water (Invitrogen).  The digestions 
were incubated at 37 °C for 30 min in a Techgene programmable thermocycler 
(Techne) and, after the addition of a volume of 25mM EDTA (Fermentas) equal 
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to one tenth of the volume of the restriction, the digestions were inactivated by 
incubating at 65 °C for 10 min in the Techgene thermocycler.  The EDTA was 
added at this stage as RNA is known to hydrolyse during heating in the absence of 
a chelating agent (Wiame et al., 2000).   
 
Following digestion of the RNA sample with DNase I, the RNA was 
reprecipitated by adding one tenth the volume of RNase-free 2M Sodium Acetate 
(Appendix II) and an equal volume of ice-cold isopropanol and placing the tube at 
-20 °C for one hour.  The RNA pellet was collected at top speed in a 
microcentrifuge (Eppendorf) for 10 min at 4 °C and the supernatant carefully 
decanted and discarded.  The pellet was washed twice in 500 µl 75% ethanol 
(Appendix II), recentrifuged and incubated to near dryness.  The RNA pellet was 
dissolved in an appropriate volume (~1 µl for each µg of RNA digested) of 
DEPC-treated water.  The concentration of RNA in each sample was determined 
by spectrophotometric analysis using a NanoDrop spectrophotometer as described 
in section 2.12.2. 
 
2.12.4  Agarose gel electrophoresis of RNA 
 
The DNase treated RNA was resolved on a 1% agarose gel containing 
formaldehyde and 1 x MOPS buffer to assess the quality of the extraction.  A     
50 ml gel was prepared by completely dissolving 0,5 g agarose (Bioline) in     
37,5 ml distilled water in a microwave oven (Farrell, 1993).  The gel was cooled 
to between 55 °C and 60 °C and 10 ml pre-warmed 5 x MOPS buffer (Appendix 
II) and 2,75 ml pre-warmed formaldehyde (Saarchem) were added.  This produced 
a 1% agarose solution in 1 x MOPS buffer and 0,66 M formaldehyde.  The gel 
was cast under a fume hood to minimise formaldehyde fumes in the room and 
allowed to set.  The RNA samples were prepared by the addition of 5 µg RNA,    
2 µl 5 x MOPS buffer, 3,3 µl formaldehyde, 10 µl formamide (Saarchem) and 
DEPC-treated water (Invitrogen) to a final volume of 20 µl, in a sterile, RNase 
free 0,5 ml thin-walled PCR tube.  The samples were mixed thoroughly and 
centrifuged briefly in a microcentrifuge to collect the components at the bottom of 
the tube.  They were then denatured at 55 °C for fifteen minutes after which 2 µl 
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of 10 x RNA gel loading buffer (Appendix II) was added to each tube.  During the 
incubation step, the now solidified gel was immersed in an electrophoresis tank 
containing sufficient 1 x MOPS running buffer to completely cover the gel.  The 
comb was only removed after immersion of the gel as this reduced the vacuum 
effect created when the comb was pulled out and thus reduced the chance of 
damaging the bottom of the wells.  The samples were loaded immediately after 
the addition of the loading buffer and electrophoresed at ~ 5 V per centimetre of 
gel length until the bromophenol blue dye front had migrated approximately 80% 
of the length of the gel.  The gel was removed from the tank and stained in a      
0,5 µg/ml solution of ethidium bromide in DEPC-treated water for one hour.  The 
gel was destained overnight in DEPC-treated water to remove the excess 
formaldehyde from the gel.  The following morning, the gel was examined under 
UV light and an image recorded using the Gel Doc XR Imaging System (Bio-
Rad). 
 
2.12.5  Reverse transcription of RNA 
 
DNase-treated RNA was reverse transcribed using SuperScript™ III Reverse 
Transcriptase (Invitrogen) as per the manufacturer’s instructions.  A 10 µl reaction 
volume containing 1 µg of total RNA together with 250 ng oligo(dT)18 primer and 
100 U SuperScript™ III Reverse Transcriptase enzyme was used resulting in the 
synthesis of ~100 ng/µl first-strand cDNA.  Non-reverse transcribed negative 
controls were prepared in an identical manner except that DEPC-treated water 
(Invitrogen) was added to each reaction instead of the reverse transcriptase 
enzyme. 
 
The success of the reverse transcription reaction was confirmed by the PCR 
amplification of a portion of the glyceraldehyde – 3 – phosphate dehydrogenase 
(GAPDH) gene.  Two hundred ng (2 µl) of cDNA was added to a 25 µl mixture 
containing 0,5 U of BIOTAQ™ DNA polymerase (Bioline), 200 µM of each 
dNTP, 500 nM of each primer (GAPDHF: 5’ – CCC TTC ATT GAC CTC AAC 
TAC ATG -3’; GAPDHR: 5’ – CAT GCC AGT GAG CTT CCC GTT CAG -3’; 
Weinberg et al., 2000), 50 mM KCl, 10 mM Tris-HCl (pH 8.8), 1,5 mM MgCl2 
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and 0,1% Triton X-100 15 mM.  Amplification was performed in a MyCycler™ 
programmable thermocycler (Bio-Rad) as follows:  denaturation at 94 °C held for 
60 s, annealing at 52 °C held for 30 s and elongation at 72 °C held for 90 s for a 
total of 30 cycles followed by a final extension at 72 °C held for 10 min.  Both 
reverse transcribed and non-reverse transcribed products were subjected to PCR 
analysis.  Amplified products were resolved on a 1% agarose gel (section 2.6).  
 
2.12.6  Amplification of cDNA 
 
Amplification of subgenomic regions of the HBV genome was performed as 
described in section 2.5.3, except that cDNA generated from the reverse 
transcription reaction was used as template instead of extracted DNA. 
 
2.13  Infection of Experimentally Naïve Baboons 
 
The transmission of HBV to experimentally naïve baboons was performed by 
Professor R. Purcell at the National Institute of Health (NIH), Bethesda, USA.  
Permission for this portion of the study was obtained from the Animal Ethics 
Committee of the NIH (Ethics Clearance Number: 98-B-428 Appendix I).  In 
order to show that HBV could be transmitted from an infected baboon to an 
experimentally naïve, domestically raised baboon, serum from 4 of the original 10 
baboons, namely baboon 9712, baboon 9732, baboon 9733 and baboon 9734, was 
used to inoculate 4 baboons at the NIH (figure 12).  The naïve baboons were 
obtained from a domestic breeder, the Mannheimer Foundation, and were free of 
all markers of HBV replication prior to their inclusion in this study.  The baboons 
were each housed separately and were each inoculated intravenously with 500 µl 
of serum from one of the original 4 infected baboons.  Following inoculation, a 
liver biopsy as well as serum was obtained from each of the 4 baboons weekly.  
The serum was used to measure ALT, isocitrate dehydrogenase (ICD) and 
gamma-glutamyltranspeptidase (gGT) levels as well for the detection of HBsAg, 
HBeAg, anti-HBe, anti-HBs and anti-HBc.   
 73 
Figure 12:  Infection of experimentally naïve baboons.  Serum from 4 of the original 10 
baboons wild-caught in the Eastern Cape Province was used to infect four experimentally 
naïve baboons.  This diagram indicates from which of the original baboons serum was 
obtained to infect the naïve baboons 
 
Twenty five weeks post inoculation, the study was terminated and the baboons 
euthanized.  At necropsy, liver tissue, snap frozen in liquid nitrogen, as well as 
serum was obtained from each baboon and these samples were shipped on dry-ice 
to Professor Kew at the Molecular Hepatology Research Unit in Johannesburg for 
further testing.  DNA was extracted from the serum using the QIAGEN QIAamp® 
DNA Blood Mini Kit (section 2.3.1) and from the tissue using the phenol-
chloroform extraction method (section 2.3.4).  Subgenomic regions of the HBV 
genome were amplified by nested PCR (section 2.5.3).  The amplified products 
were either subjected to Southern blotting analysis (section 2.11) in the case of 
serum extracts or, in the case of the tissue extracts, sequenced (section 2.8).  The 
sequences were aligned manually using the GeneDoc program and a phylogenetic 
tree generated (section 2.9) to confirm that the virus extracted from the 
experimentally naïve baboons was the same as that found in the original baboons. 
 
Baboon 1 Baboon 2 Baboon 3 Baboon 4 
Baboon 
9712 
Baboon 
9732 
Baboon 
9733 
Baboon 
9734 
Original Baboons 
Naïve Baboons 
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3.  Results 
 
HBV DNA was detected in the sera of Chacma baboons by Southern 
hybridization. The prevalence of HBV in the South African baboon (Papio 
ursinus orientalis) population was determined by extracting DNA from the serum 
of 69 wild-caught baboons and amplifying four different regions – the 
precore/core, core, polymerase and surface regions - of the viral genome.  If a 
sample amplified for three or more of these regions, the baboon was considered to 
be HBV-DNA positive.  The complete viral genome was sequenced using 
overlapping subgenomic fragments amplified from HBV DNA isolated from the 
liver tissue of baboon 9732.  Viral antigens were detected in the liver tissue using 
immunohistochemistry, and liver function tests, including alanine and aspartate 
aminotransferase levels, were performed using serum from this baboon.  
Replication of the virus was demonstrated by extracting RNA from the liver 
tissue, reverse transcribing it and amplifying subgenomic regions of the viral 
genome off this cDNA.  Replication was further confirmed by the detection of 
cccDNA in the baboon liver tissue using real-time PCR analysis.  HBV-positive 
sera from four baboons was used to infect four experimentally naïve baboons to 
demonstrate transmission. 
 
3.1  Prevalence of HBV in South African baboons 
 
3.1.1  Detection of HBV by nested PCR amplification 
 
Initially DNA was extracted from the sera of ten wild-caught baboons from the 
Eastern Cape Province (figure 14).  HBV DNA could not be amplified using a 
single round of PCR, indicating that HBV DNA was present at low levels in 
baboon serum.  Using nested PCR of four different regions of the HBV genome, 
HBV DNA was amplified successfully (figure 13).  The precore/core gene region 
(panel A) amplified for most samples and the surface gene region (panel D) for 
the least samples.   
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Figure 13:  Nested PCR amplification of four different regions of the HBV genome.  DNA 
extracted from the serum of ten wild-caught baboons was used as template for a nested PCR of 
four different regions of the HBV genome.  These amplicons were resolved on a 1% EtBr 
agarose gel alongside a 100 bp DNA ladder.   
Panel A shows the amplification of a 204 bp region of the precore/core gene (1765F – 1968R). 
Panel B shows the amplification of a 170 bp region of the core gene (2267F – 2436R). 
Panel C shows the amplification of a 293 bp region of the polymerase gene (2566F – 2858R).   
Panel D shows the amplification of a 252 bp region of the surface gene (459F – 710R).   
Abbreviations:  M – 100 bp DNA ladder; Blank 1 and Blank 2 – single and double round PCR 
amplifications respectively, containing best quality water instead of DNA; -ve control - 
negative extraction control which used DNA extracted from HBV-negative human serum as 
template; +ve control - positive control using DNA extracted from HBV-positive human serum 
as template. 
Samples positive for HBV are marked with an asterisk (*) and those positive for all four regions 
are boxed. 
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Figure 14:  Map of South Africa.  This map indicates the nine South African provinces 
and the regions from which wild baboons were captured. 
      - The region from which the original ten baboons were captured. 
      - The regions from which baboons were subsequently captured. 
 
 
The samples from baboons 9712, 9732 and 9734 amplified successfully for all 
four regions tested and the samples from baboons 9733 and 9735 amplified 
successfully for three of the four regions (figure 13). The samples from baboons 
9713, 9718, and 9736 amplified for only one or two of the regions tested, whereas 
samples from baboons 9720 and 9731 failed to amplify for any of the four 
regions.  Repetition of the amplification yielded the same results.  
  
HBV DNA-positive sera from baboons 9712, 9732, 9733 and 9734 were negative 
for both HBsAg and anti-HBc.  Alanine and aspartate aminotransferase levels 
were normal and, following high speed centrifugation and treatment with anti-
HBs, no viral particles were observed in the serum using electron microscopy. 
WESTERN 
CAPE 
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Figure 15:  Dendogram of precore/core region amplicons (nt 1800 – 1961) from the sera of 
six different baboons.  Representative samples of all eight HBV genotypes as well as the non-
human primate hepadnaviruses are included.  Samples are numbered according to their GenBank 
accession numbers followed by their country of origin and a letter indicating which genotype they 
cluster with.  The samples from the baboons are highlighted in yellow. 
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Fifty nine additional serum samples were subsequently obtained from both adult 
and juvenile baboons in the Limpopo and Western Cape provinces (figure 14) and 
tested for HBV DNA by nested PCR.  Using the criterion of at least three of the 
four regions being PCR-positive, in total 11/49 (22,4%) adult and 4/20 (20%) 
juvenile wild-caught baboons were positive for HBV.   Taken together the overall 
prevalence of hepadnaviral DNA in baboons was 21,7% (15/69).    
 
 
3.1.2  Phylogenetic analysis of HBV precore region 
 
In order to confirm the specificity of the amplification, representative samples of 
the HBV precore region (nt 1800 – 1961) amplified off DNA extracted from the 
sera of six different baboons were sequenced and analysed phylogenetically.  The 
baboon isolates clustered with genotype A (figure 15).   
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Figure 16:  Southern slot blot of baboon serum samples.  Baboon sera were blotted onto 
a nylon membrane and hybridized with an HBV-specific probe.   
Panel A shows the slot blot template.  Abbreviations: AH – serum sample from a patient 
suffering from acute hepatitis (positive control); B – adult baboon serum sample; J – 
juvenile baboon serum sample; V/M – serum sample from vervet monkey (negative 
control); Probe – HBV specific probe diluted in HBV-negative serum (positive control).  
The samples that hybridized to the HBV-specific probe are highlighted in yellow.   
Panel B shows the autoradiograph of the slot blot after a seven day exposure.  HBV DNA 
positive sera, as well as the positive controls, are indicated.   
J 9755 J 9757 A H J 9754 B 9718 B 9713 
J 9745 J 9751 J 9749 M 9656 B 9753 J 9756 
J 9750 B 9702 B 9731 B 9732 J 9746 V 42 
J 9740 J 9758 V 34 Probe B 1845 B 1894 
J 9761 M 9651 B 9726 J 9743 B 9734 J 9747 
B 1897 J 9738 B 9733 J 9742 J 9747 B 1896 
V 28 B 9712 B 1899 J 4572 V 41 B 9720 
V 35 B 9717 J 9760 B 1869 B 1858 B 9735 
A) 
A H 
Probe 
B 9734 
B 9735 
B 9712 
J 9758 
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3.1.3  Detection of HBV DNA by Southern hybridization 
 
Using Southern blot analysis, serum samples were tested for HBV DNA.  Of the 
39 samples shown in figure 16, four were positive.  Longer exposures to 
autoradiography film did not improve the detection of HBV DNA.  Sera from all 
sixty-nine baboons were screened for HBV DNA using Southern blot analysis, but 
only five were found to be positive. 
 
The low viral loads meant that the complete HBV genome could only be 
amplified subgenomically.  Because of the small volumes of sera available, liver 
tissue obtained from a single baboon (9732), which was euthanized for medico-
ethical reasons, was used to further characterise the HBV present in baboons.   
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3.1.4  Summary of HBV DNA prevalence study 
 
A summary of the results of the initial prevalence studies for the 11 adult and 4 
juvenile HBV DNA positive baboons is shown in table 8.  The remaining 38 adult 
and 14 juvenile baboons tested did not meet the criteria to be considered positive 
for HBV infection. 
 
Table 8:  Summary of results for HBV DNA positive baboons 
 
Baboona Originb SHc 
Nested PCR 
Polymerase Core Surface Pre-core/ 
core 
B9712 E. Cape + + + + + 
B9732 E. Cape + + + + + 
B9733 E. Cape - + + - + 
B9734 E. Cape + + + + + 
B9735 E. Cape + - + + + 
B9768 W. Cape - + + + + 
B9770 W. Cape - - + + + 
B9775 W. Cape - + + + + 
B97116 Limpopo - - + + + 
B97118 Limpopo - - + + + 
B97122 Limpopo - + + + + 
J9747 W. Cape - - + + + 
J9752 W. Cape - + - + + 
J9758 W. Cape + + + + + 
J9761 W. Cape - + - + + 
 
a
 Prefix of B indicates an adult baboon and prefix of J indicates a juvenile 
baboon 
b
 E. Cape – Eastern Cape province ; W. Cape – Western Cape province 
c
 SH – Southern Hybridisation 
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Figure 17:  Micrograph of liver tissue from baboon 9732 showing lobular hepatitis.  
Liver tissue obtained from baboon 9732 at necropsy was fixed in formalin, embedded in 
paraffin and sectioned.   
Panel A was stained with hematoxylin and eosin.  It shows a focus of mild lobular hepatitis 
but there is no evidence of interface hepatitis or bridging necrosis.  The portal tracts are 
normal.  Magnification: 400x 
Panel B: the section is stained with immunoperoxidase using a polyclonal antibody to the 
HBV core antigen.  HBcAg can be detected in the occasional hepatocyte nucleus.  
Magnification: 400x 
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3.2  Immunohistology of HBV DNA positive baboon liver 
tissue 
 
 Histological examination of liver tissue from baboon 9732 showed the presence 
of mild focal lobular hepatitis, but no evidence of interface hepatitis, bridging 
necrosis, dysplasia of hepatocytes, cirrhosis, or hepatocellular carcinoma (figure 
17, panel A).  Immunohistochemical staining of the liver tissue detected HBcAg 
in the nuclei of some of the hepatocytes, with a patchy distribution (figure 17, 
panel B).  HBsAg and 42nm enveloped (Dane) particles were not detected in the 
cytoplasm. 
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3.3  Extraction of DNA from liver tissue 
 
3.3.1  Quality control and quantification of the DNA extracts 
 
Using phenol chloroform, DNA was extracted from two liver tissue samples from 
baboon 9732 and from an extraction blank.  The OD 260/280 ratio for both 
samples was 1,82 indicating that the DNA was of a very high quality.  The quality 
and quantity of the DNA extracts were confirmed by resolving 20 µg of each 
extract on a 0,8% agarose gel overnight (figure 18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18:  Confirmation of the quality of the phenol-chloroform DNA extractions.  
This composite figure shows the phenol-chloroform DNA extracts from the liver tissue of 
baboon 9732 that were resolved overnight on a 0,8% EtBr agarose gel.  For each extract 
20 µg of DNA was resolved.  Both extractions are of high quality and quantity and the 
extraction blank shows no evidence of contamination. 
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3.3.2  Identification of HBV DNA in the liver tissue extracts 
 
The presence of hepadnaviral DNA in the extracts was confirmed by nested PCR 
of two viral genomic regions, namely a portion of the precore/core gene (nt 1763-
1966) and a portion of the surface gene (nt 460-711) (figure 19).  The PCR 
worked well for both regions, without any signs of amplification in the negative 
controls. 
 
     A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
               B)   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19:  Amplification of HBV DNA from baboon 9732 liver extracts.  Amplicons of 
two different regions of the HBV genome were resolved on a 1% agarose gel.   
Panel A shows the amplification of a 252 bp portion of the surface gene (459F – 710R).  
Panel B shows the amplification of a 204 bp region of the precore/core gene (1765F – 
1968R).   
Phenol chloroform extracted DNA from the liver tissue of baboon 9732 was used as 
template either neat, diluted 1 in 5, or diluted 1 in 10. 
Abbreviations:  Blank 1 - single round PCR containing best quality water instead of DNA; 
Blank 2 – double round nested PCR containing best quality water instead of DNA; Extn - 
extraction. 
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3.4  Genotyping of the HBV 
 
The HBV extracted from the baboon liver tissue was shown to belong to genotype 
A using the method described by Lindh et al. in 1997 (figure 20). 
 
        A)   
 
 
 
 
 
 
 
 
 
 
 
 
 
  B)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20:  Lindh Genotyping of B 9732 liver extracts.   
Panel A – The 541 bp nested PCR amplicons (nt 256 – 796) were resolved on a 1% EtBr 
agarose gel to confirm successful amplification.  DNA extracted from the liver tissue of 
baboon 9732 was used as template either neat or diluted 1 in 10. 
Panel B – The restricted amplicons were resolved on a 3% EtBr agarose gel.  When 
compared to the patterns described by Lindh et al. (1997), the HBV from baboon 9732 was 
genotype A. 
Abbreviations:  Blank 1 - single round PCR containing best quality water instead of DNA; 
Blank 2 – double round nested PCR containing best quality water instead of DNA; Extn - 
extraction. 
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3.5  Amplification and sequencing of the HBV genome from 
the baboon 
 
3.5.1  Amplification of the HBV genome  
 
Attempts to sequence the entire genome of baboon HBV, using full genome 
amplification (Günther et al., 1995), or amplification of two overlapping 
subgenomic fragments (Takahashi et al, 1998), proved unsuccessful.  The 
amplicons generated by either of these methods failed to hybridize to a HBV 
DNA probe following Southern hybridization.  Furthermore, when these 
amplicons were gel extracted and cloned into the pCR®-XL-TOPO® vector using 
the TOPO® XL PCR Cloning Kit (Invitrogen), HBV DNA could not be amplified 
off the resulting clones. 
 
3.5.2  Amplification of the viral genome by nested PCR amplification 
of numerous overlapping subgenomic fragments. 
 
In order to obtain the sequence of the complete HBV genome, a number of 
different nested PCR amplifications of overlapping subgenomic fragments were 
attempted (table 6, section 2.5.3).  The regions that amplified successfully and 
were sequenced to generate the complete sequence of the virus are summarised in 
figure 21 with the amplicons shown in figures 22-24.   
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Figure 21:  Amplification of the HBV genome using overlapping subgenomic fragments.  This schematic shows the eight overlapping 
subgenomic fragments, amplified by nested PCR, which were used to generate the complete HBV sequence isolated from the liver tissue of 
baboon 9732.  The first round of the nested PCR is shown in yellow and the second round in blue. 
Fragment 1 
Fragment 2 
Fragment 3 
Fragment 4 
Fragment 5 
Fragment 6 
Fragment 7 
Fragment 8 
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Fragment 8 
Fragment 2 
Fragment 1 
 
A)                 B)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         C) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22:  Nested PCR of overlapping regions of the HBV preS1/preS2/S open 
reading frame.  Subgenomic fragments amplified by nested PCR, using DNA extracted 
from the liver tissue of baboon 9732, were resolved on a 1% EtBr agarose gel.  Both the 
primers and thermocycling conditions described by Hu et al. (2000) were used. 
Panel A – PCR 1: 2800F – 1101R; PCR 2: 2853F – 409R  
Panel B – PCR 1: 2853F – 1101R; PCR 2: 58F – 730R  
Panel C – PCR 1: 58F – 1450R; PCR 2 409F – 1101R  
Abbreviations:  Blank 1 - single round PCR containing best quality water instead of DNA; 
Blank 2 – double round nested PCR containing best quality water instead of DNA; Extn - 
extraction. 
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The nested PCR of fragment 7 gave two distinct amplicons of equal intensity – 
one at the expected size of 880 bp and the other a smaller fragment of ~520 bp 
(figure 23).  The fragments were cloned into the pTZ57R/T plasmid vector using 
the Fermentas cloning kit.  Clones containing inserts were screened for HBV 
DNA by PCR.  Only the clones containing the larger of the two fragments 
amplified successfully indicating that only the larger fragment was hepadnaviral, 
whereas the smaller fragment was of chromosomal origin, as shown by 
sequencing.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23:  Nested PCR amplification of the 2440F – 58R region of the HBV genome.  
This nested PCR (PCR 1: 1860F – 409R; PCR 2: 2440F – 58R) which includes a portion of 
the surface gene of the HBV genome, was expected to yield a 881 bp fragment.  When the 
products were resolved on a 1% EtBr agarose gel however, two fragments – one the 
expected size of 881 bp and the other a smaller fragment of ~520 bp - were observed.  The 
fragments were excised individually, cloned into a suitable vector and subjected to an 
additional round of subgenomic PCR using primers internal to the 2440F – 58R region.  
Only the larger of the two fragments amplified.  Sequencing of the clones confirmed that 
only the 881 bp fragment was HBV.   
Abbreviations:  Blank 1 - single round PCR containing best quality water instead of DNA; 
Blank 2 – double round nested PCR containing best quality water instead of DNA; Extn - 
extraction. 
 
Fragment 7 
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The remaining regions of the hepatitis B viral genome were amplified by applying 
the thermocycling conditions described by Hu et al. (2000) to combinations of 
primers used routinely in the laboratory (figure 24).  To avoid the interference of 
non-specific amplicons with downstream automated sequencing, the correct sized 
fragments were gel purified. 
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Fragment 5 
Fragment 6 
 
 A)                  B)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                D)   
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Figure 24:  Agarose gel electrophoresis of nested PCR amplicons.  Subgenomic 
fragments amplified off DNA extracted from baboon 9732 by nested PCR, using the 
thermocycling conditions described by Hu et al. (2000), were resolved on 1% EtBr agarose 
gels.   
Panel A – PCR 1: 409F – 1800R; PCR 2: 730F – 1575R 
Panel B – PCR 1: 1528F – 1921R; PCR 2: 1552F – 1803R 
Panel C – PCR 1: 1732F – 2045R; PCR 2: 1765F – 1968R.  The DNA extracts were both 
diluted 1 in 10 before being used as template for the first round of amplification.   
Panel D – PCR 1: 1860F – 58R; PCR 2: 1898F – 2898R 
Abbreviations:  Blank 1 - single round PCR containing best quality water instead of DNA; 
Blank 2 – double round nested PCR containing best quality water instead of DNA; Extn - 
extraction. 
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3.5.3  Phylogenetic analysis of the HBV from baboons 
 
The overlapping subgenomic amplicons covering the entire HBV genome were 
aligned and a sequence for the complete HBV genome, isolated from the liver of 
baboon 9732, determined.  Translation of the 4 ORF’S showed them to be well 
conserved relative to the consensus sequence of subgenotype A2 with the 
following exceptions: 
• T380C ⇒  rtV84A in conserved region A of the polymerase 
⇒  C76R in HBsAg 
• A2019G ⇒  E40G core protein 
• C1470T ⇒  P33G in the X protein 
• T1765C ⇒  P145S in the X protein  
 
Mean nucleotide divergence calculations (table 9) showed that the HBV from the 
baboon was closely related to subgenotype A2 and this was confirmed by 
phylogenetic analyses of the complete genome, as well as each of the four 
individual open reading frames, (figures 25 – 27).   
 
Table 9:  Mean nucleotide divergence. 
 
 Baboon vs A1 Baboon vs A2 
Complete Genome 4,52 ± 0,42 (3,85 – 6,04) 1,00 ± 0,55 (0,50 – 3,59) 
Polymerase 4,60 ± 0,31 (4,09 – 5,52) 0,87 ± 0,57 (0,28 – 4,08) 
Pre-S1/S2/S 3,61 ± 0,42 (2,78 – 4,81) 0,84 ± 0,46 (0,17 – 2,52) 
Precore/core 4,04 ± 0,95 (2,96 – 7,64) 0,98 ± 0,69 (0,31 – 3,41) 
X 3,34 ± 0,74 (2,16 – 5,62) 1,49 ± 0,66 (0,43 – 4,30) 
 
The mean nucleotide divergences (expressed as a percentage) for the complete and the 
individual open reading frames were calculated using DAMBE 
(http://dambe.bio.uottawa.ca/dambe.asp).  The sequences compared are those shown in 
Appendix III (51 subgenotype A1 and 51 subgenotype A2 sequences).  The mean 
nucleotide divergence is followed by the standard deviation with the range given in 
parentheses. 
 94 
 
Figure 25:  Dendogram of the complete HBV genome isolated from baboon 9732.  
Samples representative of all eight HBV genotypes, as well as the primate hepadnaviruses, 
have been included.  Samples are numbered according to their GenBank accession 
numbers, followed by their country of origin.  The sample from baboon 9732, highlighted 
in yellow, clusters strongly with the genotype A2 isolates (bootstrap value of 100).    
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Figure 26:  Unrooted dendogram showing the complete HBV genome isolated from 
baboon 9732 relative to other subgenotype A2 strains.   
Fifty one subgenotype A2 samples, isolated from five different continents, have been 
included.  The GenBank accession numbers, as well as country of origin for each of these 
samples, are shown in the table below. 
 
 
 Genbank 
Accession 
Number 
Country of 
Origin   
Genbank 
Accession 
Number 
Country of 
Origin 
1 V00866   27 L13994  
2 S50225   28 AB205118 Japan 
3 X02763 USA  29 AY902775 USA 
4 X70185 Germany  30 AB116080 Japan 
5 Z35717 Poland  31 AB116079 Japan 
6 AY233286 South Africa  32 AB116078 USA 
7 AY233280 South Africa  33 AB116077 USA 
8 AF297624 South Africa  34 AB116076 USA 
9 AF090838 Belgium  35 AB116081 Japan 
10 AF090841 Belgium  36 AB126580 Russia 
11 X51970 Germany  37 AY152726 USA 
12 AF090839 Belgium  38 AY738142 Germany 
13 AF090840 Belgium  39 AY738141 Germany 
14 Z72478 Germany  40 AY738140 Germany 
15 AB064314 USA  41 AY862868 China 
16 AF537371 USA  42 AY862867 China 
17 AF537372 USA  43 AB222708 Uzbekistan 
18 AB014370 Japan  44 AM282986 New Zealand 
19 AJ344115 France  45 EF208113 Germany 
20 AY034878 USA  46 DQ788725 Germany 
21 AJ309370 France  47 AB222707 Uzbekistan 
22 AJ309369 France  48 AM295797 France 
23 AJ309371 France  49 AB246338 Japan 
24 AY128092 Canada  50 AB246337 USA 
25 AF536524 USA  51 AY738139 Germany 
26 AJ012207 Germany  
 
Baboon 9732 South Africa 
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Figure 27:  Dendograms of the four individual HBV open reading frames 
A portion of each dendogram, showing the genotype A isolates, is shown.  Samples are 
numbered according to their GenBank accession numbers, followed by their country of 
origin.  The sample from baboon 9732, highlighted in yellow, clusters within genotype A 
for all four ORFs.     
Panel A shows the polymerase ORF (nt 2307 – 1623) 
Panel B shows the preS1/preS2/surface ORF (nt 2854 – 835) 
Panel C shows the precore/core ORF (nt 1814 – 2458) 
Panel D shows the X ORF (nt 1374 – 1838) 
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A)  Polymerase ORF     B)  PreS1/preS2/surface ORF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C)  Precore/core ORF     D)  X ORF 
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3.5.4  Screening for recombination in HBV from the baboon 
 
Possible recombination with other human and/or primate genotypes was 
investigated by aligning the complete HBV genome isolated from the liver of 
baboon 9732 with HBV genomes from 228 non-recombinant HBV isolates and 
running a GroupScan analysis using Simmonic.  There was no evidence of 
recombination in the strain isolated from baboon 9732, with the HBV sequences 
deeply embedded in genotype A (figure 28). 
 
 
Figure 28:  Recombination analysis of complete HBV genome from baboon 9732.  A 
grouping scan using the Simmonic software package for the HBV strain from baboon 9732 
versus 228 selected non-recombinant HBV genotype reference strains grouped by 
genotype, was performed.  The X-axis shows the genomic position and the Y-axis indicates 
the mean distances between the baboon HBV and the reference groups.  Values close to 1 
on the     Y-axis indicate that a sample is deeply rooted in that genotype.  
Abbreviations:  Chimp – chimpanzee; WM – woolly monkey. 
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3.6  Expression of HBV RNA in baboon liver tissue  
  
3.6.1  Extraction of RNA from liver tissue 
 
RNA was extracted from the liver tissue from baboon 9732 and the quantity and 
quality assessed.  The A260/A280 ratios for all the extracts were in the expected 
2 ± 0,05 range.  The quality of the RNA was further assessed by resolving a 2 µg 
aliquot on a 1% agarose gel (figure 29).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29:  Assessment of the quality of the DNaseI treated RNA extracts.  RNA 
extracted from different starting amounts (50 mg, 100 mg and 200 mg) of liver tissue, from 
baboon 9732, was treated with DNaseI and resolved on a 1% denaturing agarose gel.  For 
each extract, 2 µg of sample was resolved.  For all three extracts, the RNA appears visually 
to be of very good quality as no degradation of either the 28S and 18S rRNA subunits can 
be seen. 
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3.6.2  Assessment of the messenger RNA quality 
 
One microgram of each of the three DNase treated RNA extracts was reverse 
transcribed using the Superscript III Reverse Transcription System from 
Invitrogen.  The resulting cDNA was amplified by nested PCR using HBV 
specific primers, to confirm the presence of hepadnaviral RNA.  Prior to this 
amplification however, the quality of the messenger RNA within the extracts was 
assessed by amplifying a portion of the glyceraldehyde – 3 – phosphate 
dehydrogenase (GAPDH) gene using the cDNA as a template (figure 30).  All 
three of the RNA extracts amplified successfully, and no amplification of the non-
reverse transcribed RNA extracts or any of the other negative controls was 
obtained.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30:  Amplification of GAPDH gene to assess mRNA quality.  A ~550 bp region 
of the glyceraldehyde – 3 – phosphate dehydrogenase (GAPDH) gene was amplified using 
the DNaseI treated reverse transcribed RNA extracts as template and resolved on a 1% EtBr 
agarose gel.  Non-reverse transcribed extracts (in which DEPC-treated water was added 
instead of enzyme during the reverse transcription reaction) were amplified as negative 
controls.  The amplification worked perfectly for all three samples with no amplification in 
any of the negative controls indicating that the mRNA was of good quality and free of 
contamination. 
Abbreviations: Blank - PCR negative control containing best quality water instead of 
cDNA; DNaseI Blank - DNaseI treatment negative control where DEPC-treated water was 
added instead of RNA; RT Blank - reverse transcription negative control where DEPC-
treated water was added instead of cDNA; Extn - extraction. 
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3.6.3  Amplification of subgenomic regions of HBV using reverse 
transcribed cDNA 
 
Following successful amplification of the GAPDH gene from all three samples, 
two different regions of the viral genome – parts of the precore/core (1765 - 1968) 
and surface (459 – 710) open reading frames – were amplified by nested PCR 
using the cDNA as template (figure 31).  Amplification of the precore/core region 
was only successful when the cDNA template was diluted 1 in 5 (figure 31, panel 
B).  Identical results were obtained when the amplification was repeated on 
reverse transcribed and non-reverse transcribed RNA diluted 1 in 5.  Sequencing 
of these amplicons found them to be identical to the sequences of the DNA 
isolated from the liver of baboon 9732. 
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Figure 31:  Nested PCR amplification of subgenomic regions from cDNA.  The reverse 
transcribed, DNaseI treated cDNA products were amplified by nested PCR and the 
amplicons resolved on a 1% EtBr agarose gel.  Non-reverse transcribed samples (in which 
DEPC-treated water was added instead of enzyme during the reverse transcription reaction) 
were included as negative controls.   
Panel A – PCR 1:  255F – 759R; PCR 2:  459F – 710R 
Panel B – PCR 1:  1723F – 2045R; PCR 2:  1765F – 1968R.  This amplification was only 
successful when the cDNA was diluted 1 in 5.   
Abbreviations:  Blank 1 - single round PCR containing best quality water instead of cDNA; 
Blank 2 – double round nested PCR containing best quality water instead of cDNA; DNaseI 
Blank - DNaseI treatment negative control where DEPC-treated water was added instead of 
RNA; RT Blank - reverse transcription negative control where DEPC-treated water was 
added instead of cDNA; +ve control - PCR positive control using DNA extracted from the 
liver tissue of baboon 9732 as template; Extn - extraction 
 
 
A) 
B) 
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Small amounts of liver tissue were obtained from five additional wild-caught 
baboons.  RNA was extracted from ~1,2 g of this tissue using the Promega SV 
total RNA isolation kit.  The RNA extracts were reverse transcribed using the 
Qiagen Sensiscript reverse transcriptase system and a region of the core open 
reading frame (2267 - 2436) amplified by nested PCR.  The products were 
resolved on an agarose gel (figure 32, panel A) and a product was visible only for 
the PLC/PRF5 positive control. In order to increase the sensitivity of detection, 
Southern hybridisation was performed on the nested PCR amplicons and 
expression of HBV RNA was demonstrated in baboon 1858 (figure 32, panel B).   
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Figure 32:  Nested PCR of HBV core region from RNA.   
Panel A is a composite figure of a 2% EtBr agarose gel on which nested PCR amplicons 
(1689 – 2509 in the first round and 2267 – 2436 in the second round), using RNA extracted 
from the liver tissue of wild-caught baboons as template, were resolved.  The only 
amplicon visible was from the positive RNA extraction control from PLC/PRF-5 cells.  The 
amplicons were therefore subjected to Southern hybridization to detect low levels of 
amplification. 
Panel B shows a portion of the autoradiograph of the Southern hybridization for the 
samples resolved in panel A.  The RNA extraction positive control from PLC/PRF-5 cells 
hybridized as expected and there was no hybridization to any of the negative controls.  The 
sample extracted from the liver tissue of B 1858 also hybridised, indicating that there was 
amplification of the core open reading frame of HBV in this baboon. 
Abbreviations: Blank 1 - single round PCR containing best quality water instead of cDNA; 
Blank 2 – double round nested PCR containing best quality water instead of cDNA; Non-
RT - Non-reverse transcribed negative controls in which DEPC-treated water was added 
instead of enzyme during the reverse transcription reaction; RT Blank - reverse 
transcription negative control where DEPC-treated water was added instead of cDNA. 
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3.7  Identification of covalently closed circular DNA in the 
liver tissue of the baboon 
 
3.7.1  Extraction of DNA for cccDNA analysis 
 
As a positive control for the cccDNA PCR, DNA was extracted from HBV DNA 
positive tumourous and non-tumourous human liver.  DNA was extracted from rat 
liver tissue to be used as a negative control.  The efficiency of the extractions was 
assessed by resolving an aliquot of each extraction overnight on a 1% agarose gel 
(figure 33).  Relatively lower levels of DNA were extracted from the baboon liver 
tissue compared to the controls.  The non-tumourous human liver tissues showed 
the highest levels of DNA per extract followed by the rat liver. 
  
Figure 33:  Assessment of DNA extracted using the QIAmp DNA Mini Kit.  DNA 
extracted from the liver tissue of baboon 9732, tumourous and non-tumourous human liver 
tissue and rat liver tissue was resolved on a 0,8% EtBr agarose gel.  Five µl of each extract 
was resolved.  All the extractions had DNA of good quality as shown by the abundance of 
intact high molecular weight DNA.  Extractions from the baboon liver tissue yielded much 
lower concentrations of DNA than the control tissues. 
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3.7.2  Real Time PCR analysis using SYBR®-green 
 
cccDNA was detected in the liver tissue of baboon 9732 using real time PCR with 
SYBR®-green dye (table 10).  The melting temperature of each sample (Tm) was 
determined by performing a dissociation curve at the end of the PCR.  The HBV 
cccDNA positive controls (human tumourous and non-tumourous HBV DNA 
positive liver tissue and plasmid DNA containing a greater than full length HBV 
genome) had melting temperatures of between 82,7 °C and 84 °C while the 
negative controls (HBV DNA negative rat liver tissue and extraction and reagent 
blanks)  had melting temperatures below 80,0 °C.  The samples extracted from the 
baboon liver tissue showed similar melting temperatures to the positive controls 
indicating that HBV cccDNA was present.  The amplification plots showed that 
the baboon extracts reached log phase after ~36 cycles compared to the positive 
control liver samples, which reached log phase after ~30 cycles and the plasmid 
positive controls, which reached log phase after ~5 cycles.  This low cccDNA 
concentration in the baboon liver was also apparent in the dissociation curves 
(figure 34). 
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Table 10:  Real Time cccDNA SYBR® green detection results 
 
A) 
   
B) 
   
 
Sample Name Detector Tm 
 Sample Name Detector Tm 
 
B 9732 Extraction 1 SYBR 83.1 
 B 9732 Liver Pooled - 1 SYBR 82.7 
 
B 9732 Liver 10 mg - Extn1 SYBR 83.1 
 B 9732 Liver Pooled - 2 SYBR 82.3 
 
B 9732 Liver 10 mg - Extn2 SYBR 83.9 
 B 9732 Liver Pooled - Blank SYBR 78.1 
 
B 9732 Liver 25 mg - Extn1 SYBR 83.1 
 B 9732 Liver Re-eluted – 25 mg SYBR 82.7 
 
B 9732 Liver 25 mg SYBR 82.7 
 B 9732 Liver Re-eluted – 50 mg SYBR 83.1 
 
Tumour 10 mg SYBR 82.7 
 B 9732 Liver Re-eluted - Blank SYBR 78.1 
 
Tumour 25 mg SYBR 83.9 
 Tumour – 10 mg SYBR 83.1 
 
Non-Tumour 10 mg SYBR 83.1 
 Tumour – 25 mg SYBR 83.1 
 
Non-Tumour 25 mg SYBR 82.7 
 Non-Tumour – 1 0mg SYBR 83.1 
 
Rat 10 mg SYBR 79.5 
 Non-Tumour – 25 mg SYBR 83.1 
 
Rat 25 mg  SYBR 79.1 
 Extraction Blank SYBR 78.1 
 
Reagent Blank SYBR 71.1 
 Rat Liver – 25 mg SYBR 79.4 
 
    Rat Liver – 50 mg SYBR 79.8 
 
    Rat Liver - Blank SYBR 76.0 
 
    Plasmid diluted 1 in 10 SYBR 84.0 
 
    Plasmid diluted 1 in 25 SYBR 84.0 
 
    Water Blank SYBR 78.6 
        
Abbreviations: Tm – melting temperature; Tumour – DNA extracted from human tumour 
liver tissue was used as template for the real-time PCR; Non-Tumour – DNA extracted 
from non-tumourous human liver tissue; Rat – DNA extracted from rat liver tissue; Plasmid 
– DNA extracted from a plasmid containing a greater than full length HBV genome was 
used as template. 
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Figure 34:  Dissociation curve of Real Time PCR amplicons.  The dissociation curve 
was performed after a real time selective PCR for covalently closed circular (ccc) DNA 
using SYBR®-green for detection.  The samples shown in this figure include two positive 
controls extracted from tumourous and non-tumourous HBV positive liver tissue 
respectively and two negative controls - a Rat Negative Control and a Reagent Blank using 
best quality water instead of DNA.  The B 9732 liver sample was extracted using the 
phenol-chloroform extraction method and the B 9732 Liver pooled sample was from ten 
identical extractions performed using the QIAmp DNA Mini Kit, which were pooled and 
re-extracted using a salt-ethanol precipitation.  The samples from the baboon liver tissue 
show a similar melting temperature to the positive controls, although the heights of the 
peaks indicate that they are at a much lower concentration. 
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3.8  Transmission of HBV to experimentally-naïve baboons 
 
Transmission of the HBV found in baboons to experimentally naïve baboons was 
performed by Professor R. Purcell at NIH in America.  Four experimentally naïve, 
domestically raised baboons were each injected with serum from one of four of 
the original HBV DNA positive baboons.  Prior to inoculation, blood was drawn 
from the baboons to determine their baseline AST, ALT and IGG levels and for 
PCR analysis to show that they were not HBV DNA positive at baseline.  Post 
inoculation, serum was drawn and a liver biopsy performed on each baboon on a 
weekly basis to determine the ALT, ICD and gGT levels as well as serological 
markers HBsAg, HBeAg, anti-HBc, anti-HBe and anti-HBs levels.  The baboons 
were transiently positive for a number of these markers, as shown in figure 35.  
Baboon #1, inoculated with serum from baboon 9712, had an increase in the level 
of HBsAg 9 weeks post inoculation with smaller increases 2, 19 and 21 weeks 
post inoculation.  This baboon also had increases in the levels of anti-HBs and 
HBeAg 7 and 4 weeks post inoculation respectively.  Baboon #2, inoculated with 
serum from baboon 9732, showed an increase in HBsAg and HBeAg levels 9 
weeks post inoculation.  Moreover, this baboon showed a coincident sharp 
increase in both ALT and HBsAg levels 17 weeks post inoculation, with the levels 
of both these markers being intermittently elevated for the following four weeks.  
Baboon #3, inoculated with serum from baboon 9733, showed an increase in 
HBsAg levels 2, 9, 10 and 17 weeks post inoculation, an increase in anti-HBs 24 
weeks post inoculation and an increase in HBeAg levels 0 weeks post inoculation 
as well as 8 and 20 weeks post inoculation.  Baboon #4, inoculated with serum 
from baboon 9734, had increased levels of HBsAg 9 weeks post inoculation.  
Anti-HBs levels in this baboon increased dramatically 15 weeks post inoculation 
and remained elevated for the next 6 weeks.  After six months (26 weeks), the 
four baboons were sacrificed and serum and liver tissue obtained from each 
baboon. 
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Figure 35:  Relative levels of ALT and HBV serological markers in experimentally-
naive baboons. 
Using serum obtained from experimentally-naive baboons, the ALT and HBV serological 
marker levels were measured at weekly intervals post inoculation and computed relative to 
baseline level.  The baseline level was taken to be the average of the values obtained at 
weekly intervals for the month prior to inoculation.  Serum for ‘Week 0’ levels was drawn 
just after inoculation. 
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3.8.1  Identification of HBV in the serum of infected baboons 
 
DNA was extracted from the serum collected at each time point using the 
QIAamp DNA extraction kit (Qiagen) and nested PCR analysis for the surface 
gene (459 – 710) was performed.  The PCR amplicons were visualised by agarose 
gel electrophoresis and subjected to Southern hybridization analysis with an HBV 
specific probe both to confirm that the amplicons were HBV and to detect any low 
levels of amplification, too faint to be visualised on the agarose gel.  The results 
for all four baboons are shown in table 11.   There was no correlation between the 
serology results shown in figure 35 and the time points at which HBV DNA was 
detected. 
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Table 11:  Amplification of surface gene (nt 459 – 710) from infected baboons 
 
Week Baboon #1 
Baboon 
#2 
Baboon 
#3 
Baboon 
#4 
Baseline - - - - 
1 - - + - 
2 - + - - 
3 - - + + 
4 - - - + 
5 + - + - 
6 - + - + 
7 - - - - 
8 - - - + 
9 + - + - 
10 + - - - 
11 - + + - 
12 - + - - 
13 - - - - 
14 + + + - 
15 - - - + 
16 - - - - 
17 - - + - 
18 - + + + 
19 - - + - 
20 - + - - 
21 + - + - 
22 - - - + 
23 - - - - 
24 - + - - 
25 - - + - 
26 - - + - 
Necropsy - + - + 
 
DNA was extracted from serum drawn from the infected baboons each week and a nested 
PCR amplification (255-761 in the first round and 459-710 in the second round) for a 252 
bp region of the surface gene performed.  Baboon #1 was inoculated with serum from 
baboon 9712, baboon #2 with serum from baboon 9732, baboon #3 with serum from 
baboon 9733 and baboon #4 was inoculated with serum from baboon 9734.  The (+) in the 
table indicates that the sample amplified successfully at this time point and the (-) indicates 
that the PCR failed.   
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3.8.2  Identification of HBV in the liver tissue of experimentally 
infected baboon #2 
 
DNA was extracted from the liver tissue of baboon #2 (inoculated with serum 
from baboon 9732), using the phenol-chloroform extraction method and a portion 
of the surface gene (409 – 1101) was amplified by nested PCR (figure 36).  The 
amplicon was sequenced using automated sequencing and the sequence aligned 
with that obtained from baboon 9732.  The sequence of the virus extracted from 
the liver tissue of baboon #2, six months after inoculation, was identical to the 
HBV sequence of this region found in the original baboon 9732.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36:  Amplification of a portion of the HBV surface gene from infected baboon 
#2.  A nested PCR amplification (58 – 1450 in the first round of amplification and 409 – 
1101 in the second round) of a 712 bp region of the surface gene was performed using 
DNA extracted from baboon #2 (inoculated with serum from baboon  9732).  Although 
three identical DNA extractions were performed, only two of them (extractions 1 and 3) 
amplified successfully. 
Abbreviations:  Blank 1 -  single round PCR containing best quality water instead of DNA; 
Blank 2 – double round nested PCR containing best quality water instead of DNA; Extn – 
extraction. 
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4.  Discussion 
 
The results of previous studies carried out in our laboratory intimated to the 
possibility that baboons may be infected with an indigenous strain of HBV.  In the 
first study, four Chacma baboons, which were HBV DNA negative at baseline, 
were inoculated with human serum and shown to be susceptible to HBV infection, 
with no biochemical evidence of liver injury at any stage and with normal liver 
histology at necropsy, 52 weeks post-inoculation (Kedda et al., 2000).  The 
inoculum was pooled serum from three patients with acute hepatitis B, and 
contained both genotype A and non-A (most likely D) strains of HBV (Baptista et 
al., 2003).  The baboon sera were negative for HBsAg and anti-HBs using 
conventional assays but positive for anti-HBc at 16 weeks post inoculation.  In a 
follow up study, very low concentrations of HBV DNA were found in the serum 
of the infected baboons and genotypes A and non-A were detected in varying 
concentrations in four baboons for the entire 52-week follow up period (Baptista 
et al., 2003).  Two baboons were excluded from these studies because they were 
HBV DNA-positive at baseline, prior to inoculation, and we therefore proceeded 
to determine the prevalence of HBV in wild-caught baboons. 
 
4.1  Prevalence of HBV DNA in Chacma baboons 
 
The Chacma baboon (Papio ursinus orientalis) is widely distributed in South 
Africa, ranging from the Cape Peninsula to just north of the Limpopo River 
(Marais, 1971).  Sixty nine wild caught Chacma baboons - forty nine adults and 
twenty juveniles - from three distinct geographical regions of South Africa were 
screened to determine the prevalence of HBV in these primates.  Serum samples 
from seven vervet monkeys (Cercopithecus pygerythrus) were initially also 
screened for HBV but, were found to be negative for all four regions and, 
thereafter used as negative controls.       
 
Two different extraction methods, the QIAGEN QIAamp® DNA Blood Mini Kit 
and GeneReleaser® were used to extract DNA from the primate serum samples 
and this DNA used as the template for the nested-PCR amplification of four non-
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overlapping regions of the HBV genome.  Although the GeneReleaser® system is 
more economical, time effective and requires a smaller amount of serum, it is 
more prone to false-negative results when HBV DNA concentrations are low 
(Kramvis et al., 1996).  It is however slightly more sensitive than the QIAamp® 
kit for detecting HBV DNA at low-titres.  In the present study, the efficiency of 
DNA extraction from the baboon sera did not differ between the two methods.    
 
Although nested PCR increases the sensitivity of detection in samples with low 
titres of HBV, there is an increased risk of false-positivity because of inadvertent 
contamination.  All the necessary controls and precautions recommended by 
Kwok and Higuchi (1989) were therefore strictly adhered to.  Moreover, the 
amplifications were repeated at different times, by different researchers, in 
independent laboratories.  The variation shown phylogenetically between the 
precore/core sequences of a representative number of samples (figure 15) 
furthermore confirmed that there were differences in the HBV strains from 
individual baboons, ruling out the possibility of a contaminant. 
 
HBV DNA was detected in five baboon sera using Southern hybridization (figure 
16).  This detection of HBV in baboon serum samples by Southern hybridization 
is an important control because it eliminates the possibility that the sera were 
contaminated in the laboratory during subsequent analyses. 
 
Samples were only considered to be positive for HBV DNA if they amplified for 
at least three of the four regions of the HBV genome.   Using this criterion, 15 out 
of 69 baboon sera were HBV DNA positive giving an overall prevalence of 
21,7%.  Considering that less stringent criteria (i.e. nested-PCR amplification of at 
least two out of three different regions (Cacciola et al., 1999; Raimondo et al., 
2007)) are used to detect HBV in serologically negative individuals and that we 
did not determine the prevalence of HBV in the liver, this may be an 
underestimation of the prevalence of HBV in baboons (Gibney et al., 2008).  
 
Using commercially available ELISA assays, the sera of four HBV DNA positive 
baboons were tested and found to be serologically negative for HBsAg and anti-
HBc.  On the other hand, immunohistochemical staining of liver tissue from one 
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of these baboons did detect HBcAg in several hepatocyte nuclei (figure 17, panel 
B) but could not detect HBsAg in the cytoplasm.  This detection of HBcAg and 
the detection by others of HBsAg and/or HBcAg in a number of naturally infected 
non-human animals including chimpanzees, gibbons, orang-utans, woolly 
monkeys, Beechy ground squirrels and tree squirrels (Marion et al., 1980; 
Feitelson et al., 1986; Lanford et al., 1998; Warren et al., 1999; Hu et al., 2000; 
Lanford et al., 2000) excludes the possibility that the lack of detection of HBsAg 
and anti-HBc was a result of the lack of cross-reactivity between the human and 
baboon antigens.  The baboon immune system is similar to that of humans 
(Murthy et al., 2006) and antigenic cross-reactivity to a number of other viruses 
including HIV and simian immunodeficiency virus (SIV) has been demonstrated 
in baboons (Langat et al., 1999).  Moreover, interspecies cross-reactivity to 
human immunoglobulins and to three distinct epitopes on human plasminogen has 
been demonstrated in baboons (Cummings et al., 1984; Shearer et al., 1995).   
 
In the present study, we could not detect HBV infection using serological tests 
alone, concurring with the findings of previous studies in baboons (Blumberg et 
al., 1972; Deinhardt, 1976; Michaels et al., 1994).  In contrast HBsAg positivity 
has been reported in 6,7% of chimpanzees, 4,6% of gorillas, 20,7% of gibbons, 
21,3% of orang-utans and 53,8% of woolly monkeys tested (Sa-Nguanmoo et al. 
2009 and references therein).  On the other hand, using nucleic acid testing, 
hepadnaviral infections were detected in 19,5% of chimpanzees, 15,1% of 
gorillas, 37,5% of gibbons, 27,3% of orang-utans and 60% of woolly monkeys 
(Sa-Nguanmoo et al. 2009 and references therein).  Michaels et al. (1996) failed 
to detect HBV DNA in four experimentally infected baboons but, since no details 
are given on the regions amplified or whether a nested PCR amplification was 
used, it is difficult to gauge whether the amplification used was sensitive enough 
to detect low levels of viral DNA.  Kedda et al. (2000) detected HBV DNA in 
experimentally infected baboons, 52 weeks post-infection using nested PCR.  In 
the present study, the first large scale cross sectional study of the prevalence of 
HBV DNA in wild-caught baboons, we found 21,7% of wild-caught Chacma 
baboons to be positive for HBV DNA, a prevalence similar to that found in other 
non-human primates (Sa-Nguanmoo et al., 2009). 
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Histological examination of the baboon liver tissue from a single baboon  showed 
mild focal lobular hepatitis but no interface hepatitis, bridging necrosis or other 
signs of liver injury (figure 17, panel A).  This is similar to what has been 
observed in chimpanzees and Barbary macaques experimentally infected with 
human HBV that develop characteristically mild symptoms of liver disease 
(Feitelson and Larkin, 2001; Gheit et al., 2002). 
 
4.2  Amplification of the complete HBV genome 
 
Both Kedda et al. (2000) and Baptista et al. (2003) showed that HBV DNA levels 
in experimentally infected baboons are very low.  Similarly, in the present study, 
the fact that HBV DNA could only be amplified using nested PCR indicated that 
low viral levels were found in the sera of naturally infected baboons.  These low 
levels made amplification of the complete genome challenging.   It has previously 
been shown that the best source of hepadnaviral DNA in carriers with low titres of 
virus is liver tissue and that the maximum amounts of high quality nucleic acids 
can be recovered using proteinase K digestion followed by phenol chloroform 
extraction and precipitation with ethanol (Michalak et al., 2007; Raimondo et al., 
2008a).  Therefore in order to ensure optimal levels of HBV DNA to allow for 
downstream sequencing, DNA was extracted from the liver tissue of baboon 9732 
using this method.   
 
In 2000, Hu et al. successfully amplified the complete hepatitis B viral genome 
from the sera of two of thirteen chimpanzees using overlapping sub-genomic 
fragments but only a portion of the surface gene from the remaining eleven 
chimpanzees.  The primers used in that study all annealed to very conserved 
regions of the viral genome and were synthesised in both the forward and reverse 
orientations so that they could be used as either forward or reverse primers. Using 
these primers together with primers designed and used routinely in our laboratory 
(table 6), the complete genome of HBV isolated from baboon 9732 liver was 
successfully amplified by the nested PCR of eight overlapping fragments. 
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4.3  Sequencing and phylogenetic analysis of baboon HBV 
 
Phylogenetic analysis of the complete genome (figures 25), as well as each of the 
four open reading frames (figure 27), of the HBV isolated from the liver of 
baboon 9732, showed it to belong to genotype A and to cluster with subgenotype 
A2.  The relatedness of the HBV isolate from the baboon to subgenotype A2 
isolates is reinforced by a mean nucleotide divergence of 1,0% across the 
complete genome compared to 4,5% when the baboon isolate is compared to 
subgenotype A1.  Phylogenetic comparison of the baboon HBV sequence with 51 
other subgenotype A2 complete HBV genomes showed that this subgenotype does 
not cluster according to geographical location (figure 26).  The baboon isolate 
branched with one of three subgenotype A2 isolates from South Africa for which 
complete sequences are available, but separately from the remaining two (figure 
26).  Subgenotype A2 is rarely detected in South Africa, where subgenotype A1 
predominates (Kimbi et al., 2004).  
 
GroupScanning analysis showed no evidence of recombination in the baboon 
HBV isolate.  The Simmonic software used tests to see how deeply a query 
sequence lies within each clade formed by a particular genotype with values 
ranging from close to 0 (showing no grouping) to 1 (the query sequence is buried 
deep within a specific genotype) (Simmonds and Midgley, 2005).  The values for 
the baboon HBV isolate never fell below 0,96 indicating a strong association with 
genotype A.  
 
Analysis of the nucleotide sequence of the complete HBV genome isolated from 
the baboon liver showed that it contained the six nucleotide insertion in the core 
ORF as well as a C at nucleotide position 1858, both characteristics of genotype 
A.  The 1858C variation is important as it stabilises the ε stem-loop structure by 
preventing a G to A mutation at position 1896 (Lok et al., 1994).   
 
The baboon HBV sequence included variations that differentiate subgenotype A2 
from A1 at both the nucleotide and amino acid levels.  These variations are 
concentrated in the pre-S1 region overlapping the polymerase spacer domain and 
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in the pregenome ε signal (Kimbi et al., 2004; Sugauchi et al., 2004; Datta et al., 
2009).  The pre-S region, particularly peptides 21 to 47 are involved in the 
binding of the virus to the hepatocytes (Neurath et al., 1986) and the ε signal is 
essential for the replication and biological functions of HBV (Kramvis and Kew, 
1998b).  The “a” determinant of the HBsAg did not contain any mutations that 
could lead to conformational changes affecting antibody binding and hence cannot 
be implicated in the failure to detect HBsAg in both the serum and liver tissue of 
the baboon (Pawlotsky, 2005; Lada et al., 2006). 
 
In contrast to other subgenotype A2 sequences, the basic core promoter and 
precore regions of the baboon HBV isolates contained the G1809T / C1812T 
double point mutation as well as the G1888A mutation.  The former is found in 
subgenotypes A1 and A3 and latter only in subgenotype A1 (Kimbi et al., 2004; 
Kramvis et al., 2008).  The 1809 / 1812 double nucleotide substitution is upstream 
of the precore initiation codon at position 1814.  Nucleotides 1808 – 1817 (5’ – 
AGCACCATGC – 3’) are well conserved in genotypes A – H and conform to the 
Kozak sequence (5’ - GC GA CCATGG – 3’), which is optimal for the initiation of 
translation (Ahn et al., 2003).  The 1809 / 1812 variation changes this sequence 
to: 5’ – ATCATCATGC – 3’ (initiation codon underlined; substitutions in bolded 
italics) and results in a more than 20% reduction of HBeAg expression through a 
ribosomal leaky scanning mechanism (Ahn et al., 2003).  This reduction in 
HBeAg expression is thought to facilitate early seroconversion to anti-HBe and is 
accompanied by a striking reduction in the replication of HBV.  Nucleotide 1888 
is found on the upper stem of the encapsidation signal and the G to A mutation 
creates a Watson-Crick pair with T1871 stabilising this structure (figure 7) 
(Kimbi, 2005).  This mutation also affects translation of the core protein as it 
introduces an out-of-frame start codon that plays a role in modulating translation 
of the core protein by a leaky scanning mechanism (Kimbi, 2005).  This decrease 
in core protein is thought to result in a less severe immune response and hence to 
less liver damage and possible persistence of the virus. 
  
Four other mutations differentiated the baboon strain of HBV from the majority of 
previously sequenced human subgenotype A2 isolates.  These included mutations: 
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T380C (rtV84A in conserved region A of the HBV polymerase and C76R in 
HBsAg), C1470T (P33G in the X protein), T1765C (P145S in the X protein) and 
A2019G (E40G in the core protein). The mutations in the polymerase and X 
proteins are not predicted to cause any significant conformational changes.  The 
cysteine (C) to arginine (R) mutation at position 76 of HBsAg could affect this 
protein as the C residues are known to form disulfide bond cross linkages 
important in the tertiary structure of proteins.  sC76R on the other hand, located in 
the first hydrophilic loop, would not be expected to have a significant effect 
because the antigenicity and infectivity of the virus are mainly affected by 
residues 101 to 172 of HBsAg (Salisse and Sureau, 2009).  Furthermore, C76 is 
not essential for assembly and secretion of the S protein (Mangold et al., 1995).  
The A2019G mutation causes an E40G substitution in the core protein.  This 
could lead to conformational changes in the core protein as this mutation results in 
the replacement of a negatively charged polar side chain with a non-polar one.  
Further functional studies would be necessary to determine the effect of these 
changes found in the baboon HBV isolate.   
 
4.4  Replication of HBV in the baboon liver 
 
Hepadnaviruses replicate by the reverse transcription of an RNA intermediate 
from cccDNA.   The presence of both cccDNA and viral RNA was therefore used 
to demonstrate viral replication in the baboon liver because the detection of HBV 
DNA alone does not necessarily correspond to infection (Hollinger and Sood, 
2010).  Moreover, HBV DNA positive baboons did not show significant 
biochemical or histological evidence of liver damage, and thus identification of 
viral replication was important to show infectivity.   
 
Using real-time PCR, HBV cccDNA was detected in the baboon liver.  This 
selective cccDNA PCR, originally devised by Kock et al. (1996), differentiates 
between intracellular HBV cccDNA, virion open circular DNA and other HBV 
replicative intermediates by using the fact that the HBV genome is partially 
double-stranded, while the cccDNA molecule has both strands complete.  The 
primers are designed to selectively amplify a region corresponding to the gap and 
incomplete regions of the viral genome, and thus amplification is unhindered in 
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cccDNA but, because of the gap found in this region in the other forms of HBV, it 
is inefficient in these forms.   
 
Extracted samples were treated with Plasmid-Safe™ ATP-Dependent DNase, 
which hydrolyses linear double stranded DNA into deoxynucleotides without 
affecting either closed circular, supercoiled or nicked circular double stranded 
DNAs (Epicentre biotechnologies).  Bowden et al. (2004) noted that extracts 
treated with Plasmid-Safe™ ATP-Dependent DNase had a log reduction in 
background amplification, so a 1000-fold excess of non-ccc HBV DNA would be 
needed in order to make a significant contribution to the HBV cccDNA assay. 
 
HBV DNA levels in the baboon are very low and similarly, low levels of cccDNA 
were detected in the liver tissue with the samples only reaching log phase after 
more than 35 cycles.  The real-time PCR made use of SYBR®-green for detection 
and so a dissociation curve was used to confirm that both the samples extracted 
from the baboon liver and the positive controls had the same melting temperature 
(figure 34).   
 
Detection of transcripts from both the core and surface ORFs showed that the 
virus is transcriptionally active in baboon hepatocytes (figure 31).  Maximum 
amounts of high quality RNA were obtained from the baboon liver using the 
guanidinium–acid-phenol extraction method.  This was found to be more efficient 
that the Promega SV total RNA isolation kit, which could only detect amplified 
products by Southern hybridisation (figure 32).  Extracts were treated with 
DNaseI to prevent any HBV DNA carryover and to ensure that only HBV 
transcripts were detected (Mason et al., 1998).   
 
4.5  Transmission of the virus to experimentally naïve baboons 
 
Transmission of the HBV found in baboons was demonstrated by successfully 
infecting four domestically raised, experimentally naïve baboons with sera from 
infected baboons.  Serum samples were collected and analysed on a weekly basis 
for 26 weeks post-inoculation.  At 26 weeks post-inoculation, the baboons were 
sacrificed and liver tissue obtained at necropsy.  Transient HBsAg and HBeAg 
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seroconversion provided serological evidence of HBV infection in all four 
baboons as illustrated in figure 35.  HBsAg and HBeAg derived from the 
inoculum have only been reported to persist in the serum of inoculated rhesus 
monkeys (Macacca mulata) for up to three weeks post inoculation (Lazizi and 
Pillot, 1993).  Therefore, we did not consider elevations in the levels of the HBV 
serological markers within the first four weeks post inoculation as an indication of 
infection.    There was however an increase in HBsAg levels in all four of the 
inoculated baboons nine weeks post inoculation indicating successful transmission 
of the virus to the experimentally naïve baboons by this stage.     
 
HBV DNA was detected intermittently in the serum of all four baboons for the 
entire six month period of follow-up (table 11).  The length of time following 
inoculation during which detectable HBV DNA from the inocula can be detected 
in the recipient serum, is contentious.  On the one hand, Lanford et al. (2003) used 
the detection of WMHBV DNA in the serum of a spider monkey six weeks post 
inoculation as evidence of replication whereas Lazizi et al. (1993) amplified HBV 
DNA in rhesus monkeys, which are resistant to HBV infection, for a maximum of 
three months post-inoculation but not thereafter.  In our case the time of follow up 
was longer than three months and since HBV DNA could be detected six months 
post inoculation, this did not represent persistence of the inoculum.     
 
The sequence of the HBV isolated from the liver of baboon #2 at necropsy was 
identical to the sequence of the inoculum, demonstrating successful transmission 
of the virus to experimentally naïve baboons.   
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Table 12:   A comparison of hepadnavirus infection in the woodchuck and baboon (modified 
from Michalak et al., 2007). 
 
Characteristic 
Woodchuck Model 
Baboon Primary Occult 
Infection 
Secondary Occult 
Infection 
Serology:    
• WHVsAg Negative Negative HBsAg Negative 
• Anti-WHVc Negative Positive HBcAg Positive 
• Anti-WHVs Negative Positive or Negative Anti-HBs Negative 
WHV-DNA load    
• Serum 210≤  vge / ml 210≤  vge / ml Low levels 
• PBMC 310≤  vge / µg 310≤  vge / µg nd* 
• Liver Not detectable 310≤  vge / µg Low levels 
Longevity of 
Persistence Unknown Life-Long Life-Long 
Infectivity Yes Yes Yes 
Spectrum of Organs 
Involved:    
• Lymphatic System Yes Yes nd* 
• Liver No Yes Yes 
Liver Histology Normal 
Intermittent minimal 
to moderate 
inflammatory changes 
with periods without 
alterations 
Mild focal lobular 
hepatitis 
Hepatocellular 
Carcinoma 
Development 
Unknown ~ 20% ? 
  
* nd – not determined 
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4.6  Characterization of the baboon HBV infection  
 
Michalak et al. (2007) defined as occult HBV infection as: 
“the existence of HBV DNA in serum, lymphoid cells (PBMC) and / or the liver 
and virus genome replicative intermediates (i.e. covalently closed circular DNA 
(cccDNA) and / or mRNA) in lymphoid and / or hepatic tissue in the absence of 
serum HBV surface antigen, symptoms and biochemical evidence of liver injury”. 
 
Using this definition, it is evident that the HBV infection found in wild-caught 
baboons meets the criteria of an occult infection.  Because OBIs in humans occur 
in asymptomatic carriers of the virus, who are not frequently screened, the 
woodchuck model, which has been extensively studied, provides a good 
alternative model system.  We therefore compared the characteristics of the 
infection in the baboon with this animal model (table 12).  The baboon infection 
had the same characteristics of infection defined as secondary occult in the 
woodchuck model.  The baboon had low viral loads in the serum and the liver, 
was serologically negative and exhibited mild focal lobular hepatitis.  
Furthermore, HBV DNA was detected in both juvenile and adult baboons, 
demonstrating the lifelong persistence of the virus.  The infection was 
successfully transmitted to experimentally naive baboons using HBV DNA-
positive serum.   
 
This study is the first to report an OBI in a non-human primate, which is similar to 
the seronegative OBI seen in humans.  These OBIs are characterised by a lack of 
all serological markers and very low or even undetectable levels of circulating 
HBV DNA (Raimondo et al., 2010), with HBV DNA detected more frequently 
intrahepatically rather than in the serum (Hu, 2002).  The detection of HBV DNA 
in liver biopsies is therefore considered to be the only reliable marker of this type 
of infection (Raimondo et al., 2008b; Raimondo et al., 2010).  OBIs in humans 
without liver injury have not been extensively studied and therefore our current 
knowledge of OBIs comes mainly from the woodchuck model.  The detection of 
an OBI in the baboon may provide a good alternative model system in an animal 
closely related to humans and not endangered.    
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4.7  Origins of HBV infection 
 
The HBV genome has a very complex organisation with more than 67% of the 
genome coding for multiple proteins and regulatory functions within overlapping 
open reading frames (Mizokami et al., 1997).  A synonymous change in one ORF 
therefore could result in a non-synonymous change in the overlapping ORF and 
so, in order to maintain its functionality, evolution of the HBV genome is 
constrained.  The HBV polymerase enzyme lacks proof-reading activity and has 
mutation rates similar to those of the related retroviruses or other RNA viruses 
(Simmonds, 2001).  If evolution of the genome, in the absence of immune 
pressure, is taken to be 5101,2 −×  substitutions per site per year, it can be 
extrapolated that the HBV genotypes evolved from a common ancestor between 
2300 and 3100 years ago.  The identification of HBV strains in wild caught 
chimpanzees, gibbons and orang-utans, equidistant both from each other and from 
the human genotypes, would mean that if the same mutation rate is adhered to, the 
primate associated HBV strains would also have originated in the last 2000 – 
3000 years (Simmonds, 2001).  Humans are the only species known to have 
travelled between continents during this period and so they would have had to be 
the vectors that spread the disease to other species. 
 
An alternate hypothesis is that HBV co-evolved with modern humans when they 
migrated from Africa approximately 100 000 years ago (Norder et al., 1994; 
Magnius and Norder, 1995).  The difficulty with this theory is that the distribution 
of the HBV genotypes does not correspond between human population groups 
(e.g. genotype F is found in the Native American population whereas genotypes B 
and C are found in their nearest genetic relatives, the Mongoloid northeast Asians) 
(Simmonds, 2001).  The other problem with this theory is the close relationship 
between the human and non-human primate strains.  In this scenario, the primate 
viruses should be far more divergent from the human variants and from each other 
given the much longer period of primate co-speciation (Simmonds, 2001). 
 
A third hypothesis for the origin of HBV speculates that the non-human primate 
HBV variants coevolved with their primate hosts over a period of 10 - 35 million 
 132 
years (MacDonald et al., 2000).  The numerous genotypes found in humans would 
have resulted from multiple zoonotic transmissions from several non-human 
primate species infected with different species-specific strains.  This hypothesis is 
supported by the fact that in areas of high HBV endemicity, there is close contact 
between humans and primates increasing the chances of cross species 
transmission (Simmonds, 2001).  Transmission by multiple zoonotic events is not 
unprecedented.  HIV type 1 has been shown to have originated from three 
separate cross species transmissions from chimpanzees and HIV type 2 originated 
through multiple contacts with sooty mangabeys (Gao et al., 1992; Gao et al., 
1999).  Supporting this theory is the fact that the most divergent of the human 
HBV genotypes, genotype F, and the most divergent of the non-human primate 
HBV strains, the woolly monkey HBV, are both found in South America.  
Furthermore, hepadnaviral isolates from the gibbon and orang-utan resident in 
east Asia grouped closest to isolates from genotype B, whereas isolates from 
chimpanzees in  Africa grouped closest to genotype A, when ~60% of the 
polymerase ORF and the overlapping S gene was compared (Simmonds and 
Midgley, 2005).  In both cases, these are the predominant human HBV genotypes 
found in humans sharing the natural habitats of these primates.  The recently 
described “genotype J” isolate was found to cluster phylogenetically with isolates 
from the gibbon and the orang-utan, both of which occur in Borneo, where the 
patient is presumed to have been exposed (Tatematsu et al., 2009).   
 
A shortcoming of the “non-human primate origin”  hypothesis has been that, apart 
from one HBV genotype E strain in a wild-caught chimpanzee (Takahashi et al., 
2000), there have been no reports of an HBV genotype being shared by both 
humans and primates and thus the actual species involved in transmission of HBV 
to humans has so far remained unidentified (Simmonds, 2001).  The identification 
in the present study of the occult HBV infection in wild-caught baboons with 
subgenotype A2 share by humans strengthens the argument for a non-human 
primate origin of HBV infection and may provide a key to the puzzle.   
 
The nucleotide divergence of genotype A is highest in Africa (4%) than elsewhere 
(2,96%) leading to the hypothesis that genotype A originated in Africa and then 
spread to the rest of the world (Kramvis and Kew, 2007; Andernach et al., 2009a).  
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The relatively large nucleotide divergence between subgenotypes A1 and A2 
suggests that they diverged more than 2000 years ago.  The low variability seen 
within the circulating strains of subgenotype A2, which is characterized by a 
relatively slow evolutionary rate ( 4109,0~ −× ) (Zehender et al., 2008), suggests 
that this subgenotype arrived in Europe from Africa in the last 500 years, most 
likely by the Portuguese sailors who first came to Southern Africa in the late 
1400s (Hannoun et al., 2005).  Subgenotype A2 has been shown to preferentially 
be transmitted sexually especially in men-having-sex-with-men (De Maddalena et 
al., 2007) The greater intragroup genetic diversity of African subgenotype A2 
strains (1,97%) compared to A2 strains from the rest of the world (1,17%) 
(Andernach et al., 2009a) supports this hypothesis.  
 
The finding of subgenotype A2 in the HBV isolate from the liver of baboon 9732 
may seem paradoxical as subgenotype A1 is the predominant strain presently 
circulating in South Africa.  One possible explanation for this is that subgenotype 
A1 has over time become more predominant than subgenotype A2.   An 
analogous trend may have occurred  in the Mediterranean region where genotype 
D now predominates over genotype A (Norder et al., 1993).  Similarly a change in 
the prevalent HBV genotype in central and western Africa has been postulated to 
have occurred over the past 200 years, with the genotype E expanding in the 
human population (Andernach et al., 2009a; Forbi et al., 2010).    Genotype E, 
which was originally restricted to the west coast of Africa, has now spread over a 
large crescent stretching from The Gambia, through Nigeria and the Democratic 
Republic of Congo into Namibia and Mozambique (Andernach et al., 2009a).  
This recent spread is supported by the low sequence divergence (1,75%) of this 
genotype (Mulders et al., 2004; Kramvis et al., 2005b; Forbi et al., 2010) and by   
the very sporadic detection of genotype E outside of Africa (Singh et al., 2009; 
Alvarado Mora et al., 2010), suggesting that this genotype  was rare in Africa at 
the time of the forced migration of African slaves to the New World between the 
16th and 19th centuries (Andernach et al., 2009a; Forbi et al., 2010).  Instead, the 
subgenotypes found in descendants of Africans in South America are subgenotype 
A1 in Brazil (Araujo et al., 2004) and subgenotype A2 in Venezuela (Quintero et 
al., 2002).The higher nucleotide divergence of African subgenotype A2 strains 
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relative to non-African strains intimates that subgenotype A2 may be of African 
origin (Hannoun et al., 2005).  However, since  only three complete subgenotype 
A2 HBV genomes from Africa have been published with a few partial genomes 
from Kenya (Mwangi et al., 2008), no firm conclusions can be drawn.  
 
4.8  Cross species transmission of HBV between humans and 
baboons 
 
HBV is highly contagious virus and is approximately ten times more contagious 
than HCV and a hundred more times contagious than HIV (WHO, 2008).  HBV is 
transmitted through the exchange of blood and bodily fluids including via bites 
and saliva (Scott et al., 1980; Stornello, 1991).  Documented close links between 
humans and baboons mean that cross species transmission of the virus is 
extremely plausible.  
 
In Africa, primates are often slaughtered for bushmeat, so this could be another 
source of exposure to the virus (Robertson, 2001).  Simian foamy virus, for 
example, regularly infects hunters of bushmeat as do avian influenza and Hendra 
viruses (Wolfe et al., 2005).  These viruses show little to no evidence of human-
to-human transmission but it is hypothesised that through repeated transmissions, 
they will gradually adapt and ultimately evolve into viral strains capable of being 
transmitted by humans.  This is what is believed to have happened with SIV and 
HIV.  SIV naturally infects the red-capped mangabey (Cercocebus torquatus) and 
the greater spot-nosed monkey (Cercopithecus nictitans) (Lovgren, 2003).  
Chimpanzees (Pan troglodytes) acquired SIV by eating these monkeys giving rise 
to a hybrid form of the virus.  This hybrid virus was transmitted to humans as 
HIV-1, probably through the hunting and butchering of chimpanzees for bushmeat 
(Lovgren, 2003). 
 
Zoonotic transmissions of viruses are common.  Avian influenza A virus (subtype 
H5N1) can be spread to domestic cats, tigers, leopards and of course humans 
(Keawcharoen et al., 2004; Kuiken et al., 2006).  Human influenza A viruses can 
be transmitted to ferrets, guinea pigs and chimpanzees (Ferber, 2000; Lowen et 
al., 2006) and the influenza B virus, supposedly restricted to humans, has been 
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found in harbour seals (Osterhaus et al., 2000).  The herpes simplex virus can be 
passed from humans to various species of ape including gorillas, chimpanzees and 
apes (Eberle and Hilliard, 1989) and an outbreak of the human measles virus in 
gorillas in Rwanda killed six of these primates (Ferber, 2000).  Other human 
viruses have simian origins, for example the human T-cell leukaemia virus 
(HTLV) is the counterpart to the simian T-cell leukaemia virus (STLV) 
(Courgnaud et al., 2004).  Among the hepatitis viruses, hepatitis E has zoonotic 
tendencies and is found in humans, domestic pigs, rodents, deer and macaques 
(Hirano et al., 2003; Christensen et al., 2008).  Baboons are susceptible to STLV 
(Takemura et al., 2002) and are one of only a few non-human primates that when 
infected with HIV, develop an AIDS-like disease (Locher et al., 2003).  This latter 
fact, together with the fact that the baboon immune system, like its human 
counterpart, has all four IgG subclasses makes the baboon an ideal animal model 
system for human infections and vaccine development (Locher et al., 2003). 
 
In Africa, the majority of HBV carriers are HBeAg negative, and in these 
individuals, the spread of HBV is mainly horizontal (Kramvis and Kew, 2007).  In 
South Africa, HBsAg positivity peaks between five and six years of age (Kew, 
1996; Vardas et al., 1999).  In baboons, their natural habits mean that horizontal 
baboon to baboon transmission of HBV is highly likely.  Baboons are very 
sociable animals living in troops of between 20 and 150 animals (Barrett, 2000).  
Bonds are strengthened by daily grooming with several related and unrelated 
partners including offspring (Cheney and Seyfarth, 2007).  Infant baboons hold 
immense attraction for both adult and juvenile females who gather round to touch, 
hug and examine the infant.  Young baboons, like their human counterparts, spend 
much of the day playing together.  The games can become quite physical often 
leading to mock fights.  This behaviour is generally tolerated by the other 
members of the troop although the occasional old male has been observed to 
heavily punish youngsters who disturb him (Marais, 1971).  There is a strict 
hierarchy within troops of baboons, which is actively enforced.  Although 
physical fights amongst both males and females are rare, they are not unknown.  
Alpha males especially tend to be very aggressive and displays of dominance and 
chases are a daily occurrence.  An alpha male seldom lasts in that position for 
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more than a year and the new alpha male will often kill infants fathered by the 
male they have just usurped (Cheney and Seyfarth, 2007). 
 
Subgenotype A2, which was found in the baboon has the unusual characteristic of 
being confined to the peripheral blood leukocytes (PBLs) of Indians, a population 
where subgenotype A1 and genotype D predominate  (Datta et al., 2009).  The 
active replication of the virus in the PBLs may be the result of differential 
immune pressures, which allow different viral strains to evolve independently 
(Datta et al., 2009).  Although the results of the study by Datta et al. were 
challenged as being the result of  contamination (Thio et al., 2010) , the authors 
defended their work by explaining the necessary precautions and controls taken to 
prevent contamination.  They also pointed out that HBV has a much slower 
mutation rate than RNA based viruses such as HIV, and so the publication of 
HBV sequences from unrelated isolates that are identical or differ in only one or 
two nucleotides is quite common. This unique compartmentalization of 
subgenotype A2 in the PBLs may explain the spread and transmission of HBV in 
baboons but further studies are necessary.   
 
From the results of the present study, it is impossible to determine whether the 
HBV found in baboons initially came from humans, or if humans were infected by 
baboons.  However, as noted by Michael Lai, a virus expert at the University of 
Southern California, Los Angeles, “When we expose ourselves to exotic animals, 
there is always a risk of being exposed to something unknown…When we perturb 
the existing peace between human beings and nature, we are opening a Pandora 
box, which may contain surprises.” (Lovgren, 2003). 
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5.  Conclusion 
 
The detection of HBV DNA in the sera of two Chacma baboons prior to 
inoculation with human HBV intimated that baboons are chronically infected with 
HBV.  The objective of the present study was to determine the prevalence of HBV 
in wild caught Chacma baboons and to molecularly characterise the virus isolated 
from these animals. 
 
Using nested PCR of four separate genomic regions, and taking a sample to be 
positive only if it amplified for three or more of these regions, HBV DNA was 
detected in the serum of 11/49 adult and 4/20 juvenile baboons resulting in an 
overall prevalence of 21,7%.  This prevalence is similar to the HBV prevalence in 
humans and other non-human primates in highly endemic areas, including sub-
Saharan Africa.  Serologically, the baboons were negative for all markers of HBV 
infection, although HBcAg was detected in liver tissue by immunohistochemical 
staining.  The detection of low levels of HBV DNA in the baboon liver tissue, as 
well as the serum, in the absence of HBsAg classifies this infection as occult 
(Raimondo et al. 2008a).  The lack of any serological markers of HBV infection 
further distinguishes this as a seronegative OBI.  OBIs are a common 
consequence of the resolution of acute hepatitis infections but may also occur 
after asymptomatic exposures to HBV (Michalak et al. 2007).   
 
The complete HBV genome isolated from the liver of an adult male Chacma 
baboon, baboons 9732, was amplified by the nested PCR of eight overlapping 
subgenomic fragments.  A 160 bp portion of the precore/core region of the viral 
genome was also successfully amplified and sequenced using DNA isolated from 
the serum of baboon 9732 as well as five other baboons.   Phylogenetic and 
GroupScanning analysis of the baboon HBV isolate showed it to belong to 
genotype A, clustering with subgenotype A2, an unexpected result considering 
that subgenotype A1 predominates in South Africa.  The baboon HBV had 
mutations in both the basic core promoter and precore regions not found in 
subgenotype A2.  These mutations included the G1809T / C1812T double 
mutation in the Kozak sequence preceding the precore protein start codon 
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characteristic of subgenotypes A1 and A3, and G1888A in the precore region 
unique to subgenotype A1. The G1809T / C1812T double mutation and the 
G1888A mutation affect the translation of the precore and core proteins, 
respectively, by a leaky scanning mechanism, resulting in reduced expression of 
both proteins (Ahn et al. 2003; Kimbi 2005).  Four additional mutations in the 
polymerase, surface, X and core regions of the baboon HBV strain differentiated 
the baboon isolate from the majority of previously sequenced subgenotype A2 
isolates.   
 
Low levels of cccDNA were detected in the liver tissue of baboon 9732 using a 
selective real-time PCR and SYBR®-green detection.  The low levels were clearly 
demonstrated by length of time taken for the   baboon HBV isolate to reach log 
phase (~35 cycles) when compared to isolates from both the tumorous and non-
tumorous controls (~30 cycles).  RNA extracted from the liver tissue of baboon 
9732 was reverse transcribed and regions of the HBV precore/core and surface 
ORFs amplified by nested PCR.  This detection of cccDNA and viral RNA in the 
liver tissue of baboon 9732  shows that the HBV is replicating at low levels in the 
baboon liver, , a characteristic of occult infections 
 
The HBV found in baboons was successfully transmitted to four experimentally 
naïve baboons by injecting them individually with serum from four HBV DNA 
positive baboons.  The inoculated baboons were transiently seropositive for both 
HBsAg and HBeAg and had intermittent increases in ALT levels.  HBV DNA 
was detected at various time points post inoculation throughout the 26 week 
period and amplification of a portion of the HBV genome isolated from the liver 
tissue of one of the baboons post inoculation showed it to be identical in sequence 
to the inoculum.  This demonstration of transmissibility of the baboon HBV is 
important as it shows that the virus is not only present in baboons but, taken 
together with the evidence of viral replication, establishes infectivity of the virus.  
The HBV found in baboons can therefore be classified as an occult HBV 
infection (Hollinger and Sood, 2010). 
 
The well documented interactions between humans and baboons make cross 
species transmission of this virus a possible event.  The identification of 
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subgenotype A2 in the baboon when subgenotypes A1 and A3 predominate in 
Africa, may indicate that subgenotype A2 is an older strain that previously 
circulated on the African continent.  There is a paucity of sequencing data for 
subgenotype A2 from Africa, with only four complete subgenotype A2 genomes 
from South Africa deposited in GenBank.  Shorter subgenomic sequences of 
subgenotype A2 from South Africa (Bowyer and Sim 2000), Tunisia (Meldal et 
al. 2009) and Kenya (Mwangi et al. 2008) have also been deposited.  It is possible 
that more extensive molecular epidemiological studies in Africa may uncover a 
higher circulation of subgenotype A2 in more remote regions.  Furthemore, in a 
recently published study it was shown that, in India, subgenotype A2 
preferentially infects the peripheral blood lymphocytes as opposed to the liver 
(Datta et al. 2009).  Subgeneotype A1 is the major strain of genotype A 
circulating in India.  Therefore the possibility exists that this alternative 
compartmentalization of the subgenotype A2 infection has resulted in the lack of 
detection of this subgenotype in Africa.  This possibility, which was not explored 
in the present study because of ethical and time constraints, should be investigated 
by extracting DNA from the PBL compartment of both baboons and Africans. 
 
The detection of HBV in both adult and juvenile baboon sera, albeit at low levels 
is an indication of the lifelong persistence of this virus in these animals.  HBV 
DNA was detected in the absence of serological markers, an indication of 
secondary occult infection (Michalak et al. 2007).  The detection of cccDNA and 
HBV RNA in the liver tissue of baboons provided evidence of replication of the 
virus and the infection was transmitted to experimentally naive baboons. 
Although secondary occult infection has been demonstrated in the woodchuck 
animal model, to our knowledge, this is the first study to demonstrate, a naturally 
occurring occult HBV infection in a non-human primates. 
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Appendix I 
 
Animal ethics clearance certificate from the University of the Witwatersrand: 
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Animal ethics clearance certificate from the National Institute of Health, 
Bethesda, USA: 
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Appendix II 
 
0,7% or 1% or 3% Agarose gel 
 
 0,7 g (0,7%) or 1 g (1%) or 3 g (3%) Agarose 
 100 ml    1 x TBE buffer 
Dissolve agarose in 1 x TBE buffer by heating in a microwave oven for 
~4 minutes, swirling occasionally, until all the agarose particles are 
completely dissolved.  Care must be taken that especially the high 
percentage gels do not boil over. 
Cool to ~60 °C. 
Add 10µl mg / ml Ethidium Bromide and swirl to mix. 
Pour into a prepared casting tray and allow to solidify completely at room 
temperature. 
 
0,8% Agarose gel with Crystal Violet 
 
 0,8g     Agarose 
 100 ml    1 x TAE buffer 
Dissolve agarose in 1 x TAE buffer by heating in a microwave oven for 
~4 minutes, swirling occasionally, until all the agarose particles are 
completely dissolved. 
Cool to ~60 °C. 
Add 30µl 20 mg/ml Crystal Violet solution and swirl to mix. 
Pour into a prepared casting tray and allow to solidify completely at room 
temperature. 
  
24:1 Chloroform: isoamyl alcohol 
 
To a sterile bottle, add: 
48 ml    Chloroform 
 2 ml    Isoamyl alcohol 
 Mix thoroughly before using and store at room temperature. 
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0,5 M Ethylene diamine tetra-acetic acid (EDTA) (pH 8.0) 
 
18,61 g   Ethylene diamine tetra-acetic acid 
80 ml    Distilled water 
 Stir vigorously on a magnetic stirrer. 
 Adjust pH to 8.0 with 10 M Sodium hydroxide. 
 Adjust volume to 100ml with distilled water. 
Sterilize by autoclaving and store at room temperature. 
 
Luria-Bertani (LB) medium 
 
 10 g    Tryptone 
 5 g    Yeast 
 10 g    Sodium chloride 
Adjust volume to 1000ml with distilled water. 
Sterilize by autoclaving and store at 4 °C. 
 
LB agar plates 
 
10 g    Tryptone 
 5 g    Yeast 
 10 g    Sodium chloride 
15 g     Bacteriological agar 
Adjust volume to 1000ml with distilled water. 
Sterilize by autoclaving. 
Cool to approximately 50 °C before adding 1 ml of either 50 mg/ml 
ampicillin or 50 mg/ml kanamycin as required. 
After pouring, allow plates to solidify completely at room temperature 
before storing at 4 °C. 
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5 x MOPS buffer 
 
41,86 g   3-[N-morpholino]-2-hydroxypropanesulphonic acid (MOPS) 
4,12 g    Sodium acetate 
10 ml    0,5 M EDTA (pH 8.0) 
800 ml    Distilled water 
 Adjust pH to 7.0 with 10 M Sodium hydroxide. 
Adjust volume to 1000 ml with distilled water. 
 Add 1 ml DEPC and stir at room temperature overnight. 
 Sterilise by autoclaving and store at room temperature. 
 
Phosphate Buffered Saline (PBS) (pH 7.4) 
 
8 g    Sodium chloride 
0,2 g    Potassium chloride 
1,44 g    Na2HPO4 (Di-sodium hydrogen orthophosphate) 
0,24 g    KH2PO4 (Potassium di-hydrogen orthophosphate) 
800 ml Distilled water 
Adjust pH to 7.4 with hydrochloric acid. 
Adjust volume to 1000 ml with distilled water. 
Sterilise by autoclaving and store at room temperature. 
 
Phenol chloroform extraction lysing buffer 
 
 7 M    Urea  
 0,3 M    Sodium chloride  
 10 mM   EDTA  
 10 mM   Tris base  
 Sterilise by autoclaving and store at room temperature. 
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RNA extraction Solutions 
 
     49:1 Chloroform: isoamyl alcohol 
 
To a RNase free, sterile bottle, add: 
49 ml    Chloroform 
 1 ml    Isoamyl alcohol 
 Mix thoroughly before using and store at room temperature. 
 
     Diethyl pyrocarbonate (DEPC) treated water 
  
Prepare a 0,1% solution of DEPC in distilled water. 
 Stir overnight at room temperature. 
Sterilize by autoclaving and store at room temperature. 
 
     75% Ethanol 
 
To a RNase free, sterile bottle, add: 
 75 ml    Absolute ethanol 
 25 ml    DEPC treated water 
 Store at -20 °C. 
 
     2M Sodium acetate 
 
16,42 g   Sodium acetate 
35 ml    Glacial acetic acid 
Adjust volume to 100 ml with distilled water. 
Add 100 µl DEPC and stir overnight at room temperature. 
Sterilize by autoclaving and store at room temperature. 
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     0,75 M Sodium citrate 
 
 22 g Sodium citrate 
 Adjust volume to 100 ml with distilled water. 
Sterilize by autoclaving and store at room temperature. 
 
     Solution D 
 
47,28 g   Guanidinium thiocyanate 
3,33 ml   0,75 M sodium citrate (pH 7.0) 
     5 ml   sarcosyl 
 700 µl    β-mercaptoethanol 
 Adjust volume to100 ml with distilled water. 
Add 100 µl DEPC and stir overnight at room temperature. 
Sterilize by autoclaving and store at room temperature. 
      
     Water saturated phenol 
 
 10 ml    UltraPure™ Phenol: Water (3,75 : 1 v/v) (Invitrogen) 
1,3 ml     RNase free water (Invitrogen) 
Mix thoroughly. 
 
RNA gel loading buffer 
 
 5 ml    Glycerol 
 20 µl    0,5 M EDTA (pH 8.0) 
 0,04 g    Bromophenol Blue 
 0,04 g    Xylene Cyanol 
 Adjust volume to 10 ml with DEPC treated water. 
 Store in 1 ml aliquots at room temperature. 
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10 mg/ml Salmon sperm DNA 
 
 100 mg Salmon sperm DNA 
 Adjust volume to 10 ml with TE buffer (pH 8.0). 
 Dissolve overnight. 
Sonicate 10 times (2 minutes on, 30 seconds off) and denature by boiling 
for 10 minutes. 
Store frozen at -20 °C in 1 ml aliquots. 
 
5% Sephadex 
 
 5 g     Sephadex G50 
 100 ml    TE buffer (pH 8.0) 
 Allow to stand overnight to equilibrate. 
 
Sephadex spin columns 
 
Plug the bottom of a 1 ml syringe with fish wool and place the syringe in a 
10 ml collection tube. 
Pipette 5% Sephadex into the syringe until full and centrifuge at              
35 000 x g for 5 min,  discard the filtrate and return the syringe to the    
10 ml collection tube. 
Repeat until the swollen sephadex is compacted to ~0,9 ml in the syringe. 
Equilibrate the column by adding 100 µl TE buffer to the column and 
centrifuge for 5 min.  Discard the filtrate, return the syringe to the 10 ml 
collection tube and repeat. 
Place the syringe in a clean 10 ml collection tube, add 100 µl TE buffer to 
the column and centrifuge for 5 min. 
Check that the volume of filtrate in the collection tube is 100 µl.  If not, 
repeat the final step until 100 µl is eluted.   
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Slot Blot Denaturing Solution 
 
 5 mM     Tris-HCl (pH 8,0) 
 2,5 mM  EDTA 
0,125% (w/v)  SDS 
250 µg / ml   Proteinase K 
Filter sterilise and use immediately. 
 
10% Sodium dodecyl sulphate (SDS) 
 
 10 g    SDS  
 Adjust volume to 100 ml with distilled water. 
 Filter sterilise and store at room temperature. 
 
0,4 M Sodium Hydroxide (NaOH) 
 
16 g    Sodium hydroxide 
 Adjust volume to 100 ml with distilled water. 
 
10 M Sodium Hydroxide 
 
40 g    Sodium hydroxide 
 Adjust volume to 100 ml with distilled water. 
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Southern blot Church and Gilbert (C&G) hybridisation buffer (Church 
and Gilbert, 1984) 
 
 12,78 g   Na2HPO4 Di-sodium hydrogen orthophosphate 
 4,20 g    NaH2PO4 Sodium di-hydrogen orthophosphate 
17,5 g     SDS 
5 ml    0,5 M EDTA (pH 8.0) 
200 ml    Distilled water 
Adjust pH to 7.2  
Adjust volume to 250 ml with distilled water. 
 Filter sterilise and store at room temperature. 
 
Southern blot denaturation solution 
 
 87,66 g   Sodium Chloride 
 20 g    Sodium hydroxide 
Adjust volume to 1000 ml with distilled water. 
 Sterilise by autoclaving and store at room temperature. 
 
Southern blot depurination solution 
 
22 ml    Hydrochloric acid 
978 ml    Distilled water 
Store at room temperature. 
 
Southern blot neutralisation solution 
 
 175,2 g   Sodium Chloride 
 120 g    Tris base 
 800 ml    Distilled water 
Adjust pH to 7.5 with concentrated HCl. 
Adjust volume to 1000 ml with distilled water. 
 Sterilise by autoclaving and store at room temperature. 
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Southern blot first wash buffer 
 
 50 ml    20 x SSC 
 5 ml    10% SDS 
 Adjust volume to 500 ml with distilled water and use immediately. 
 
Southern blot second wash buffer 
 
 25 ml    20 x SSC 
 5 ml    10% SDS 
 Adjust volume to 500 ml with distilled water and use immediately. 
 
Southern blot third wash buffer 
 
 2,5 ml    20 x SSC 
 Adjust volume to 500 ml with distilled water and use immediately. 
 
2 x Saline sodium citrate (SSC) 
 
 100 ml    20 x SSC 
 800 ml    Distilled water 
 Mix thoroughly. 
 
20 x SSC 
 
88,23 g    Tri-sodium citrate 
175,32 g  Sodium Chloride 
800 ml     Distilled water 
Adjust pH to between 7.0 and 8.0 with concentrated HCl. 
Adjust volume to 1000 ml with distilled water. 
 Sterilise by autoclaving and store at room temperature. 
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1 x TAE buffer 
 
 100 ml    10 x TAE Buffer 
 900 ml    Distilled water 
 Mix thoroughly. 
 
10 x TAE buffer 
 
48,4 g    Tris base 
11,4 ml   Glacial acetic acid  
3,7 g     EDTA  
Adjust volume to 1000 ml with distilled water. 
 Sterilise by autoclaving and store at room temperature. 
 
1 x TBE buffer 
 
 100 ml    10 x TBE Buffer 
 900 ml    Distilled water 
 Mix thoroughly. 
 
10 x TBE buffer 
 
108 g    Tris base 
55 g     Boric acid  
9,3 g     EDTA  
Adjust volume to 1000 ml with distilled water. 
 Sterilise by autoclaving and store at room temperature. 
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TE Buffer (pH 8)  
 
 2 ml    0,5 M EDTA 
 10 ml    1 M Tris-HCl (pH 8.0) 
 800 ml    Distilled water 
Adjust pH to 8.0 with concentrated HCl. 
 Adjust volume to 1000 ml with distilled water. 
 Sterilise by autoclaving and store at room temperature. 
 
1 M Tris-HCl (pH 8.0) 
 
121,1 g   Tris base 
 800 ml    Distilled water 
 Adjust pH to 8.0 with concentrated HCl. 
 Adjust volume to 1000 ml with distilled water. 
 Sterilise by autoclaving and store at room temperature. 
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Appendix III 
GenBank accession numbers and countries of origin for the subgenotype A1 and A2 
isolates used to calculate the mean nucleotide divergences shown in table 8. 
Subgenotype A1     
 
      
AB076678 - Malawi  AY233279 - South Africa 
AB076679 - Malawi  AY233281 - South Africa 
AB116082 - Bangladesh  AY233282 - South Africa 
AB116083 - Bangladesh  AY233283 - South Africa 
AB116084 - Bangladesh  AY233284 - South Africa 
AB116085 - Bangladesh  AY233285 - South Africa 
AB116086 - India  AY233287 - South Africa 
AB116087 - India  AY233288 - South Africa 
AB116088 - Nepal  AY233289 - South Africa 
AB116089 - Nepal  AY233290 - South Africa 
AB116091 - Philippines  AY373432 - India 
AB116092 - Philippines  AY903452 - South Africa 
AB116093 - Philippines  AY934765 - Somalia 
AB116094 - Philippines  AY934766 - Somalia 
AB241114 - Philippines  AY934767 - Somalia 
AB241115 - Philippines  AY934768 - Somalia 
AB246335 - India  AY934769 - Somalia 
AB246336 - South Africa  AY934770 - Somalia 
AF297621 - South Africa  AY934771 - Somalia 
AF297625 - South Africa  AY934772 - Uganda 
AY161140 - India  AY934773 - Tanzania 
AY233274 - South Africa  AY934774 - Philippines 
AY233275 - South Africa  DQ020002 - Congo 
AY233276 - South Africa  DQ020003 - United Arab Emirates 
AY233277 - South Africa  M57663AP - Philippines 
AY233278 - South Africa     
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Subgenotype A2     
 
      
AB014370 - Japan  AJ344115 - France 
AB064314 - USA  AM282986 - New Zealand 
AB116076 - USA  AM295797 - France 
AB116077 - USA  AY034878 - USA 
AB116078 - USA  AY128092 - Canada 
AB116079 - Japan  AY152726 - USA 
AB116080 - Japan  AY233280 - South Africa 
AB116081 - Japan  AY233286 - South Africa 
AB126580 - Russia  AY738139 - Germany 
AB205118 - Japan  AY738140 - Germany 
AB222707 - Uzbekistan  AY738141 - Germany 
AB222708 - Uzbekistan  AY738142 - Germany 
AB246337 - USA  AY862867 - China 
AB246338 - Japan  AY862868 - China 
AF090838 - Belgium  AY902775 - USA 
AF090839 - Belgium  DQ788725 - Germany 
AF090840 - Belgium  EF208113 - Germany 
AF090841 - Belgium  L13994 -  
AF297624 - South Africa  S50225A -  
AF536524 - USA  V00866A -  
AF537371 - USA  X02763 - USA 
AF537372 - USA  X51970 - Germany 
AJ012207 - Germany  X70185A - Germany 
AJ309369 - France  Z35717 - Poland 
AJ309370 - France  Z72478 - Germany 
AJ309371 - France     
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